<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialResultsOutput xmlns:ns2="local" hits="10" offset="0" totalResults="99"><Filters total="48"><Filter label="Trial Technologies" name="trialTechnologies" total="59"><FilterOption id="762" count="82" label="Small molecule therapeutic"></FilterOption><FilterOption id="585" count="74" label="Oral formulation"></FilterOption><FilterOption id="595" count="66" label="Tablet formulation"></FilterOption><FilterOption id="751" count="50" label="Film coating"></FilterOption><FilterOption id="746" count="29" label="Solution"></FilterOption><FilterOption id="586" count="26" label="Capsule formulation"></FilterOption><FilterOption id="648" count="25" label="Intravenous formulation"></FilterOption><FilterOption id="898" count="22" label="Formulation powder"></FilterOption><FilterOption id="740" count="19" label="Infusion"></FilterOption><FilterOption id="593" count="16" label="Oral liquid formulation"></FilterOption><FilterOption id="594" count="15" label="Oral suspension formulation"></FilterOption><FilterOption id="647" count="13" label="Subcutaneous formulation"></FilterOption><FilterOption id="761" count="12" label="Biological therapeutic"></FilterOption><FilterOption id="175" count="12" label="Drug combination"></FilterOption><FilterOption id="743" count="10" label="Granule"></FilterOption><FilterOption id="902" count="9" label="Orally disintegrating tablet"></FilterOption><FilterOption id="1652" count="9" label="Prodrug"></FilterOption><FilterOption id="680" count="7" label="Buccal formulation systemic"></FilterOption><FilterOption id="660" count="7" label="Oral sustained release formulation"></FilterOption><FilterOption id="805" count="6" label="Daily dosing"></FilterOption><FilterOption id="85" count="6" label="Protein recombinant"></FilterOption><FilterOption id="630" count="6" label="Stereochemistry"></FilterOption><FilterOption id="617" count="5" label="Aerosol formulation inhalant"></FilterOption><FilterOption id="616" count="5" label="Inhalant formulation"></FilterOption><FilterOption id="169" count="5" label="Monoclonal antibody humanized"></FilterOption><FilterOption id="618" count="5" label="Powder formulation inhalant"></FilterOption><FilterOption id="66" count="4" label="Antibiotic"></FilterOption><FilterOption id="750" count="4" label="Freeze drying"></FilterOption><FilterOption id="573" count="4" label="Immunoglobulin-G"></FilterOption><FilterOption id="753" count="4" label="Microparticle formulation"></FilterOption><FilterOption id="742" count="4" label="Pellet"></FilterOption><FilterOption id="667" count="4" label="Peptidomimetic"></FilterOption><FilterOption id="90" count="4" label="Steroid"></FilterOption><FilterOption id="74" count="3" label="Glycoprotein"></FilterOption><FilterOption id="894" count="3" label="Liquid formulation"></FilterOption><FilterOption id="1647" count="3" label="Natural product"></FilterOption><FilterOption id="701" count="3" label="Nucleoside synthesis"></FilterOption><FilterOption id="80" count="3" label="Peptide"></FilterOption><FilterOption id="180" count="2" label="Antibody fragment"></FilterOption><FilterOption id="641" count="2" label="Controlled release formulation"></FilterOption><FilterOption id="723" count="2" label="Drug coating"></FilterOption><FilterOption id="590" count="2" label="Enteric coated formulation"></FilterOption><FilterOption id="1646" count="2" label="Injectable controlled release formulation"></FilterOption><FilterOption id="651" count="2" label="Intramuscular formulation"></FilterOption><FilterOption id="168" count="2" label="Monoclonal antibody human"></FilterOption><FilterOption id="102" count="2" label="Nucleotide and derivatives"></FilterOption><FilterOption id="159" count="2" label="Oligosaccharide"></FilterOption><FilterOption id="348" count="2" label="PEGylated formulation"></FilterOption><FilterOption id="207" count="2" label="Protein conjugated"></FilterOption><FilterOption id="745" count="2" label="Suspension"></FilterOption><FilterOption id="615" count="1" label="Aerosol formulation dermatological"></FilterOption><FilterOption id="111" count="1" label="Cloning technology"></FilterOption><FilterOption id="611" count="1" label="Dermatological formulation"></FilterOption><FilterOption id="559" count="1" label="Oral controlled release formulation"></FilterOption><FilterOption id="776" count="1" label="Oral gel formulation"></FilterOption><FilterOption id="661" count="1" label="Oral quick release formulation"></FilterOption><FilterOption id="901" count="1" label="Recombinant enzyme"></FilterOption><FilterOption id="589" count="1" label="Sustained release formulation"></FilterOption><FilterOption id="558" count="1" label="Transdermal formulation"></FilterOption></Filter><Filter label="Indications" name="indications" total="71"><FilterOption id="837" count="16" label="Non-insulin dependent diabetes"></FilterOption><FilterOption id="159" count="8" label="HIV-1 infection"></FilterOption><FilterOption id="57" count="7" label="Cardiovascular disease"></FilterOption><FilterOption id="178" count="5" label="Hypertension"></FilterOption><FilterOption id="3439" count="5" label="Partial seizure"></FilterOption><FilterOption id="31" count="4" label="Asthma"></FilterOption><FilterOption id="224" count="4" label="Myocardial infarction"></FilterOption><FilterOption id="1185" count="3" label="Chronic obstructive pulmonary disease"></FilterOption><FilterOption id="119" count="3" label="Epilepsy"></FilterOption><FilterOption id="3366" count="3" label="Essential hypertension"></FilterOption><FilterOption id="1295" count="3" label="Neuropathic pain"></FilterOption><FilterOption id="20" count="3" label="Pain"></FilterOption><FilterOption id="2285" count="2" label="Albuminuria"></FilterOption><FilterOption id="1542" count="2" label="Atrial fibrillation"></FilterOption><FilterOption id="3897" count="2" label="Complicated skin and skin structure infection"></FilterOption><FilterOption id="404" count="2" label="Constipation"></FilterOption><FilterOption id="80" count="2" label="Coronary artery disease"></FilterOption><FilterOption id="100" count="2" label="Diabetic nephropathy"></FilterOption><FilterOption id="3251" count="2" label="End stage renal disease"></FilterOption><FilterOption id="2527" count="2" label="Fibromyalgia"></FilterOption><FilterOption id="153" count="2" label="Hepatitis C virus infection"></FilterOption><FilterOption id="3676" count="2" label="Ischemic stroke"></FilterOption><FilterOption id="584" count="2" label="Lipid metabolism disorder"></FilterOption><FilterOption id="3437" count="2" label="Lower back pain"></FilterOption><FilterOption id="3665" count="2" label="Metastatic non small cell lung cancer"></FilterOption><FilterOption id="260" count="2" label="Peripheral vascular disease"></FilterOption><FilterOption id="2549" count="2" label="Postmenopausal osteoporosis"></FilterOption><FilterOption id="276" count="2" label="Prostate tumor"></FilterOption><FilterOption id="287" count="2" label="Respiratory syncytial virus infection"></FilterOption><FilterOption id="291" count="2" label="Rheumatoid arthritis"></FilterOption><FilterOption id="1009" count="2" label="Urinary tract infection"></FilterOption><FilterOption id="341" count="2" label="Uveitis"></FilterOption><FilterOption id="1731" count="1" label="Acute myelogenous leukemia"></FilterOption><FilterOption id="1776" count="1" label="Adult varicella zoster virus infection"></FilterOption><FilterOption id="33" count="1" label="Atherosclerosis"></FilterOption><FilterOption id="40" count="1" label="Bacterial infection"></FilterOption><FilterOption id="485" count="1" label="Bacterial skin infection"></FilterOption><FilterOption id="3114" count="1" label="Bipolar I disorder"></FilterOption><FilterOption id="49" count="1" label="Breast tumor"></FilterOption><FilterOption id="55" count="1" label="Cardiac failure"></FilterOption><FilterOption id="64" count="1" label="Cerebrovascular disease"></FilterOption><FilterOption id="101" count="1" label="Diabetic neuropathy"></FilterOption><FilterOption id="1243" count="1" label="Gastroesophageal reflux"></FilterOption><FilterOption id="2535" count="1" label="Growth hormone deficiency"></FilterOption><FilterOption id="623" count="1" label="Head and neck tumor"></FilterOption><FilterOption id="3455" count="1" label="Influenza virus A infection"></FilterOption><FilterOption id="70" count="1" label="Liver cirrhosis"></FilterOption><FilterOption id="2318" count="1" label="Liver fibrosis"></FilterOption><FilterOption id="4898" count="1" label="Major depressive disorder"></FilterOption><FilterOption id="2548" count="1" label="Male osteoporosis"></FilterOption><FilterOption id="3673" count="1" label="Metastatic head and neck cancer"></FilterOption><FilterOption id="1828" count="1" label="Multiple myeloma"></FilterOption><FilterOption id="913" count="1" label="Muscle hypertonia"></FilterOption><FilterOption id="1272" count="1" label="Myelodysplastic syndrome"></FilterOption><FilterOption id="1520" count="1" label="Narcolepsy"></FilterOption><FilterOption id="678" count="1" label="Neuropathy"></FilterOption><FilterOption id="1262" count="1" label="Non-small-cell lung cancer"></FilterOption><FilterOption id="246" count="1" label="Osteoporosis"></FilterOption><FilterOption id="1845" count="1" label="Phlebothrombosis"></FilterOption><FilterOption id="1274" count="1" label="Premature ejaculation"></FilterOption><FilterOption id="1241" count="1" label="Prostate hyperplasia"></FilterOption><FilterOption id="284" count="1" label="Pyelonephritis"></FilterOption><FilterOption id="3907" count="1" label="Renal insufficiency"></FilterOption><FilterOption id="1774" count="1" label="Restless legs syndrome"></FilterOption><FilterOption id="1665" count="1" label="Secondary hyperparathyroidism"></FilterOption><FilterOption id="2921" count="1" label="Spondylarthritis"></FilterOption><FilterOption id="308" count="1" label="Staphylococcus aureus infection"></FilterOption><FilterOption id="65" count="1" label="Stroke"></FilterOption><FilterOption id="1585" count="1" label="Syndrome X"></FilterOption><FilterOption id="324" count="1" label="Thrombocytopenia"></FilterOption><FilterOption id="325" count="1" label="Thromboembolism"></FilterOption></Filter><Filter label="Endpoint Index" name="trialEndpointIndex" total="100"><FilterOption id="1626" count="11" label="Non-insulin dependent diabetes - Assessment of Adverse Events"></FilterOption><FilterOption id="1359" count="9" label="Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels - Change in HbA1c"></FilterOption><FilterOption id="1624" count="8" label="Non-insulin dependent diabetes - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="1503" count="7" label="Non-insulin dependent diabetes - Anthropometric Assessments - Assessment of body weight"></FilterOption><FilterOption id="1580" count="7" label="Non-insulin dependent diabetes - Assessment of Blood Pressure (BP)"></FilterOption><FilterOption id="1345" count="7" label="Non-insulin dependent diabetes - Glycemic Control Analysis - Assessment of fasting blood glucose"></FilterOption><FilterOption id="25983" count="7" label="Pain - Assessment of Sleep"></FilterOption><FilterOption id="25" count="5" label="Hypertension - Assessment of Systolic Blood Pressure (SBP) - Seated SBP"></FilterOption><FilterOption id="1358" count="5" label="Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels"></FilterOption><FilterOption id="1561" count="5" label="Non-insulin dependent diabetes - Assessment of Mortality/Death Rates - Cardiovascular mortality"></FilterOption><FilterOption id="25873" count="5" label="Pain - Assessment of Intensity of Pain"></FilterOption><FilterOption id="25985" count="5" label="Pain - Assessment of Neuropsychological Function - Assessment by Clinical Global Impression (CGI)"></FilterOption><FilterOption id="25986" count="5" label="Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Patient Global Impression Scale (PGI)"></FilterOption><FilterOption id="2634" count="4" label="Coronary artery disease - Assessment of Adverse Events"></FilterOption><FilterOption id="9246" count="4" label="HIV infection - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="1502" count="4" label="Non-insulin dependent diabetes - Anthropometric Assessments - Assessment of BMI"></FilterOption><FilterOption id="1535" count="4" label="Non-insulin dependent diabetes - Assessment of Morbidity"></FilterOption><FilterOption id="1579" count="4" label="Non-insulin dependent diabetes - Assessment of Vital Signs"></FilterOption><FilterOption id="26033" count="4" label="Pain - Assessment of adverse events"></FilterOption><FilterOption id="5985" count="3" label="Asthma - Assessment of Exacerbations - Number/rate/frequency/duration of exacerbation"></FilterOption><FilterOption id="5986" count="3" label="Asthma - Assessment of Exacerbations - Severity of exacerbation"></FilterOption><FilterOption id="5987" count="3" label="Asthma - Assessment of Exacerbations - Time to first exacerbation"></FilterOption><FilterOption id="5983" count="3" label="Asthma - Assessment of Exacerbations"></FilterOption><FilterOption id="2622" count="3" label="Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality"></FilterOption><FilterOption id="2515" count="3" label="Coronary artery disease - Assessment of Thrombotic/Thromboembolic Events - Fatal /Non-fatal stroke"></FilterOption><FilterOption id="22596" count="3" label="End stage renal disease - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="22507" count="3" label="End stage renal disease - Assessment of Serum Creatinine"></FilterOption><FilterOption id="22595" count="3" label="End stage renal disease - Assessment of adverse events"></FilterOption><FilterOption id="17058" count="3" label="Epilepsy - Assessment of Seizure Activity - Assessment of seizure frequency"></FilterOption><FilterOption id="9255" count="3" label="HIV infection - Assessment of Therapy Related Outcomes - Assessment of treatment discontinuation"></FilterOption><FilterOption id="9213" count="3" label="HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels"></FilterOption><FilterOption id="23556" count="3" label="Menopause - Assessment of Biomarkers - Assessment of bone markers"></FilterOption><FilterOption id="23553" count="3" label="Menopause - Assessment of Bone - Assessment by Bone mineral density (BMD)"></FilterOption><FilterOption id="1548" count="3" label="Non-insulin dependent diabetes - Assessment of Cardiovascular Events - Assessment of myocardial infarction"></FilterOption><FilterOption id="1543" count="3" label="Non-insulin dependent diabetes - Assessment of Cardiovascular Events"></FilterOption><FilterOption id="13771" count="3" label="Osteoporosis - Assessment of Bone - Assessment by Bone mineral density (BMD)"></FilterOption><FilterOption id="25875" count="3" label="Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]"></FilterOption><FilterOption id="34788" count="3" label="Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Euro Quality of Life (EQ-5D) Questionnaire"></FilterOption><FilterOption id="5984" count="2" label="Asthma - Assessment of Exacerbations - Exacerbation requiring hospitalization"></FilterOption><FilterOption id="6083" count="2" label="Asthma - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="6082" count="2" label="Asthma - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="6067" count="2" label="Asthma - Assessment of use of Rescue Medication - Corticosteroid usage"></FilterOption><FilterOption id="6069" count="2" label="Asthma - Assessment of use of Rescue Medication - Frequency/rate of medication use"></FilterOption><FilterOption id="6111" count="2" label="Asthma - Patient Reported Outcomes/Quality of Life Assessments - Asthma control questionnaire (ACQ)"></FilterOption><FilterOption id="6108" count="2" label="Asthma - Patient Reported Outcomes/Quality of Life Assessments"></FilterOption><FilterOption id="14742" count="2" label="Bacterial skin infection - Assessment of Clinical Response - Clinical success/cure"></FilterOption><FilterOption id="14756" count="2" label="Bacterial skin infection - Assessment of Disease Relapse/Recurrence"></FilterOption><FilterOption id="14739" count="2" label="Bacterial skin infection - Assessment of Incidence of Bacterial Skin Infection"></FilterOption><FilterOption id="14771" count="2" label="Bacterial skin infection - Assessment of Laboratory/Diagnostic Measures"></FilterOption><FilterOption id="14751" count="2" label="Bacterial skin infection - Assessment of Microbiological Response - Persistence/colonization"></FilterOption><FilterOption id="14749" count="2" label="Bacterial skin infection - Assessment of Microbiological Response - Super-infection"></FilterOption><FilterOption id="14766" count="2" label="Bacterial skin infection - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="14761" count="2" label="Bacterial skin infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="14767" count="2" label="Bacterial skin infection - Assessment of Vital Signs"></FilterOption><FilterOption id="690" count="2" label="Cardiac failure - Assessment of Cardiovascular Events - Assessment of fatal/non-fatal myocardial infarction"></FilterOption><FilterOption id="770" count="2" label="Cardiac failure - Assessment of Cardiovascular Events - Worsening of Heart Failure"></FilterOption><FilterOption id="558" count="2" label="Cardiac failure - Assessment of Non Cardiovascular Events - Assessment of cerebrovascular adverse events (Stroke/TIA)"></FilterOption><FilterOption id="823" count="2" label="Cardiac failure - Assessment of hospitalization - Hospitalization due to other cardiovascular events"></FilterOption><FilterOption id="4473" count="2" label="Chronic obstructive pulmonary disease - Assessment of Exacerbations"></FilterOption><FilterOption id="4277" count="2" label="Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1)"></FilterOption><FilterOption id="4526" count="2" label="Chronic obstructive pulmonary disease - Assessment of use of Rescue Medication"></FilterOption><FilterOption id="2492" count="2" label="Coronary artery disease - Assessment of Cardiovascular Events - Acute/New Myocardial infarction (MI)/MI (Q-wave and non-Q wave)"></FilterOption><FilterOption id="2494" count="2" label="Coronary artery disease - Assessment of Cardiovascular Events - Fatal MI/Non-fatal MI"></FilterOption><FilterOption id="2775" count="2" label="Coronary artery disease - Assessment of hospitalization - Admissions for CAD and adverse events of CAD"></FilterOption><FilterOption id="22539" count="2" label="End stage renal disease - Assessment of Cardiac Function"></FilterOption><FilterOption id="22537" count="2" label="End stage renal disease - Glycemic Control Analysis - Assessment of glycosylated hemoglobin (HbA1c)"></FilterOption><FilterOption id="17073" count="2" label="Epilepsy - Assessment of Partial Seizures"></FilterOption><FilterOption id="17167" count="2" label="Epilepsy - Assessment of Response Rates (RR) - Assessment of response rate"></FilterOption><FilterOption id="17164" count="2" label="Epilepsy - Assessment of Therapy Related Outcomes - Assessment of drop-out rate/withdrawal rate"></FilterOption><FilterOption id="17156" count="2" label="Epilepsy - Assessment of adverse events"></FilterOption><FilterOption id="3808" count="2" label="Hepatitis C virus infection - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="16816" count="2" label="Herpesvirus infection - Assessment of Post Herpetic Neuralgia"></FilterOption><FilterOption id="9215" count="2" label="HIV infection - Assessment of CD4 Cell Responses - Assessment of CD4 cell count/percentage"></FilterOption><FilterOption id="9209" count="2" label="HIV infection - Assessment of HIV Resistance - Assessment of genotypic/phenotypic resistance"></FilterOption><FilterOption id="9218" count="2" label="HIV infection - Assessment of Immune Response"></FilterOption><FilterOption id="9247" count="2" label="HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="9195" count="2" label="HIV infection - Assessment of virological response"></FilterOption><FilterOption id="2" count="2" label="Hypertension - Assessment of Blood Pressure (BP) - BP control rate"></FilterOption><FilterOption id="1" count="2" label="Hypertension - Assessment of Blood Pressure (BP)"></FilterOption><FilterOption id="40" count="2" label="Hypertension - Assessment of Diastolic Blood Pressure (DBP) - Seated DBP"></FilterOption><FilterOption id="170" count="2" label="Hypertension - Assessment of Hemoglobin A1c (HbA1c) Levels"></FilterOption><FilterOption id="16" count="2" label="Hypertension - Assessment of Systolic Blood Pressure (SBP)"></FilterOption><FilterOption id="1504" count="2" label="Non-insulin dependent diabetes - Anthropometric Assessments - Assessment of abdominal circumference"></FilterOption><FilterOption id="1632" count="2" label="Non-insulin dependent diabetes - Assessment of Adverse Events - Nausea &amp; vomiting"></FilterOption><FilterOption id="1395" count="2" label="Non-insulin dependent diabetes - Assessment of Beta Cell Function - Homeostasis model assessment (HOMA)- beta cell function Index (HOMA-B)"></FilterOption><FilterOption id="1389" count="2" label="Non-insulin dependent diabetes - Assessment of Beta Cell Function"></FilterOption><FilterOption id="1544" count="2" label="Non-insulin dependent diabetes - Assessment of Cardiovascular Events - Angina pectoris"></FilterOption><FilterOption id="1360" count="2" label="Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels - HbA1c response rates"></FilterOption><FilterOption id="1361" count="2" label="Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels - Time to HbA1c response [Time to HbA1c target]"></FilterOption><FilterOption id="1429" count="2" label="Non-insulin dependent diabetes - Assessment of Inflammatory &amp; Oxidative Stress Markers - High-sensitivity C-reactive protein (hsCRP)"></FilterOption><FilterOption id="1365" count="2" label="Non-insulin dependent diabetes - Assessment of Insulin Levels - Proinsulin/insulin ratio"></FilterOption><FilterOption id="1634" count="2" label="Non-insulin dependent diabetes - Assessment of Safety and Tolerability - Assessment of serious adverse events"></FilterOption><FilterOption id="1611" count="2" label="Non-insulin dependent diabetes - Assessment of Serum Creatinine"></FilterOption><FilterOption id="1540" count="2" label="Non-insulin dependent diabetes - Assessment of Stroke"></FilterOption><FilterOption id="1554" count="2" label="Non-insulin dependent diabetes - Assessment of hospitalization - Hospitalization due to cardiovascular events"></FilterOption><FilterOption id="1557" count="2" label="Non-insulin dependent diabetes - Assessment of hospitalization - Hospitalization due to heart failure"></FilterOption><FilterOption id="1452" count="2" label="Non-insulin dependent diabetes - Assessment of lipid profiles - Assessment of Total Cholesterol"></FilterOption><FilterOption id="1454" count="2" label="Non-insulin dependent diabetes - Assessment of lipid profiles - HDL-C (High-density lipoprotein cholesterol)"></FilterOption><FilterOption id="1455" count="2" label="Non-insulin dependent diabetes - Assessment of lipid profiles - LDL-C (Low-density lipoprotein cholesterol)"></FilterOption><FilterOption id="1451" count="2" label="Non-insulin dependent diabetes - Assessment of lipid profiles"></FilterOption></Filter><Filter label="Trial Drug Phase Highest" name="trialDrugPhaseHighest" total="7"><FilterOption id="L" count="81" label="Launched"></FilterOption><FilterOption id="DX" count="5" label="Discontinued"></FilterOption><FilterOption id="NDR" count="2" label="No Development Reported"></FilterOption><FilterOption id="C1" count="2" label="Phase 1 Clinical"></FilterOption><FilterOption id="C3" count="2" label="Phase 3 Clinical"></FilterOption><FilterOption id="C2" count="1" label="Phase 2 Clinical"></FilterOption><FilterOption id="S" count="1" label="Suspended"></FilterOption></Filter><Filter label="Trial Company Sponsor" name="trialCompaniesSponsor" total="65"><FilterOption id="14190" count="21" label="AstraZeneca plc"></FilterOption><FilterOption id="1091809" count="12" label="Janssen-Cilag International NV (BE)"></FilterOption><FilterOption id="14881" count="9" label="Boehringer Ingelheim International GmbH"></FilterOption><FilterOption id="1067538" count="9" label="Janssen Research &amp; Development LLC"></FilterOption><FilterOption id="18767" count="7" label="Pfizer Inc"></FilterOption><FilterOption id="1020322" count="5" label="Daiichi Sankyo Inc"></FilterOption><FilterOption id="23137" count="5" label="Novartis AG"></FilterOption><FilterOption id="20452" count="5" label="UCB SA"></FilterOption><FilterOption id="30062" count="4" label="AstraZeneca AB"></FilterOption><FilterOption id="22586" count="4" label="Boehringer Ingelheim Corp"></FilterOption><FilterOption id="22546" count="4" label="Boehringer Ingelheim GmbH"></FilterOption><FilterOption id="22554" count="3" label="Boehringer Ingelheim BV"></FilterOption><FilterOption id="1122527" count="3" label="Boehringer Ingelheim Finland Ky"></FilterOption><FilterOption id="22563" count="3" label="Boehringer Ingelheim Ltd"></FilterOption><FilterOption id="15065" count="3" label="Bristol-Myers Squibb Co"></FilterOption><FilterOption id="1123634" count="3" label="Daiichi Sankyo Development Ltd"></FilterOption><FilterOption id="1122528" count="3" label="SCS Boehringer Ingelheim Comm.V"></FilterOption><FilterOption id="22545" count="2" label="Boehringer Ingelheim AB"></FilterOption><FilterOption id="22549" count="2" label="Boehringer Ingelheim Austria GmbH"></FilterOption><FilterOption id="22555" count="2" label="Boehringer Ingelheim Ellas AE"></FilterOption><FilterOption id="16587" count="2" label="Grunenthal GmbH"></FilterOption><FilterOption id="1003570" count="2" label="Janssen R&amp;D (Ireland)"></FilterOption><FilterOption id="17392" count="2" label="Janssen-Cilag Ltd"></FilterOption><FilterOption id="17332" count="2" label="Johnson &amp; Johnson"></FilterOption><FilterOption id="22186" count="2" label="Solvay Pharmaceuticals Inc"></FilterOption><FilterOption id="22784" count="2" label="UCB Pharma Inc"></FilterOption><FilterOption id="22598" count="2" label="Unilfarma Lda"></FilterOption><FilterOption id="21321" count="2" label="Upsher-Smith Laboratories Inc"></FilterOption><FilterOption id="20954" count="2" label="XOMA Corp"></FilterOption><FilterOption id="13601" count="1" label="Abbott Laboratories"></FilterOption><FilterOption id="21152" count="1" label="Abbott Products GmbH"></FilterOption><FilterOption id="1072507" count="1" label="AbbVie Inc"></FilterOption><FilterOption id="14109" count="1" label="Amgen Inc"></FilterOption><FilterOption id="16924" count="1" label="Astra Pharmaceuticals (HK) Ltd"></FilterOption><FilterOption id="16919" count="1" label="Astra-IDL Ltd"></FilterOption><FilterOption id="14455" count="1" label="Bayer AG"></FilterOption><FilterOption id="22582" count="1" label="Boehringer Ingelheim (Canada) Ltd"></FilterOption><FilterOption id="1103352" count="1" label="Boehringer Ingelheim Espana Sa"></FilterOption><FilterOption id="22556" count="1" label="Boehringer Ingelheim France SARL"></FilterOption><FilterOption id="22560" count="1" label="Boehringer Ingelheim Italia SpA"></FilterOption><FilterOption id="22566" count="1" label="Boehringer Ingelheim Pharma Ges mbH"></FilterOption><FilterOption id="22590" count="1" label="Boehringer Ingelheim SA"></FilterOption><FilterOption id="1044439" count="1" label="Develco Pharma Schweiz Ag"></FilterOption><FilterOption id="1016499" count="1" label="Digna Biotech SL"></FilterOption><FilterOption id="15872" count="1" label="Eisai Co Ltd"></FilterOption><FilterOption id="17810" count="1" label="Eli Lilly &amp; Co"></FilterOption><FilterOption id="29708" count="1" label="Ferring Pharmaceuticals SA"></FilterOption><FilterOption id="17259" count="1" label="Ipsen"></FilterOption><FilterOption id="30131" count="1" label="Janssen Diagnostics BVBA"></FilterOption><FilterOption id="17397" count="1" label="Janssen Farmaceutica SA de CV"></FilterOption><FilterOption id="17408" count="1" label="Janssen Pharmaceutical KK"></FilterOption><FilterOption id="25863" count="1" label="Janssen Pharmaceuticals Inc"></FilterOption><FilterOption id="17401" count="1" label="Janssen-Cilag SA"></FilterOption><FilterOption id="17534" count="1" label="Johnson &amp; Johnson (Pvt) Ltd"></FilterOption><FilterOption id="29481" count="1" label="Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC"></FilterOption><FilterOption id="18614" count="1" label="Novo Nordisk A/S"></FilterOption><FilterOption id="23634" count="1" label="Novo Nordisk Bioindustriale Srl"></FilterOption><FilterOption id="19087" count="1" label="Pierre Fabre SA"></FilterOption><FilterOption id="1089968" count="1" label="Quintiles East Asia Pte Ltd"></FilterOption><FilterOption id="19214" count="1" label="Regeneron Pharmaceuticals Inc"></FilterOption><FilterOption id="1104050" count="1" label="UCB Biopharma SPRL"></FilterOption><FilterOption id="29819" count="1" label="UCB BIOSCIENCES GmbH"></FilterOption><FilterOption id="1050515" count="1" label="ViiV Healthcare Ltd"></FilterOption><FilterOption id="27724" count="1" label="Warner Chilcott plc"></FilterOption><FilterOption id="14112" count="1" label="Wyeth"></FilterOption></Filter><Filter label="Trial Recruitment Status" name="trialRecruitmentStatus" total="4"><FilterOption id="4" count="83" label="Completed"></FilterOption><FilterOption id="6" count="12" label="Terminated"></FilterOption><FilterOption id="2" count="3" label="Recruiting"></FilterOption><FilterOption id="3" count="1" label="No longer recruiting"></FilterOption></Filter><Filter label="Trial Commercially Significant" name="trialIsCommerciallySignificant" total="2"><FilterOption id="YES" count="79" label="Yes"></FilterOption><FilterOption id="NO" count="20" label="No"></FilterOption></Filter><Filter label="Trial Indications Pioneer" name="trialIndicationsPioneer" total="27"><FilterOption id="57" count="5" label="Cardiovascular disease"></FilterOption><FilterOption id="100" count="2" label="Diabetic nephropathy"></FilterOption><FilterOption id="3366" count="2" label="Essential hypertension"></FilterOption><FilterOption id="178" count="2" label="Hypertension"></FilterOption><FilterOption id="224" count="2" label="Myocardial infarction"></FilterOption><FilterOption id="837" count="2" label="Non-insulin dependent diabetes"></FilterOption><FilterOption id="260" count="2" label="Peripheral vascular disease"></FilterOption><FilterOption id="1776" count="1" label="Adult varicella zoster virus infection"></FilterOption><FilterOption id="2285" count="1" label="Albuminuria"></FilterOption><FilterOption id="33" count="1" label="Atherosclerosis"></FilterOption><FilterOption id="64" count="1" label="Cerebrovascular disease"></FilterOption><FilterOption id="3251" count="1" label="End stage renal disease"></FilterOption><FilterOption id="119" count="1" label="Epilepsy"></FilterOption><FilterOption id="2527" count="1" label="Fibromyalgia"></FilterOption><FilterOption id="2535" count="1" label="Growth hormone deficiency"></FilterOption><FilterOption id="153" count="1" label="Hepatitis C virus infection"></FilterOption><FilterOption id="3676" count="1" label="Ischemic stroke"></FilterOption><FilterOption id="584" count="1" label="Lipid metabolism disorder"></FilterOption><FilterOption id="1295" count="1" label="Neuropathic pain"></FilterOption><FilterOption id="678" count="1" label="Neuropathy"></FilterOption><FilterOption id="20" count="1" label="Pain"></FilterOption><FilterOption id="3439" count="1" label="Partial seizure"></FilterOption><FilterOption id="3907" count="1" label="Renal insufficiency"></FilterOption><FilterOption id="291" count="1" label="Rheumatoid arthritis"></FilterOption><FilterOption id="308" count="1" label="Staphylococcus aureus infection"></FilterOption><FilterOption id="1585" count="1" label="Syndrome X"></FilterOption><FilterOption id="1009" count="1" label="Urinary tract infection"></FilterOption></Filter><Filter label="Registry Id" name="trialRegistries" total="17"><FilterOption id="1000" count="99" label="CT.gov"></FilterOption><FilterOption id="1001" count="65" label="EudraCT"></FilterOption><FilterOption id="1030" count="18" label="RSRM CTR"></FilterOption><FilterOption id="1021" count="10" label="NMRR"></FilterOption><FilterOption id="1006" count="9" label="JapicCTI"></FilterOption><FilterOption id="1012" count="7" label="CTRI"></FilterOption><FilterOption id="1033" count="6" label="Mexico CTR"></FilterOption><FilterOption id="1019" count="4" label="DRKS"></FilterOption><FilterOption id="1023" count="4" label="UKCRN"></FilterOption><FilterOption id="1009" count="3" label="HKClinicalTrials.com"></FilterOption><FilterOption id="1039" count="2" label="CDE"></FilterOption><FilterOption id="1002" count="2" label="ISRCTN"></FilterOption><FilterOption id="1038" count="2" label="PHRR"></FilterOption><FilterOption id="1008" count="1" label="Hong Kong CCTCTR"></FilterOption><FilterOption id="1035" count="1" label="Singapore HSA CTR"></FilterOption><FilterOption id="1018" count="1" label="SLCTR"></FilterOption><FilterOption id="1004" count="1" label="WHO ICTRP"></FilterOption></Filter><Filter label="Trial Reason for Discontinuation" name="trialReasonForDiscontinuation" total="7"><FilterOption id="2" count="4" label="Not Reported"></FilterOption><FilterOption id="5" count="3" label="Patient Enrollment Issues"></FilterOption><FilterOption id="7" count="3" label="Safety Issues"></FilterOption><FilterOption id="1" count="1" label="Lack of Efficacy"></FilterOption><FilterOption id="3" count="1" label="Operational Issues"></FilterOption><FilterOption id="4" count="1" label="Other"></FilterOption><FilterOption id="8" count="1" label="Sponsor/Business Decision"></FilterOption></Filter><Filter label="Active Controls" name="trialActiveControls" total="29"><FilterOption id="6050" count="3" label="metformin hydrochloride"></FilterOption><FilterOption id="32981" count="2" label="darunavir"></FilterOption><FilterOption id="17814" count="2" label="pregabalin"></FilterOption><FilterOption id="7310" count="2" label="ritonavir"></FilterOption><FilterOption id="44401" count="2" label="vancomycin"></FilterOption><FilterOption id="44375" count="2" label="warfarin"></FilterOption><FilterOption id="6242" count="1" label="abacavir"></FilterOption><FilterOption id="2500" count="1" label="amlodipine"></FilterOption><FilterOption id="2807" count="1" label="atorvastatin"></FilterOption><FilterOption id="44438" count="1" label="ciprofloxacin hydrochloride"></FilterOption><FilterOption id="2836" count="1" label="clopidogrel"></FilterOption><FilterOption id="8399" count="1" label="doripenem"></FilterOption><FilterOption id="4728" count="1" label="emtricitabine"></FilterOption><FilterOption id="13928" count="1" label="enoxaparin sodium"></FilterOption><FilterOption id="14336" count="1" label="fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline"></FilterOption><FilterOption id="3188" count="1" label="gabapentin"></FilterOption><FilterOption id="8832" count="1" label="glimepiride"></FilterOption><FilterOption id="32355" count="1" label="indacaterol"></FilterOption><FilterOption id="3474" count="1" label="lamivudine"></FilterOption><FilterOption id="54142" count="1" label="NAHE-001"></FilterOption><FilterOption id="2902" count="1" label="Oxis Turbuhaler"></FilterOption><FilterOption id="4196" count="1" label="ramipril"></FilterOption><FilterOption id="56791" count="1" label="tapentadol (sustained release, pain) J&amp;J PRD/Grunenthal"></FilterOption><FilterOption id="5051" count="1" label="telmisartan"></FilterOption><FilterOption id="14493" count="1" label="tenofovir disoproxil fumarate"></FilterOption><FilterOption id="8165" count="1" label="tiotropium bromide"></FilterOption><FilterOption id="44363" count="1" label="trimethoprim + sulphamethoxazole"></FilterOption><FilterOption id="44316" count="1" label="zidovudine"></FilterOption><FilterOption id="2765" count="1" label="zoledronic acid"></FilterOption></Filter><Filter label="Exclusion Criteria Index" name="trialExclusionCriteriaIndex" total="100"><FilterOption id="20112" count="7" label="Pain - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="17519" count="6" label="End stage renal disease - Subjects co-morbid with cardiovascular diseases/disorders"></FilterOption><FilterOption id="6859" count="6" label="HIV infection - Pregnant or Breast Feeding Subjects"></FilterOption><FilterOption id="891" count="6" label="Non-insulin dependent diabetes - Subjects co-morbid with heart disorders/diseases"></FilterOption><FilterOption id="911" count="6" label="Non-insulin dependent diabetes - Subjects co-morbid with hepatobiliary disorders/diseases"></FilterOption><FilterOption id="837" count="6" label="Non-insulin dependent diabetes - Subjects co-morbid with renal disease/disorder"></FilterOption><FilterOption id="6845" count="5" label="HIV infection - Subjects with Co-morbid Conditions - Subjects co-morbid with hepatobiliary diseases/disorders"></FilterOption><FilterOption id="5620" count="5" label="Non-insulin dependent diabetes - Subjects with Abnormal Laboratory Findings - Abnormal liver function test"></FilterOption><FilterOption id="20182" count="5" label="Pain - Protocol Specified Other Exclusion Criteria"></FilterOption><FilterOption id="17524" count="4" label="End stage renal disease - Subjects co-morbid with Endocrine/Metabolic Disorders"></FilterOption><FilterOption id="7555" count="4" label="HIV infection - Subjects with Progressive/Treatment Refractory Disease - Subjects with resistant mutations"></FilterOption><FilterOption id="351" count="4" label="Hypertension - Subjects co-morbid with cardiovascular diseases/disorders"></FilterOption><FilterOption id="342" count="4" label="Hypertension - Subjects with Primary/Essential Hypertension - Stage 3 (JNC 6) hypertension"></FilterOption><FilterOption id="9" count="4" label="Hypertension - Subjects with Secondary Hypertension"></FilterOption><FilterOption id="834" count="4" label="Non-insulin dependent diabetes - Subjects co-morbid with Cerebrovascular Disorders/Diseases - Subjects co-morbid with stroke"></FilterOption><FilterOption id="957" count="4" label="Non-insulin dependent diabetes - Subjects with History of/Scheduled to Receive Therapy - Subjects on/treated with insulin"></FilterOption><FilterOption id="983" count="4" label="Non-insulin dependent diabetes - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients"></FilterOption><FilterOption id="20108" count="4" label="Pain - Subjects with Abnormal Organ Function - Subjects with abnormal/unacceptable cardiac function"></FilterOption><FilterOption id="17518" count="3" label="End stage renal disease - Subjects co-morbid with neurological disorders/diseases"></FilterOption><FilterOption id="17508" count="3" label="End stage renal disease - Subjects co-morbid with renal disease/disorder"></FilterOption><FilterOption id="17539" count="3" label="End stage renal disease - Subjects with History of/Scheduled for Renal Replacement Therapy - Subjects with protocol specified transplantation related criteria"></FilterOption><FilterOption id="12709" count="3" label="Epilepsy - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="40" count="3" label="Hypertension - Subjects co-morbid with Cerebrovascular Disorders/Diseases - Subjects co-morbid with stroke"></FilterOption><FilterOption id="47" count="3" label="Hypertension - Subjects co-morbid with heart disorders/diseases - Subjects co-morbid with myocardial infarction"></FilterOption><FilterOption id="225" count="3" label="Hypertension - Subjects co-morbid with hepatobiliary disorders/diseases"></FilterOption><FilterOption id="167" count="3" label="Hypertension - Subjects co-morbid with renal disease/disorder"></FilterOption><FilterOption id="223" count="3" label="Hypertension - Subjects with Electrolyte Imbalances - Hyperkalemia"></FilterOption><FilterOption id="75" count="3" label="Hypertension - Subjects with Heart Failure"></FilterOption><FilterOption id="147" count="3" label="Hypertension - Subjects with History of/Scheduled for Intervention/Surgery - Subjects with history of/schdeuled for percutaneous transluminal coronary angioplasty (PTCA)"></FilterOption><FilterOption id="130" count="3" label="Hypertension - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Hypersensitivity/contraindication to angiotensin II receptor blockers"></FilterOption><FilterOption id="961" count="3" label="Non-insulin dependent diabetes - Conditions Altering Blood Glucose Levels - Subjects on glucocorticoid/steroid therapy"></FilterOption><FilterOption id="836" count="3" label="Non-insulin dependent diabetes - Subjects co-morbid with Cerebrovascular Disorders/Diseases - Subjects co-morbid with transient ischemic attack"></FilterOption><FilterOption id="831" count="3" label="Non-insulin dependent diabetes - Subjects co-morbid with Cerebrovascular Disorders/Diseases"></FilterOption><FilterOption id="5070" count="3" label="Non-insulin dependent diabetes - Subjects co-morbid with Endocrine/Metabolic Disorders"></FilterOption><FilterOption id="895" count="3" label="Non-insulin dependent diabetes - Subjects co-morbid with cardiovascular diseases/disorders - Subjects co-morbid with heart failure"></FilterOption><FilterOption id="894" count="3" label="Non-insulin dependent diabetes - Subjects co-morbid with heart disorders/diseases - Subjects with coronary artery disease"></FilterOption><FilterOption id="5083" count="3" label="Non-insulin dependent diabetes - Subjects with Abnormal Laboratory Findings - Subjects with increased blood glucose level/FBS not meeting the study requirement"></FilterOption><FilterOption id="936" count="3" label="Non-insulin dependent diabetes - Subjects with Co-morbid Conditions - Subjects co-morbid with hematological disease/disorders"></FilterOption><FilterOption id="925" count="3" label="Non-insulin dependent diabetes - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="964" count="3" label="Non-insulin dependent diabetes - Subjects with History of/Current Use of a Prohibited Medication - Subjects on/treated with drugs having any impact on body weight"></FilterOption><FilterOption id="981" count="3" label="Non-insulin dependent diabetes - Subjects with History of/Scheduled for Other Treatments - GI surgery"></FilterOption><FilterOption id="10248" count="3" label="Osteoporosis - Subjects co-morbid with endocrine/metabolic diseases/disorders"></FilterOption><FilterOption id="20124" count="3" label="Pain - Immunocompromised Subjects - Subjects immunocompromised with cancer/malignancy"></FilterOption><FilterOption id="20115" count="3" label="Pain - Subjects co-morbid with cardiovascular diseases/disorders"></FilterOption><FilterOption id="20119" count="3" label="Pain - Subjects co-morbid with inflammatory disorders"></FilterOption><FilterOption id="20114" count="3" label="Pain - Subjects with Co-morbid Conditions - Subjects co-morbid with CNS disorders/diseases"></FilterOption><FilterOption id="3839" count="2" label="Asthma - Subjects co-morbid with Respiratory Diseases/Disorders"></FilterOption><FilterOption id="3951" count="2" label="Asthma - Subjects with Asthma Exacerbations"></FilterOption><FilterOption id="20247" count="2" label="Asthma - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="20255" count="2" label="Asthma - Subjects with History of/Scheduled for Other Treatments"></FilterOption><FilterOption id="20249" count="2" label="Asthma - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for asthma drugs"></FilterOption><FilterOption id="3954" count="2" label="Asthma - Subjects with specific cigarette smoking activity - Smokers"></FilterOption><FilterOption id="7208" count="2" label="Atrial fibrillation - Subjects co-morbid with cardiovascular diseases/disorders"></FilterOption><FilterOption id="7174" count="2" label="Atrial fibrillation - Subjects co-morbid with renal disease/disorder"></FilterOption><FilterOption id="7198" count="2" label="Atrial fibrillation - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="7402" count="2" label="Atrial fibrillation - Subjects with History of Cerebrovascular Events - Subjects with history of stroke"></FilterOption><FilterOption id="11293" count="2" label="Bacterial skin infection - Subjects co-morbid with hepatobiliary disorders/diseases"></FilterOption><FilterOption id="11287" count="2" label="Bacterial skin infection - Subjects co-morbid with infections"></FilterOption><FilterOption id="11294" count="2" label="Bacterial skin infection - Subjects co-morbid with renal disease/disorder"></FilterOption><FilterOption id="11298" count="2" label="Bacterial skin infection - Subjects on Anti-bacterial Therapy"></FilterOption><FilterOption id="11304" count="2" label="Bacterial skin infection - Subjects with Abnormal Laboratory Findings - Subjects with abnormal/unacceptable hematological values"></FilterOption><FilterOption id="11297" count="2" label="Bacterial skin infection - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="11282" count="2" label="Bacterial skin infection - Subjects with Uncomplicated Skin and Skin Structure Infections"></FilterOption><FilterOption id="569" count="2" label="Cardiac failure - Subjects co-morbid with CNS disorders - Subjects co-morbid with cerebrovascular events"></FilterOption><FilterOption id="503" count="2" label="Cardiac failure - Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy"></FilterOption><FilterOption id="653" count="2" label="Cardiac failure - Subjects with Other Non-Cardiovascular Medical Conditions"></FilterOption><FilterOption id="3239" count="2" label="Chronic obstructive pulmonary disease - Protocol Specified Other Exclusion Criteria"></FilterOption><FilterOption id="3058" count="2" label="Chronic obstructive pulmonary disease - Subjects co-morbid with Respiratory Diseases/Disorders"></FilterOption><FilterOption id="3076" count="2" label="Chronic obstructive pulmonary disease - Subjects co-morbid with cardiovascular diseases/disorders"></FilterOption><FilterOption id="1766" count="2" label="Coronary artery disease - Subjects co-morbid with Endocrine/Metabolic Disorders"></FilterOption><FilterOption id="1696" count="2" label="Coronary artery disease - Subjects co-morbid with renal disease/disorder"></FilterOption><FilterOption id="1861" count="2" label="Coronary artery disease - Subjects with Abnormal Laboratory Findings - Abnormal liver function test"></FilterOption><FilterOption id="1858" count="2" label="Coronary artery disease - Subjects with Abnormal Laboratory Findings - Subjects with abnormal renal function tests"></FilterOption><FilterOption id="1851" count="2" label="Coronary artery disease - Subjects with History of/Scheduled for Diagnostic/Therapeutic Procedures - Percutaneous coronary intervention (PCI) - Angioplasty"></FilterOption><FilterOption id="1853" count="2" label="Coronary artery disease - Subjects with History of/Scheduled for Diagnostic/Therapeutic Procedures - Recent history/planned major surgery"></FilterOption><FilterOption id="1880" count="2" label="Coronary artery disease - Subjects with Hypersensitivity/Contraindication to Therapy"></FilterOption><FilterOption id="1820" count="2" label="Coronary artery disease - Subjects with history of/scheduled to receive therapy for other indication"></FilterOption><FilterOption id="17525" count="2" label="End stage renal disease - Subjects co-morbid with Endocrine/Metabolic Disorders - Subjects co-morbid with diabetes mellitus"></FilterOption><FilterOption id="17522" count="2" label="End stage renal disease - Subjects co-morbid with hepatobiliary disorders/diseases"></FilterOption><FilterOption id="17545" count="2" label="End stage renal disease - Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy - Subjects with history of/scheduled for immunomodulators"></FilterOption><FilterOption id="12700" count="2" label="Epilepsy - Subjects with Cluster Seizures"></FilterOption><FilterOption id="12710" count="2" label="Epilepsy - Subjects with Co-morbid Conditions - Subjects with other central nervous system diseases/disorders"></FilterOption><FilterOption id="12751" count="2" label="Epilepsy - Subjects with History/ Scheduled to receive Anti-epileptic Therapy - Subjects with history/ scheduled to receive GABA transaminase inhibitors"></FilterOption><FilterOption id="12754" count="2" label="Epilepsy - Subjects with History/ Scheduled to receive Anti-epileptic Therapy - Subjects with history/ scheduled to receive glutamate blockers"></FilterOption><FilterOption id="12701" count="2" label="Epilepsy - Subjects with Status Epilepticus"></FilterOption><FilterOption id="2689" count="2" label="Hepatitis C virus infection - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="2589" count="2" label="Hepatitis C virus infection - Subjects with Hepatitis C Infection"></FilterOption><FilterOption id="13528" count="2" label="Herpesvirus infection - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="13537" count="2" label="Herpesvirus infection - Subjects with history of/scheduled to receive therapy for other indication"></FilterOption><FilterOption id="6949" count="2" label="HIV infection - Subjects co-morbid with infections - Subjects with HIV-1 infection"></FilterOption><FilterOption id="6951" count="2" label="HIV infection - Subjects with AIDS/AIDS Defining Events"></FilterOption><FilterOption id="6863" count="2" label="HIV infection - Subjects with Abnormal Laboratory Findings - Abnormal liver function test"></FilterOption><FilterOption id="6860" count="2" label="HIV infection - Subjects with Abnormal Laboratory Findings"></FilterOption><FilterOption id="6843" count="2" label="HIV infection - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="6941" count="2" label="HIV infection - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Hypersensitivity/Contraindications to study medications or its excipients"></FilterOption><FilterOption id="6820" count="2" label="HIV infection - Subjects with Opportunistic/Other Infections"></FilterOption><FilterOption id="6968" count="2" label="HIV infection - Subjects with Prior Vaccination - Subjects with prior HIV vaccination"></FilterOption><FilterOption id="6892" count="2" label="HIV infection - Subjects with history of/scheduled to receive therapy for other indication"></FilterOption><FilterOption id="237" count="2" label="Hypertension - Subjects co-morbid with Psychiatric Disease/Disorder"></FilterOption><FilterOption id="43" count="2" label="Hypertension - Subjects co-morbid with cardiovascular diseases/disorders - Subjects co-morbid with coronary artery disease"></FilterOption></Filter><Filter label="Trial Date Enrollment End By Month" name="trialDateEnrollmentEndByMonth" total="42"><FilterOption count="2" label="200603"></FilterOption><FilterOption count="2" label="200801"></FilterOption><FilterOption count="2" label="200802"></FilterOption><FilterOption count="2" label="200903"></FilterOption><FilterOption count="2" label="200911"></FilterOption><FilterOption count="2" label="201109"></FilterOption><FilterOption count="2" label="201208"></FilterOption><FilterOption count="2" label="201209"></FilterOption><FilterOption count="2" label="201703"></FilterOption><FilterOption count="1" label="200512"></FilterOption><FilterOption count="1" label="200601"></FilterOption><FilterOption count="1" label="200606"></FilterOption><FilterOption count="1" label="200610"></FilterOption><FilterOption count="1" label="200712"></FilterOption><FilterOption count="1" label="200809"></FilterOption><FilterOption count="1" label="200812"></FilterOption><FilterOption count="1" label="200909"></FilterOption><FilterOption count="1" label="200910"></FilterOption><FilterOption count="1" label="201012"></FilterOption><FilterOption count="1" label="201105"></FilterOption><FilterOption count="1" label="201107"></FilterOption><FilterOption count="1" label="201201"></FilterOption><FilterOption count="1" label="201207"></FilterOption><FilterOption count="1" label="201212"></FilterOption><FilterOption count="1" label="201302"></FilterOption><FilterOption count="1" label="201304"></FilterOption><FilterOption count="1" label="201305"></FilterOption><FilterOption count="1" label="201307"></FilterOption><FilterOption count="1" label="201311"></FilterOption><FilterOption count="1" label="201402"></FilterOption><FilterOption count="1" label="201408"></FilterOption><FilterOption count="1" label="201501"></FilterOption><FilterOption count="1" label="201503"></FilterOption><FilterOption count="1" label="201504"></FilterOption><FilterOption count="1" label="201506"></FilterOption><FilterOption count="1" label="201507"></FilterOption><FilterOption count="1" label="201512"></FilterOption><FilterOption count="1" label="201603"></FilterOption><FilterOption count="1" label="201609"></FilterOption><FilterOption count="1" label="201610"></FilterOption><FilterOption count="1" label="201706"></FilterOption><FilterOption count="1" label="201801"></FilterOption></Filter><Filter label="Funder Type" name="trialFunderType" total="2"><FilterOption id="CMP" count="99" label="Company"></FilterOption><FilterOption id="ACA" count="6" label="Academic"></FilterOption></Filter><Filter label="Trial Region" name="trialRegions" total="10"><FilterOption id="NSWE" count="99" label="Northern, Southern &amp; Western Europe"></FilterOption><FilterOption id="EEUR" count="67" label="Eastern Europe"></FilterOption><FilterOption id="USCA" count="57" label="US &amp; Canada"></FilterOption><FilterOption id="SOAM" count="43" label="South America"></FilterOption><FilterOption id="AUNZ" count="40" label="Australia &amp; New Zealand"></FilterOption><FilterOption id="MENA" count="35" label="Middle East &amp; North Africa"></FilterOption><FilterOption id="CAAC" count="33" label="Central America &amp; Caribbean"></FilterOption><FilterOption id="EAPO" count="33" label="East Asia &amp; Pacific Ocean"></FilterOption><FilterOption id="CSAF" count="29" label="Central &amp; Southern Africa"></FilterOption><FilterOption id="SOCA" count="14" label="Southern &amp; Central Asia"></FilterOption></Filter><Filter label="Patient Segment Index" name="trialPatientSegmentIndex" total="100"><FilterOption id="145" count="13" label="Non-insulin dependent diabetes - Subjects with Moderate Glycemic Control"></FilterOption><FilterOption id="102" count="11" label="Non-insulin dependent diabetes - Subjects with Good Glycemic Control"></FilterOption><FilterOption id="103" count="11" label="Non-insulin dependent diabetes - Subjects with Poor/Inadequate Glycemic Control"></FilterOption><FilterOption id="7126" count="8" label="HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection"></FilterOption><FilterOption id="1" count="6" label="Hypertension - Subjects with Primary/Essential Hypertension"></FilterOption><FilterOption id="100" count="6" label="Non-insulin dependent diabetes - Subjects on Treatment/Requiring &gt;1 Antidiabetic Agent"></FilterOption><FilterOption id="108" count="6" label="Non-insulin dependent diabetes - Subjects with comorbid conditions - Subjects with obesity"></FilterOption><FilterOption id="11612" count="4" label="Menopause - Subjects with Protocol Specified Menstrual Status - Postmenopausal Subjects"></FilterOption><FilterOption id="144" count="4" label="Non-insulin dependent diabetes - Oral Hypoglycemic Treatment Naive Type 2 Diabetes Subjects"></FilterOption><FilterOption id="7654" count="4" label="Osteoporosis - Subjects with Primary Osteoporosis"></FilterOption><FilterOption id="11963" count="3" label="Asthma - Subjects with History of/Scheduled for Therapy - Subjects with history of/scheduled for asthma drugs"></FilterOption><FilterOption id="11960" count="3" label="Asthma - Subjects with Persistent Asthma - Subjects with mild persistent asthma"></FilterOption><FilterOption id="11961" count="3" label="Asthma - Subjects with Persistent Asthma - Subjects with moderate persistent asthma"></FilterOption><FilterOption id="11962" count="3" label="Asthma - Subjects with Persistent Asthma - Subjects with severe persistent asthma"></FilterOption><FilterOption id="224" count="3" label="Coronary artery disease - Subjects with High Cardiovascular Risk Profile"></FilterOption><FilterOption id="7708" count="3" label="End stage renal disease - Subjects with Diabetes/Diabetic Nephropathy"></FilterOption><FilterOption id="10308" count="3" label="Epilepsy - Subjects with Partial Seizures - Subjects with complex partial seizures"></FilterOption><FilterOption id="10309" count="3" label="Epilepsy - Subjects with Partial Seizures - Subjects with partial seizures with secondary generalization"></FilterOption><FilterOption id="10307" count="3" label="Epilepsy - Subjects with Partial Seizures - Subjects with simple partial seizures"></FilterOption><FilterOption id="10306" count="3" label="Epilepsy - Subjects with Partial Seizures"></FilterOption><FilterOption id="10764" count="3" label="Herpesvirus infection - Subjects with Varicella Zoster Virus Infections - Subjects with shingles/herpes zoster"></FilterOption><FilterOption id="7116" count="3" label="HIV infection - Subjects Refractory/Intolerant to Anti Retroviral Therapy"></FilterOption><FilterOption id="7111" count="3" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent protease inhibitors"></FilterOption><FilterOption id="7108" count="3" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy"></FilterOption><FilterOption id="34" count="3" label="Hypertension - Subjects on Hypertensive Treatment"></FilterOption><FilterOption id="10295" count="3" label="Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with locally advanced/stage III lung cancer"></FilterOption><FilterOption id="3634" count="3" label="Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with metastatic/stage IV lung cancer"></FilterOption><FilterOption id="3617" count="3" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)"></FilterOption><FilterOption id="170" count="3" label="Non-insulin dependent diabetes - Diabetes Mellitus Subjects with CVD Risk Factors"></FilterOption><FilterOption id="97" count="3" label="Non-insulin dependent diabetes - Subjects on Monotherapy"></FilterOption><FilterOption id="106" count="3" label="Non-insulin dependent diabetes - Subjects with comorbid conditions - Subjects with heart disease"></FilterOption><FilterOption id="96" count="3" label="Non-insulin dependent diabetes - Type 2 Diabetes Subjects Controlled by Diet/Exercise"></FilterOption><FilterOption id="7657" count="3" label="Osteoporosis - Subjects with Postmenopausal Osteoporosis"></FilterOption><FilterOption id="8387" count="3" label="Pain - Subjects with Chronic Pain"></FilterOption><FilterOption id="8392" count="3" label="Pain - Subjects with Neuropathic Pain - Subjects with post herpetic neuralgia"></FilterOption><FilterOption id="8668" count="2" label="Bacterial skin infection - Subjects with Complicated Skin and Skin Structure Infections"></FilterOption><FilterOption id="561" count="2" label="Chronic obstructive pulmonary disease - Subjects with GOLD Stage 2/Moderate COPD"></FilterOption><FilterOption id="562" count="2" label="Chronic obstructive pulmonary disease - Subjects with GOLD Stage 3/Severe COPD"></FilterOption><FilterOption id="182" count="2" label="Coronary artery disease - Subjects with Angina"></FilterOption><FilterOption id="225" count="2" label="Coronary artery disease - Subjects with High Cardiovascular Risk Profile - Diabetes mellitus/impaired glucose tolerance"></FilterOption><FilterOption id="180" count="2" label="Coronary artery disease - Subjects with Multiple Vessel CAD"></FilterOption><FilterOption id="7699" count="2" label="End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 2 chronic kidney disease"></FilterOption><FilterOption id="7700" count="2" label="End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 3 chronic kidney disease"></FilterOption><FilterOption id="7755" count="2" label="End stage renal disease - Subjects with Other Cardiac Disease/Associated Nephropathy"></FilterOption><FilterOption id="11420" count="2" label="End stage renal disease - Subjects with Proteinuria/Albuminuria"></FilterOption><FilterOption id="10327" count="2" label="Epilepsy - Subjects with Medically Intractable Epilepsy"></FilterOption><FilterOption id="3778" count="2" label="Head and neck tumor - Subjects with Specific Histological Sub-type of HNC - Subjects with squamous cell carcinoma"></FilterOption><FilterOption id="7487" count="2" label="Hepatitis C virus infection - Subjects Infected with HCV Genotype 1"></FilterOption><FilterOption id="461" count="2" label="Hepatitis C virus infection - Subjects with Chronic Hepatitis C Infection"></FilterOption><FilterOption id="7112" count="2" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent HAART"></FilterOption><FilterOption id="7107" count="2" label="HIV infection - Treatment Naive Subjects"></FilterOption><FilterOption id="6" count="2" label="Hypertension - Subjects with Primary/Essential Hypertension - Subjects with stage 2 (JNC 6) hypertension"></FilterOption><FilterOption id="37" count="2" label="Hypertension - Subjects with Primary/Essential Hypertension - Subjects with stage 3 (JNC 6) hypertension"></FilterOption><FilterOption id="16" count="2" label="Hypertension - Subjects with comorbid conditions - Subjects with type 2 diabetes mellitus"></FilterOption><FilterOption id="33" count="2" label="Hypertension - Treatment Naive Subjects"></FilterOption><FilterOption id="11319" count="2" label="Lipid metabolism disorder - Subjects with Risk Factors for Coronary Heart Disease(CHD)"></FilterOption><FilterOption id="3623" count="2" label="Lung tumor - Subjects with Advanced Stage Lung Cancer"></FilterOption><FilterOption id="12053" count="2" label="Lung tumor - Treatment Naive Subjects"></FilterOption><FilterOption id="11622" count="2" label="Menopause - Subjects with Bone Disorders"></FilterOption><FilterOption id="107" count="2" label="Non-insulin dependent diabetes - Subjects with comorbid conditions - Subjects with hypertension"></FilterOption><FilterOption id="113" count="2" label="Non-insulin dependent diabetes - Subjects with diabetic nephropathy"></FilterOption><FilterOption id="7665" count="2" label="Osteoporosis - Subjects at risk of developing disease - Women at risk of developing osteoporosis"></FilterOption><FilterOption id="8390" count="2" label="Pain - Subjects with Neuropathic Pain"></FilterOption><FilterOption id="8416" count="2" label="Pain - Subjects with Somatic Pain - Subjects with back pain"></FilterOption><FilterOption id="8415" count="2" label="Pain - Subjects with Somatic Pain - Subjects with fibromyalgia"></FilterOption><FilterOption id="502" count="2" label="Rheumatoid arthritis - Active Rheumatoid Arthritis"></FilterOption><FilterOption id="513" count="2" label="Rheumatoid arthritis - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="8169" count="2" label="Urinary tract infection - Subjects with Complicated Urinary Tract Infection"></FilterOption><FilterOption id="9754" count="2" label="Uveitis - Subjects with Non-Infectious Uveitis"></FilterOption><FilterOption id="9743" count="2" label="Uveitis - Subjects with Posterior Uveitis"></FilterOption><FilterOption id="9748" count="2" label="Uveitis - Subjects with specific disease - Subjects with Panuveitis"></FilterOption><FilterOption id="302" count="1" label="Acute coronary syndrome - ST Segment Elevation Myocardial Infarction(STEMI) Subjects"></FilterOption><FilterOption id="383" count="1" label="Ankylosing spondylitis - Active Ankylosing Spondylitis"></FilterOption><FilterOption id="3303" count="1" label="Asthma - Subjects with Stable Asthma"></FilterOption><FilterOption id="3720" count="1" label="Asthma - Subjects with Symptomatic Disease - Subjects with acute/exacerbation of asthma"></FilterOption><FilterOption id="3328" count="1" label="Asthma - Subjects with comorbid conditions - Subjects co-morbid with chronic obstructive pulmonary disease"></FilterOption><FilterOption id="7286" count="1" label="Atrial fibrillation - Atrial fibrillation subjects scheduled for intervention"></FilterOption><FilterOption id="7189" count="1" label="Atrial fibrillation - Subjects at risk of developing disease - Subjects with cardiac intervention"></FilterOption><FilterOption id="7183" count="1" label="Atrial fibrillation - Subjects at risk of developing disease - Subjects with coronary artery disease"></FilterOption><FilterOption id="7191" count="1" label="Atrial fibrillation - Subjects at risk of developing disease - Subjects with diabetes mellitus"></FilterOption><FilterOption id="7188" count="1" label="Atrial fibrillation - Subjects at risk of developing disease - Subjects with other cardiovascular disorders"></FilterOption><FilterOption id="7182" count="1" label="Atrial fibrillation - Subjects at risk of developing disease"></FilterOption><FilterOption id="7204" count="1" label="Atrial fibrillation - Subjects with Nonvalvular Atrial Fibrillation"></FilterOption><FilterOption id="7206" count="1" label="Atrial fibrillation - Subjects with specific disease - Subjects with Other Forms of Atrial Fibrillation"></FilterOption><FilterOption id="8682" count="1" label="Bacterial skin infection - Subjects with Staphylococcal Skin and Skin Structure Infections"></FilterOption><FilterOption id="8687" count="1" label="Bacterial skin infection - Subjects with Treatment Resistant Disease - Subjects with methicillin resistant staphylococcal infections"></FilterOption><FilterOption id="7290" count="1" label="Bipolar disorder - Subjects with Bipolar I Disorder"></FilterOption><FilterOption id="3931" count="1" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Estrogen receptor positive (ER+) breast cancer"></FilterOption><FilterOption id="3932" count="1" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Progesterone receptor positive (PR+) breast cancer"></FilterOption><FilterOption id="3955" count="1" label="Breast tumor - Subjects with Resectable/Operable Breast Cancer"></FilterOption><FilterOption id="8997" count="1" label="Cancer supportive care - Chemotherapy Induced Myelosuppression - Chemotherapy induced thrombocytopenia"></FilterOption><FilterOption id="9009" count="1" label="Cancer supportive care - Hematological cancer subjects for supportive care"></FilterOption><FilterOption id="72" count="1" label="Cardiac failure - Chronic Heart Failure Subjects"></FilterOption><FilterOption id="79" count="1" label="Cardiac failure - Subjects at risk of developing disease - Subjects with coronary artery disease as a risk factor"></FilterOption><FilterOption id="61" count="1" label="Cardiac failure - Subjects with Symptomatic Disease"></FilterOption><FilterOption id="3736" count="1" label="Chronic obstructive pulmonary disease - Subjects at risk of developing disease - Smokers"></FilterOption><FilterOption id="556" count="1" label="Chronic obstructive pulmonary disease - Subjects with Stable COPD"></FilterOption><FilterOption id="574" count="1" label="Chronic obstructive pulmonary disease - Subjects with comorbid conditions - Subjects with asthma"></FilterOption><FilterOption id="10708" count="1" label="Constipation - Elderly Subjects"></FilterOption><FilterOption id="10697" count="1" label="Constipation - Subjects with Opiod Induced Constipation"></FilterOption></Filter><Filter label="Primary Completion Filter by Month" name="trialPrimaryCompletionDateByMonth" total="59"><FilterOption count="3" label="201202"></FilterOption><FilterOption count="3" label="201602"></FilterOption><FilterOption count="2" label="200606"></FilterOption><FilterOption count="2" label="200803"></FilterOption><FilterOption count="2" label="200806"></FilterOption><FilterOption count="2" label="200902"></FilterOption><FilterOption count="2" label="201008"></FilterOption><FilterOption count="2" label="201012"></FilterOption><FilterOption count="2" label="201212"></FilterOption><FilterOption count="2" label="201406"></FilterOption><FilterOption count="2" label="201702"></FilterOption><FilterOption count="2" label="201707"></FilterOption><FilterOption count="2" label="201803"></FilterOption><FilterOption count="1" label="200402"></FilterOption><FilterOption count="1" label="200508"></FilterOption><FilterOption count="1" label="200511"></FilterOption><FilterOption count="1" label="200601"></FilterOption><FilterOption count="1" label="200603"></FilterOption><FilterOption count="1" label="200607"></FilterOption><FilterOption count="1" label="200702"></FilterOption><FilterOption count="1" label="200705"></FilterOption><FilterOption count="1" label="200706"></FilterOption><FilterOption count="1" label="200707"></FilterOption><FilterOption count="1" label="200709"></FilterOption><FilterOption count="1" label="200801"></FilterOption><FilterOption count="1" label="200807"></FilterOption><FilterOption count="1" label="200808"></FilterOption><FilterOption count="1" label="200906"></FilterOption><FilterOption count="1" label="200912"></FilterOption><FilterOption count="1" label="201002"></FilterOption><FilterOption count="1" label="201005"></FilterOption><FilterOption count="1" label="201009"></FilterOption><FilterOption count="1" label="201010"></FilterOption><FilterOption count="1" label="201101"></FilterOption><FilterOption count="1" label="201105"></FilterOption><FilterOption count="1" label="201109"></FilterOption><FilterOption count="1" label="201111"></FilterOption><FilterOption count="1" label="201201"></FilterOption><FilterOption count="1" label="201204"></FilterOption><FilterOption count="1" label="201207"></FilterOption><FilterOption count="1" label="201210"></FilterOption><FilterOption count="1" label="201308"></FilterOption><FilterOption count="1" label="201403"></FilterOption><FilterOption count="1" label="201405"></FilterOption><FilterOption count="1" label="201408"></FilterOption><FilterOption count="1" label="201501"></FilterOption><FilterOption count="1" label="201503"></FilterOption><FilterOption count="1" label="201504"></FilterOption><FilterOption count="1" label="201605"></FilterOption><FilterOption count="1" label="201606"></FilterOption><FilterOption count="1" label="201609"></FilterOption><FilterOption count="1" label="201701"></FilterOption><FilterOption count="1" label="201704"></FilterOption><FilterOption count="1" label="201711"></FilterOption><FilterOption count="1" label="201804"></FilterOption><FilterOption count="1" label="201807"></FilterOption><FilterOption count="1" label="201810"></FilterOption><FilterOption count="1" label="201911"></FilterOption><FilterOption count="1" label="202105"></FilterOption></Filter><Filter label="Trial Country" name="trialCountries" total="79"><FilterOption id="ES" count="99" label="Spain"></FilterOption><FilterOption id="DE" count="63" label="Germany"></FilterOption><FilterOption id="GB" count="56" label="UK"></FilterOption><FilterOption id="PL" count="47" label="Poland"></FilterOption><FilterOption id="US" count="47" label="US"></FilterOption><FilterOption id="FR" count="46" label="France"></FilterOption><FilterOption id="CA" count="45" label="Canada"></FilterOption><FilterOption id="IT" count="44" label="Italy"></FilterOption><FilterOption id="RU" count="41" label="Russian Federation"></FilterOption><FilterOption id="BE" count="40" label="Belgium"></FilterOption><FilterOption id="AU" count="38" label="Australia"></FilterOption><FilterOption id="NL" count="37" label="Netherlands"></FilterOption><FilterOption id="HU" count="35" label="Hungary"></FilterOption><FilterOption id="AR" count="33" label="Argentina"></FilterOption><FilterOption id="CZ" count="32" label="Czech Republic"></FilterOption><FilterOption id="SE" count="31" label="Sweden"></FilterOption><FilterOption id="BR" count="29" label="Brazil"></FilterOption><FilterOption id="MX" count="28" label="Mexico"></FilterOption><FilterOption id="ZA" count="28" label="South Africa"></FilterOption><FilterOption id="AT" count="27" label="Austria"></FilterOption><FilterOption id="GR" count="27" label="Greece"></FilterOption><FilterOption id="BG" count="22" label="Bulgaria"></FilterOption><FilterOption id="DK" count="22" label="Denmark"></FilterOption><FilterOption id="RO" count="22" label="Romania"></FilterOption><FilterOption id="IL" count="21" label="Israel"></FilterOption><FilterOption id="TW" count="21" label="Taiwan"></FilterOption><FilterOption id="PT" count="20" label="Portugal"></FilterOption><FilterOption id="SK" count="19" label="Slovakia"></FilterOption><FilterOption id="TR" count="17" label="Turkey"></FilterOption><FilterOption id="UA" count="17" label="Ukraine"></FilterOption><FilterOption id="HK" count="16" label="Hong Kong"></FilterOption><FilterOption id="KR" count="16" label="South Korea"></FilterOption><FilterOption id="CH" count="16" label="Switzerland"></FilterOption><FilterOption id="CN" count="15" label="China"></FilterOption><FilterOption id="FI" count="15" label="Finland"></FilterOption><FilterOption id="NZ" count="15" label="New Zealand"></FilterOption><FilterOption id="NO" count="15" label="Norway"></FilterOption><FilterOption id="PR" count="15" label="Puerto Rico"></FilterOption><FilterOption id="IN" count="14" label="India"></FilterOption><FilterOption id="MY" count="14" label="Malaysia"></FilterOption><FilterOption id="CL" count="13" label="Chile"></FilterOption><FilterOption id="JP" count="11" label="Japan"></FilterOption><FilterOption id="PH" count="11" label="Philippines"></FilterOption><FilterOption id="TH" count="11" label="Thailand"></FilterOption><FilterOption id="IE" count="10" label="Ireland"></FilterOption><FilterOption id="HR" count="9" label="Croatia"></FilterOption><FilterOption id="LT" count="9" label="Lithuania"></FilterOption><FilterOption id="PE" count="9" label="Peru"></FilterOption><FilterOption id="RS" count="8" label="Serbia"></FilterOption><FilterOption id="CO" count="7" label="Colombia"></FilterOption><FilterOption id="EE" count="7" label="Estonia"></FilterOption><FilterOption id="LV" count="5" label="Latvia"></FilterOption><FilterOption id="SG" count="5" label="Singapore"></FilterOption><FilterOption id="SI" count="4" label="Slovenia"></FilterOption><FilterOption id="GT" count="3" label="Guatemala"></FilterOption><FilterOption id="LB" count="3" label="Lebanon"></FilterOption><FilterOption id="LU" count="3" label="Luxembourg"></FilterOption><FilterOption id="AE" count="3" label="United Arab Emirates"></FilterOption><FilterOption id="VN" count="3" label="Vietnam"></FilterOption><FilterOption id="AM" count="2" label="Armenia"></FilterOption><FilterOption id="BY" count="2" label="Belarus"></FilterOption><FilterOption id="EG" count="2" label="Egypt"></FilterOption><FilterOption id="GE" count="2" label="Georgia"></FilterOption><FilterOption id="IS" count="2" label="Iceland"></FilterOption><FilterOption id="ID" count="2" label="Indonesia"></FilterOption><FilterOption id="TN" count="2" label="Tunisia"></FilterOption><FilterOption id="BD" count="1" label="Bangladesh"></FilterOption><FilterOption id="BA" count="1" label="Bosnia and Herzegovina"></FilterOption><FilterOption id="CM" count="1" label="Cameroon"></FilterOption><FilterOption id="SV" count="1" label="El Salvador"></FilterOption><FilterOption id="X5" count="1" label="Europe"></FilterOption><FilterOption id="JO" count="1" label="Jordan"></FilterOption><FilterOption id="MO" count="1" label="Macau"></FilterOption><FilterOption id="MK" count="1" label="Macedonia, The Former Yugoslav Republic of"></FilterOption><FilterOption id="KP" count="1" label="North Korea"></FilterOption><FilterOption id="PA" count="1" label="Panama"></FilterOption><FilterOption id="SA" count="1" label="Saudi Arabia"></FilterOption><FilterOption id="LK" count="1" label="Sri Lanka"></FilterOption><FilterOption id="VE" count="1" label="Venezuela"></FilterOption></Filter><Filter label="Trial Patient Selection" name="trialTermsPatientSelection" total="15"><FilterOption id="EAMAA" count="96" label="Middle-aged Adults (45-64 yrs)"></FilterOption><FilterOption id="EAAAD" count="95" label="Aged Adults (65-79 yrs)"></FilterOption><FilterOption id="EAYAD" count="84" label="Young Adults (18-44 yrs)"></FilterOption><FilterOption id="EAELD" count="81" label="Elderly Adults (80 and over)"></FilterOption><FilterOption id="EAADL" count="7" label="Adolescents (13-17 yrs)"></FilterOption><FilterOption id="EGMAL" count="5" label="Male"></FilterOption><FilterOption id="EACHI" count="4" label="Children (6-12 yrs)"></FilterOption><FilterOption id="ECEUR" count="4" label="European Ancestry"></FilterOption><FilterOption id="EGFEM" count="4" label="Female"></FilterOption><FilterOption id="EVHVA" count="2" label="Healthy volunteers accepted"></FilterOption><FilterOption id="ECAFR" count="1" label="African Ancestry"></FilterOption><FilterOption id="ECASI" count="1" label="Asian Ancestry"></FilterOption><FilterOption id="EAINF" count="1" label="Infants (6-23 months)"></FilterOption><FilterOption id="EANEW" count="1" label="Newborn Infants (up to 5 months)"></FilterOption><FilterOption id="EAPRE" count="1" label="Preschool Children (2-5 yrs)"></FilterOption></Filter><Filter label="Trial Terms Design" name="trialTermsDesign" total="22"><FilterOption id="SSTINV" count="81" label="Interventional"></FilterOption><FilterOption id="SIPTRE" count="76" label="Treatment"></FilterOption><FilterOption id="SISPRL" count="69" label="Parallel Assignment"></FilterOption><FilterOption id="SIARND" count="67" label="Randomized"></FilterOption><FilterOption id="SIMMBD" count="58" label="Multiple Blind"></FilterOption><FilterOption id="SICPLC" count="42" label="Placebo Control"></FilterOption><FilterOption id="SICACT" count="21" label="Active Control"></FilterOption><FilterOption id="SIMOPN" count="21" label="Open Label"></FilterOption><FilterOption id="SSTOBS" count="18" label="Observational"></FilterOption><FilterOption id="SOSCOH" count="12" label="Cohort"></FilterOption><FilterOption id="SOTPRO" count="12" label="Prospective"></FilterOption><FilterOption id="SIANON" count="9" label="Non-Randomized"></FilterOption><FilterOption id="SISSNG" count="7" label="Single Group Assignment"></FilterOption><FilterOption id="SICNOC" count="6" label="No Control"></FilterOption><FilterOption id="SIPPRE" count="5" label="Prevention"></FilterOption><FilterOption id="SODXSC" count="3" label="Cross-sectional"></FilterOption><FilterOption id="SODLNG" count="3" label="Longitudinal"></FilterOption><FilterOption id="SOTRET" count="3" label="Retrospective"></FilterOption><FilterOption id="SICDSC" count="2" label="Dose Comparison"></FilterOption><FilterOption id="SOSDEF" count="1" label="Defined Population"></FilterOption><FilterOption id="SISEAA" count="1" label="Expanded Access Assignment"></FilterOption><FilterOption id="SICHST" count="1" label="Historical Control"></FilterOption></Filter><Filter label="Trial Source" name="trialSources" total="2"><FilterOption id="CTGOVOTHERS" count="72" label="ClinicalTrials.gov and others"></FilterOption><FilterOption id="CTGOV" count="26" label="ClinicalTrials.gov only"></FilterOption></Filter><Filter label="Trial Actions Secondary Interventions Primary" name="trialActionsSecondaryInterventionsPrimary" total="72"><FilterOption id="1545" count="20" label="Anticancer"></FilterOption><FilterOption id="399" count="17" label="Hypoglycemic agent"></FilterOption><FilterOption id="2953" count="14" label="Anti-inflammatory"></FilterOption><FilterOption id="991" count="12" label="Antiviral"></FilterOption><FilterOption id="70" count="11" label="Anticonvulsant agent"></FilterOption><FilterOption id="2946" count="6" label="Analgesic"></FilterOption><FilterOption id="449" count="6" label="Antiarrhythmic agent"></FilterOption><FilterOption id="2657" count="6" label="Antihypertensive"></FilterOption><FilterOption id="38206" count="6" label="Biguanide antidiabetic product"></FilterOption><FilterOption id="2667" count="5" label="Antiarteriosclerotic"></FilterOption><FilterOption id="659" count="5" label="Coagulation inhibitor"></FilterOption><FilterOption id="1594" count="4" label="Antibacterial"></FilterOption><FilterOption id="2941" count="4" label="Antidepressant"></FilterOption><FilterOption id="89" count="4" label="Bone resorption inhibitor"></FilterOption><FilterOption id="646" count="4" label="Bronchodilator"></FilterOption><FilterOption id="3189" count="4" label="Corticosteroid agonist"></FilterOption><FilterOption id="38439" count="4" label="DPP IV inhibitor antidiabetic product"></FilterOption><FilterOption id="2954" count="4" label="Steroidal anti-inflammatory"></FilterOption><FilterOption id="15187" count="4" label="Systemic dermatological antibacterial product"></FilterOption><FilterOption id="55685" count="3" label="Anticancer monoclonal antibody"></FilterOption><FilterOption id="62255" count="3" label="Anticancer protein kinase inhibitor"></FilterOption><FilterOption id="72" count="3" label="Antihyperlipidemic agent"></FilterOption><FilterOption id="1537" count="3" label="Cephalosporin"></FilterOption><FilterOption id="747" count="3" label="HIV replication inhibitor"></FilterOption><FilterOption id="1615" count="3" label="Neuroprotectant"></FilterOption><FilterOption id="285" count="3" label="Norepinephrine uptake inhibitor"></FilterOption><FilterOption id="12596" count="3" label="Osteoclast inhibitor"></FilterOption><FilterOption id="312" count="3" label="Platelet aggregation inhibitor"></FilterOption><FilterOption id="7292" count="3" label="Vulnerary agent"></FilterOption><FilterOption id="3" count="2" label="5-HT uptake inhibitor"></FilterOption><FilterOption id="71" count="2" label="Antihypercholesterolemic agent"></FilterOption><FilterOption id="2947" count="2" label="Antiparkinsonian"></FilterOption><FilterOption id="1589" count="2" label="Apoptosis stimulator"></FilterOption><FilterOption id="767" count="2" label="Cell cycle inhibitor"></FilterOption><FilterOption id="137" count="2" label="Diuretic agent"></FilterOption><FilterOption id="1332" count="2" label="Gastrointestinal system agent"></FilterOption><FilterOption id="3246" count="2" label="Insulin release stimulator"></FilterOption><FilterOption id="695" count="2" label="Metastasis inhibitor"></FilterOption><FilterOption id="15128" count="2" label="Ophthalmological agent"></FilterOption><FilterOption id="38205" count="2" label="Sulphonylurea antidiabetic product"></FilterOption><FilterOption id="7293" count="2" label="Synergist"></FilterOption><FilterOption id="15184" count="2" label="Systemic antipsoriatic product"></FilterOption><FilterOption id="1532" count="2" label="Viral replication inhibitor"></FilterOption><FilterOption id="38200" count="1" label="Acid pump inhibitor antiulcerant product"></FilterOption><FilterOption id="2970" count="1" label="Anti-emetic"></FilterOption><FilterOption id="50" count="1" label="Anticancer alkylating agent"></FilterOption><FilterOption id="2943" count="1" label="Antipsychotic"></FilterOption><FilterOption id="2942" count="1" label="Anxiolytic"></FilterOption><FilterOption id="104" count="1" label="Bacterial cell wall synthesis inhibitor"></FilterOption><FilterOption id="3984" count="1" label="Bacterial nucleic acid synthesis inhibitor"></FilterOption><FilterOption id="1535" count="1" label="Beta lactam antibiotic"></FilterOption><FilterOption id="2659" count="1" label="Cardioprotectant"></FilterOption><FilterOption id="2939" count="1" label="CNS modulator"></FilterOption><FilterOption id="140" count="1" label="DNA synthesis inhibitor"></FilterOption><FilterOption id="166" count="1" label="Fibrinolysis stimulator"></FilterOption><FilterOption id="1748" count="1" label="Fungicide"></FilterOption><FilterOption id="2491" count="1" label="HDL cholesterol enhancer"></FilterOption><FilterOption id="610" count="1" label="Hematopoietic stimulator"></FilterOption><FilterOption id="32411" count="1" label="Hepatitis B virus replication inhibitor"></FilterOption><FilterOption id="15319" count="1" label="Hepatitis C virus replication inhibitor"></FilterOption><FilterOption id="32415" count="1" label="Influenza A virus replication inhibitor"></FilterOption><FilterOption id="2575" count="1" label="Microtubule inhibitor"></FilterOption><FilterOption id="2576" count="1" label="Microtubule stabilizer"></FilterOption><FilterOption id="1129" count="1" label="Non-steroid hormone receptor antagonist"></FilterOption><FilterOption id="284" count="1" label="Nootropic agent"></FilterOption><FilterOption id="1060" count="1" label="Parathyroid hormone modulator"></FilterOption><FilterOption id="1536" count="1" label="Penicillin"></FilterOption><FilterOption id="439" count="1" label="RNA synthesis inhibitor"></FilterOption><FilterOption id="15190" count="1" label="Systemic dermatological antiviral product"></FilterOption><FilterOption id="2969" count="1" label="Vascular damaging agent"></FilterOption><FilterOption id="388" count="1" label="Vasodilator"></FilterOption><FilterOption id="2660" count="1" label="Vasoprotectant"></FilterOption></Filter><Filter label="Trial Endpoint Achieved" name="trialEndpointsAchieved" total="3"><FilterOption id="UNSPECIFIED" count="34" label="Unspecified"></FilterOption><FilterOption id="YES" count="27" label="Yes"></FilterOption><FilterOption id="NO" count="10" label="No"></FilterOption></Filter><Filter label="Endpoint Index Secondary" name="trialEndpointIndexSecondary" total="100"><FilterOption id="1503" count="7" label="Non-insulin dependent diabetes - Anthropometric Assessments - Assessment of body weight"></FilterOption><FilterOption id="25983" count="7" label="Pain - Assessment of Sleep"></FilterOption><FilterOption id="1626" count="5" label="Non-insulin dependent diabetes - Assessment of Adverse Events"></FilterOption><FilterOption id="1345" count="5" label="Non-insulin dependent diabetes - Glycemic Control Analysis - Assessment of fasting blood glucose"></FilterOption><FilterOption id="25985" count="5" label="Pain - Assessment of Neuropsychological Function - Assessment by Clinical Global Impression (CGI)"></FilterOption><FilterOption id="25986" count="5" label="Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Patient Global Impression Scale (PGI)"></FilterOption><FilterOption id="9213" count="4" label="HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels"></FilterOption><FilterOption id="25" count="4" label="Hypertension - Assessment of Systolic Blood Pressure (SBP) - Seated SBP"></FilterOption><FilterOption id="1561" count="4" label="Non-insulin dependent diabetes - Assessment of Mortality/Death Rates - Cardiovascular mortality"></FilterOption><FilterOption id="2622" count="3" label="Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality"></FilterOption><FilterOption id="22539" count="3" label="End stage renal disease - Assessment of Cardiac Function"></FilterOption><FilterOption id="22596" count="3" label="End stage renal disease - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="17058" count="3" label="Epilepsy - Assessment of Seizure Activity - Assessment of seizure frequency"></FilterOption><FilterOption id="23553" count="3" label="Menopause - Assessment of Bone - Assessment by Bone mineral density (BMD)"></FilterOption><FilterOption id="1548" count="3" label="Non-insulin dependent diabetes - Assessment of Cardiovascular Events - Assessment of myocardial infarction"></FilterOption><FilterOption id="1543" count="3" label="Non-insulin dependent diabetes - Assessment of Cardiovascular Events"></FilterOption><FilterOption id="1535" count="3" label="Non-insulin dependent diabetes - Assessment of Morbidity"></FilterOption><FilterOption id="13771" count="3" label="Osteoporosis - Assessment of Bone - Assessment by Bone mineral density (BMD)"></FilterOption><FilterOption id="25875" count="3" label="Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]"></FilterOption><FilterOption id="26033" count="3" label="Pain - Assessment of adverse events"></FilterOption><FilterOption id="34788" count="3" label="Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Euro Quality of Life (EQ-5D) Questionnaire"></FilterOption><FilterOption id="5985" count="2" label="Asthma - Assessment of Exacerbations - Number/rate/frequency/duration of exacerbation"></FilterOption><FilterOption id="5986" count="2" label="Asthma - Assessment of Exacerbations - Severity of exacerbation"></FilterOption><FilterOption id="6069" count="2" label="Asthma - Assessment of use of Rescue Medication - Frequency/rate of medication use"></FilterOption><FilterOption id="6111" count="2" label="Asthma - Patient Reported Outcomes/Quality of Life Assessments - Asthma control questionnaire (ACQ)"></FilterOption><FilterOption id="14742" count="2" label="Bacterial skin infection - Assessment of Clinical Response - Clinical success/cure"></FilterOption><FilterOption id="14756" count="2" label="Bacterial skin infection - Assessment of Disease Relapse/Recurrence"></FilterOption><FilterOption id="14739" count="2" label="Bacterial skin infection - Assessment of Incidence of Bacterial Skin Infection"></FilterOption><FilterOption id="14771" count="2" label="Bacterial skin infection - Assessment of Laboratory/Diagnostic Measures"></FilterOption><FilterOption id="14751" count="2" label="Bacterial skin infection - Assessment of Microbiological Response - Persistence/colonization"></FilterOption><FilterOption id="14749" count="2" label="Bacterial skin infection - Assessment of Microbiological Response - Super-infection"></FilterOption><FilterOption id="14766" count="2" label="Bacterial skin infection - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="14761" count="2" label="Bacterial skin infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"></FilterOption><FilterOption id="14767" count="2" label="Bacterial skin infection - Assessment of Vital Signs"></FilterOption><FilterOption id="770" count="2" label="Cardiac failure - Assessment of Cardiovascular Events - Worsening of Heart Failure"></FilterOption><FilterOption id="823" count="2" label="Cardiac failure - Assessment of hospitalization - Hospitalization due to other cardiovascular events"></FilterOption><FilterOption id="4526" count="2" label="Chronic obstructive pulmonary disease - Assessment of use of Rescue Medication"></FilterOption><FilterOption id="2634" count="2" label="Coronary artery disease - Assessment of Adverse Events"></FilterOption><FilterOption id="2494" count="2" label="Coronary artery disease - Assessment of Cardiovascular Events - Fatal MI/Non-fatal MI"></FilterOption><FilterOption id="2652" count="2" label="Coronary artery disease - Assessment of Hemorrhagic Complications"></FilterOption><FilterOption id="2515" count="2" label="Coronary artery disease - Assessment of Thrombotic/Thromboembolic Events - Fatal /Non-fatal stroke"></FilterOption><FilterOption id="2775" count="2" label="Coronary artery disease - Assessment of hospitalization - Admissions for CAD and adverse events of CAD"></FilterOption><FilterOption id="11355" count="2" label="Diabetic complication - Assessment of Cardiovascular Events - Assessment of myocardial infarction"></FilterOption><FilterOption id="11369" count="2" label="Diabetic complication - Assessment of Mortality/Death Rates - Cardiovascular mortality"></FilterOption><FilterOption id="11364" count="2" label="Diabetic complication - Assessment of Stroke"></FilterOption><FilterOption id="11376" count="2" label="Diabetic complication - Assessment of hospitalization - Hospitalization due to heart failure"></FilterOption><FilterOption id="22507" count="2" label="End stage renal disease - Assessment of Serum Creatinine"></FilterOption><FilterOption id="22511" count="2" label="End stage renal disease - Assessment of Urinary Protein Excretion/Proteinuria - Assessment of proteinuria/albuminuria/macroalbuminuria"></FilterOption><FilterOption id="22595" count="2" label="End stage renal disease - Assessment of adverse events"></FilterOption><FilterOption id="17073" count="2" label="Epilepsy - Assessment of Partial Seizures"></FilterOption><FilterOption id="17167" count="2" label="Epilepsy - Assessment of Response Rates (RR) - Assessment of response rate"></FilterOption><FilterOption id="7312" count="2" label="Head and neck tumor - Assessment of adverse events"></FilterOption><FilterOption id="16816" count="2" label="Herpesvirus infection - Assessment of Post Herpetic Neuralgia"></FilterOption><FilterOption id="30918" count="2" label="Herpesvirus infection - Patient Reported Outcomes/Quality of Life Assessments - McGill pain questionnaire (SF-MPQ-2)"></FilterOption><FilterOption id="30921" count="2" label="Herpesvirus infection - Patient Reported Outcomes/Quality of Life Assessments - Sleep interference score"></FilterOption><FilterOption id="9215" count="2" label="HIV infection - Assessment of CD4 Cell Responses - Assessment of CD4 cell count/percentage"></FilterOption><FilterOption id="9218" count="2" label="HIV infection - Assessment of Immune Response"></FilterOption><FilterOption id="9246" count="2" label="HIV infection - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="9195" count="2" label="HIV infection - Assessment of virological response"></FilterOption><FilterOption id="78" count="2" label="Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - 24-hour mean ADBP"></FilterOption><FilterOption id="82" count="2" label="Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - Day-time mean ADBP"></FilterOption><FilterOption id="86" count="2" label="Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - Night-time mean ADBP"></FilterOption><FilterOption id="2" count="2" label="Hypertension - Assessment of Blood Pressure (BP) - BP control rate"></FilterOption><FilterOption id="3" count="2" label="Hypertension - Assessment of Blood Pressure (BP) - BP response rate"></FilterOption><FilterOption id="40" count="2" label="Hypertension - Assessment of Diastolic Blood Pressure (DBP) - Seated DBP"></FilterOption><FilterOption id="23556" count="2" label="Menopause - Assessment of Biomarkers - Assessment of bone markers"></FilterOption><FilterOption id="1502" count="2" label="Non-insulin dependent diabetes - Anthropometric Assessments - Assessment of BMI"></FilterOption><FilterOption id="1395" count="2" label="Non-insulin dependent diabetes - Assessment of Beta Cell Function - Homeostasis model assessment (HOMA)- beta cell function Index (HOMA-B)"></FilterOption><FilterOption id="1389" count="2" label="Non-insulin dependent diabetes - Assessment of Beta Cell Function"></FilterOption><FilterOption id="1580" count="2" label="Non-insulin dependent diabetes - Assessment of Blood Pressure (BP)"></FilterOption><FilterOption id="1544" count="2" label="Non-insulin dependent diabetes - Assessment of Cardiovascular Events - Angina pectoris"></FilterOption><FilterOption id="1429" count="2" label="Non-insulin dependent diabetes - Assessment of Inflammatory &amp; Oxidative Stress Markers - High-sensitivity C-reactive protein (hsCRP)"></FilterOption><FilterOption id="1365" count="2" label="Non-insulin dependent diabetes - Assessment of Insulin Levels - Proinsulin/insulin ratio"></FilterOption><FilterOption id="1624" count="2" label="Non-insulin dependent diabetes - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="1611" count="2" label="Non-insulin dependent diabetes - Assessment of Serum Creatinine"></FilterOption><FilterOption id="1540" count="2" label="Non-insulin dependent diabetes - Assessment of Stroke"></FilterOption><FilterOption id="1579" count="2" label="Non-insulin dependent diabetes - Assessment of Vital Signs"></FilterOption><FilterOption id="1557" count="2" label="Non-insulin dependent diabetes - Assessment of hospitalization - Hospitalization due to heart failure"></FilterOption><FilterOption id="1451" count="2" label="Non-insulin dependent diabetes - Assessment of lipid profiles"></FilterOption><FilterOption id="1346" count="2" label="Non-insulin dependent diabetes - Glycemic Control Analysis - Assessment of postprandial glucose"></FilterOption><FilterOption id="13795" count="2" label="Osteoporosis - Assessment of Bone Resorption Markers - Serum and urinary collagen type I cross-linked C-terminal telopeptide(CTX)"></FilterOption><FilterOption id="25874" count="2" label="Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]"></FilterOption><FilterOption id="26038" count="2" label="Pain - Assessment of Therapy Related Outcomes"></FilterOption><FilterOption id="25992" count="2" label="Pain - Assessment of Underlying Conditions - Musculoskeletal disease related outcomes"></FilterOption><FilterOption id="34873" count="2" label="Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Hospital Anxiety and Depression Scale (HADS)"></FilterOption><FilterOption id="34812" count="2" label="Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-36)"></FilterOption><FilterOption id="43315" count="2" label="Respiratory syncytial virus infection - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="43738" count="2" label="Respiratory syncytial virus infection - Assessment of adverse events"></FilterOption><FilterOption id="24177" count="2" label="Stroke - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="2999" count="1" label="Acute coronary syndrome - Assessment of Co-morbidity"></FilterOption><FilterOption id="3013" count="1" label="Acute coronary syndrome - Assessment of Hemorrhagic Complications"></FilterOption><FilterOption id="2941" count="1" label="Acute coronary syndrome - Assessment of Therapy Related Outcomes - Safety parameters"></FilterOption><FilterOption id="3167" count="1" label="Ankylosing spondylitis - Assessment of Functional Disability/Physical Function - Bath ankylosing spondylitis functional index (BASFI)"></FilterOption><FilterOption id="3146" count="1" label="Ankylosing spondylitis - Assessment of Pain - Numeric rating scale (NRS)"></FilterOption><FilterOption id="3178" count="1" label="Ankylosing spondylitis - Patient Reported Outcomes/Quality of Life Assessments - Patient Global Assessment of Disease Activity"></FilterOption><FilterOption id="3201" count="1" label="Ankylosing spondylitis - Response to Therapy (ASAS criteria) - Percentages of patients achieving ASAS20"></FilterOption><FilterOption id="3204" count="1" label="Ankylosing spondylitis - Response to Therapy (ASAS criteria) - Percentages of patients achieving ASAS40"></FilterOption><FilterOption id="3186" count="1" label="Ankylosing spondylitis - Response to Therapy (BASDAI criteria)"></FilterOption><FilterOption id="5984" count="1" label="Asthma - Assessment of Exacerbations - Exacerbation requiring hospitalization"></FilterOption><FilterOption id="5983" count="1" label="Asthma - Assessment of Exacerbations"></FilterOption></Filter><Filter label="Biomarker" name="trialBiomarkerNames" total="100"><FilterOption id="289" count="16" label="Hemoglobin A, glycosylated"></FilterOption><FilterOption id="332" count="15" label="Diastolic blood pressure"></FilterOption><FilterOption id="330" count="15" label="Systolic blood pressure"></FilterOption><FilterOption id="12058" count="15" label="Total body mass"></FilterOption><FilterOption id="2586" count="14" label="Blood pressure"></FilterOption><FilterOption id="213" count="13" label="Creatinine"></FilterOption><FilterOption id="1735" count="13" label="Glucose"></FilterOption><FilterOption id="1904" count="11" label="Heart rate"></FilterOption><FilterOption id="153" count="11" label="High-density lipoprotein cholesterol"></FilterOption><FilterOption id="152" count="11" label="Low-density lipoprotein cholesterol"></FilterOption><FilterOption id="133" count="11" label="Total cholesterol"></FilterOption><FilterOption id="217" count="10" label="Triglycerides"></FilterOption><FilterOption id="7895" count="9" label="Estimated glomerular filtration rate"></FilterOption><FilterOption id="118" count="8" label="Albumin"></FilterOption><FilterOption id="113" count="8" label="Body Mass Index"></FilterOption><FilterOption id="46" count="7" label="C-reactive protein"></FilterOption><FilterOption id="1211" count="6" label="Alanine transaminase"></FilterOption><FilterOption id="1236" count="6" label="Hemoglobin"></FilterOption><FilterOption id="2527" count="5" label="Aspartate aminotransferase"></FilterOption><FilterOption id="2054" count="5" label="Blood platelets"></FilterOption><FilterOption id="1183" count="5" label="Urinary albumin to creatinine ratio"></FilterOption><FilterOption id="418" count="5" label="Waist circumference"></FilterOption><FilterOption id="28899" count="4" label="Alkaline phosphatase"></FilterOption><FilterOption id="2387" count="4" label="Bilirubin"></FilterOption><FilterOption id="44216" count="4" label="Body temperature"></FilterOption><FilterOption id="2713" count="4" label="Forced expiratory volume"></FilterOption><FilterOption id="2098" count="4" label="Potassium"></FilterOption><FilterOption id="288" count="4" label="Uric acid"></FilterOption><FilterOption id="215" count="3" label="Apolipoprotein B-100"></FilterOption><FilterOption id="17697" count="3" label="Body height"></FilterOption><FilterOption id="7938" count="3" label="Conserved oligomeric Golgi complex subunit 2"></FilterOption><FilterOption id="8" count="3" label="Epidermal growth factor receptor"></FilterOption><FilterOption id="1221" count="3" label="Hematocrit"></FilterOption><FilterOption id="44218" count="3" label="Human immunodeficiency virus RNA"></FilterOption><FilterOption id="2662" count="3" label="Sodium"></FilterOption><FilterOption id="1857" count="3" label="T-cell surface glycoprotein CD4"></FilterOption><FilterOption id="1880" count="3" label="T-Helper Lymphocytes"></FilterOption><FilterOption id="172" count="2" label="Adiponectin"></FilterOption><FilterOption id="2102" count="2" label="Arterial stiffness"></FilterOption><FilterOption id="4529" count="2" label="Bicarbonates"></FilterOption><FilterOption id="7586" count="2" label="Body fat percentage"></FilterOption><FilterOption id="3374" count="2" label="Bone mineral density"></FilterOption><FilterOption id="130" count="2" label="C-C motif chemokine 2"></FilterOption><FilterOption id="2417" count="2" label="Calcium"></FilterOption><FilterOption id="483" count="2" label="Collagen type I trimeric cross-linked peptide"></FilterOption><FilterOption id="8024" count="2" label="Creatine kinase"></FilterOption><FilterOption id="781" count="2" label="Erythrocyte sedimentation rate"></FilterOption><FilterOption id="45698" count="2" label="Fat mass"></FilterOption><FilterOption id="49662" count="2" label="Femoral neck bone mineral density"></FilterOption><FilterOption id="1912" count="2" label="Forced Vital Capacity"></FilterOption><FilterOption id="9815" count="2" label="Hip circumference"></FilterOption><FilterOption id="808" count="2" label="Insulin"></FilterOption><FilterOption id="176" count="2" label="Interleukin-6"></FilterOption><FilterOption id="10753" count="2" label="Intraocular pressure"></FilterOption><FilterOption id="303" count="2" label="Leptin"></FilterOption><FilterOption id="14767" count="2" label="Lipids"></FilterOption><FilterOption id="48953" count="2" label="Lumbar spine bone mineral density"></FilterOption><FilterOption id="106" count="2" label="N-terminal Pro Brain Natriuretic Peptide"></FilterOption><FilterOption id="1925" count="2" label="Neutrophils"></FilterOption><FilterOption id="2053" count="2" label="Non-high density lipoprotein cholesterol"></FilterOption><FilterOption id="420" count="2" label="Nonesterified fatty acids"></FilterOption><FilterOption id="2382" count="2" label="Phosphorus"></FilterOption><FilterOption id="10260" count="2" label="Respiratory frequency"></FilterOption><FilterOption id="12516" count="2" label="Urinary protein"></FilterOption><FilterOption id="18315" count="2" label="Visual acuity"></FilterOption><FilterOption id="2864" count="1" label="Aldosterone"></FilterOption><FilterOption id="450" count="1" label="Alkaline phosphatase, tissue-nonspecific isozyme"></FilterOption><FilterOption id="6993" count="1" label="Alpha-amylase 1"></FilterOption><FilterOption id="146" count="1" label="Ankle-brachial index"></FilterOption><FilterOption id="214" count="1" label="Apolipoprotein A-I"></FilterOption><FilterOption id="449" count="1" label="Apolipoprotein C-III"></FilterOption><FilterOption id="150" count="1" label="Apolipoprotein(a)"></FilterOption><FilterOption id="434" count="1" label="Appetite regulating hormone"></FilterOption><FilterOption id="1913" count="1" label="Arterial oxygen saturation"></FilterOption><FilterOption id="1175" count="1" label="B-lymphocyte antigen CD19"></FilterOption><FilterOption id="6663" count="1" label="B-lymphocytes"></FilterOption><FilterOption id="5234" count="1" label="Body surface area"></FilterOption><FilterOption id="22086" count="1" label="Bone strength"></FilterOption><FilterOption id="425" count="1" label="C-peptide"></FilterOption><FilterOption id="30391" count="1" label="C-terminal telopeptide of collagen type I"></FilterOption><FilterOption id="1005" count="1" label="C-X-C motif chemokine 10"></FilterOption><FilterOption id="2245" count="1" label="CD27 antigen"></FilterOption><FilterOption id="802" count="1" label="Complement C3"></FilterOption><FilterOption id="484" count="1" label="Complement C4"></FilterOption><FilterOption id="5016" count="1" label="Creatine"></FilterOption><FilterOption id="120" count="1" label="Cystatin C"></FilterOption><FilterOption id="183" count="1" label="D-dimer"></FilterOption><FilterOption id="2196" count="1" label="E/E'-wave ratio"></FilterOption><FilterOption id="248" count="1" label="Eosinophils"></FilterOption><FilterOption id="4522" count="1" label="Erythrocytes"></FilterOption><FilterOption id="5326" count="1" label="Estradiol"></FilterOption><FilterOption id="25891" count="1" label="Fat-free mass index"></FilterOption><FilterOption id="2200" count="1" label="Fibroblast growth factor 23"></FilterOption><FilterOption id="2029" count="1" label="Forced expiratory flow"></FilterOption><FilterOption id="30834" count="1" label="Fractional concentration of exhaled nitric oxide"></FilterOption><FilterOption id="192" count="1" label="Galectin-3"></FilterOption><FilterOption id="8458" count="1" label="gamma-Glutamyltransferase"></FilterOption><FilterOption id="3" count="1" label="HER2"></FilterOption><FilterOption id="13886" count="1" label="Homeostasis model assessment Beta cell function"></FilterOption><FilterOption id="3044" count="1" label="Homeostasis model assessment insulin resistance"></FilterOption></Filter><Filter label="Trial Terms Endpoint" name="trialTermsEndpoint" total="4"><FilterOption id="SIEEFC" count="80" label="Efficacy"></FilterOption><FilterOption id="SIESFT" count="78" label="Safety"></FilterOption><FilterOption id="SIEPCK" count="22" label="Pharmacokinetics"></FilterOption><FilterOption id="SIEPCD" count="11" label="Pharmacodynamics"></FilterOption></Filter><Filter label="Trial Interventions Primary In Regimen Name Display" name="trialInterventionsPrimaryInRegimenNameDisplay" total="50"><FilterOption id="6050" count="6" label="metformin hydrochloride"></FilterOption><FilterOption id="32981" count="4" label="darunavir"></FilterOption><FilterOption id="7310" count="4" label="ritonavir"></FilterOption><FilterOption id="55852" count="3" label="linagliptin"></FilterOption><FilterOption id="10172" count="2" label="efavirenz"></FilterOption><FilterOption id="4728" count="2" label="emtricitabine"></FilterOption><FilterOption id="30682" count="2" label="etravirine"></FilterOption><FilterOption id="3474" count="2" label="lamivudine"></FilterOption><FilterOption id="4126" count="2" label="pioglitazone"></FilterOption><FilterOption id="54488" count="2" label="raltegravir"></FilterOption><FilterOption id="6242" count="1" label="abacavir"></FilterOption><FilterOption id="52209" count="1" label="avibactam sodium + ceftazidime (iv, urinary tract infection), AstraZeneca/Allergan"></FilterOption><FilterOption id="57592" count="1" label="canagliflozin"></FilterOption><FilterOption id="44383" count="1" label="carboplatin"></FilterOption><FilterOption id="44438" count="1" label="ciprofloxacin hydrochloride"></FilterOption><FilterOption id="2836" count="1" label="clopidogrel"></FilterOption><FilterOption id="52192" count="1" label="dapagliflozin propanediol"></FilterOption><FilterOption id="2953" count="1" label="docetaxel"></FilterOption><FilterOption id="59062" count="1" label="dolutegravir"></FilterOption><FilterOption id="58762" count="1" label="empagliflozin"></FilterOption><FilterOption id="13928" count="1" label="enoxaparin sodium"></FilterOption><FilterOption id="4414" count="1" label="eprosartan"></FilterOption><FilterOption id="11603" count="1" label="gefitinib"></FilterOption><FilterOption id="46890" count="1" label="glibenclamide"></FilterOption><FilterOption id="8832" count="1" label="glimepiride"></FilterOption><FilterOption id="45998" count="1" label="interferon alfa-2b"></FilterOption><FilterOption id="48181" count="1" label="lamivudine + abacavir, GlaxoSmithKline"></FilterOption><FilterOption id="5148" count="1" label="liraglutide"></FilterOption><FilterOption id="14681" count="1" label="lopinavir + ritonavir"></FilterOption><FilterOption id="6168" count="1" label="moxonidine"></FilterOption><FilterOption id="33451" count="1" label="muraglitazar"></FilterOption><FilterOption id="54142" count="1" label="NAHE-001"></FilterOption><FilterOption id="13460" count="1" label="oseltamivir"></FilterOption><FilterOption id="3803" count="1" label="paclitaxel"></FilterOption><FilterOption id="72787" count="1" label="pimodivir"></FilterOption><FilterOption id="3317" count="1" label="quetiapine IR"></FilterOption><FilterOption id="4196" count="1" label="ramipril"></FilterOption><FilterOption id="5369" count="1" label="ribavirin"></FilterOption><FilterOption id="56791" count="1" label="tapentadol (sustained release, pain) J&amp;J PRD/Grunenthal"></FilterOption><FilterOption id="10096" count="1" label="telaprevir"></FilterOption><FilterOption id="5051" count="1" label="telmisartan"></FilterOption><FilterOption id="9032" count="1" label="tenecteplase"></FilterOption><FilterOption id="49219" count="1" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"></FilterOption><FilterOption id="14493" count="1" label="tenofovir disoproxil fumarate"></FilterOption><FilterOption id="12731" count="1" label="tipranavir"></FilterOption><FilterOption id="44363" count="1" label="trimethoprim + sulphamethoxazole"></FilterOption><FilterOption id="12551" count="1" label="vadimezan"></FilterOption><FilterOption id="5265" count="1" label="valproic acid (oral extended-release), Sanofi"></FilterOption><FilterOption id="44316" count="1" label="zidovudine"></FilterOption><FilterOption id="2765" count="1" label="zoledronic acid"></FilterOption></Filter><Filter label="Trial Document Source" name="trialDocumentSource" total="5"><FilterOption id="SERIAL" count="50" label="Serial Publications"></FilterOption><FilterOption id="PR" count="42" label="Press Releases"></FilterOption><FilterOption id="OTHER" count="39" label="Other Publications"></FilterOption><FilterOption id="CONFERENCE" count="9" label="Conference Reports"></FilterOption><FilterOption id="CORPORATE" count="7" label="Corporate Publications"></FilterOption></Filter><Filter label="Trial Interventions Primary Alone Name Display" name="trialInterventionsPrimaryAloneNameDisplay" total="62"><FilterOption id="30712" count="4" label="budesonide + formoterol fumarate, AstraZeneca"></FilterOption><FilterOption id="21038" count="3" label="lacosamide"></FilterOption><FilterOption id="32677" count="3" label="rivaroxaban"></FilterOption><FilterOption id="57592" count="2" label="canagliflozin"></FilterOption><FilterOption id="42107" count="2" label="ceftaroline fosamil"></FilterOption><FilterOption id="21138" count="2" label="certolizumab pegol"></FilterOption><FilterOption id="58762" count="2" label="empagliflozin"></FilterOption><FilterOption id="11603" count="2" label="gefitinib"></FilterOption><FilterOption id="54374" count="2" label="gevokizumab"></FilterOption><FilterOption id="6050" count="2" label="metformin hydrochloride"></FilterOption><FilterOption id="68827" count="2" label="mirogabalin besylate"></FilterOption><FilterOption id="65375" count="2" label="topiramate (extended-release, epilepsy), Upsher-Smith"></FilterOption><FilterOption id="54449" count="1" label="afatinib"></FilterOption><FilterOption id="61090" count="1" label="amlodipine + telmisartan"></FilterOption><FilterOption id="3321" count="1" label="anastrozole"></FilterOption><FilterOption id="2807" count="1" label="atorvastatin"></FilterOption><FilterOption id="75656" count="1" label="BI-655064"></FilterOption><FilterOption id="3311" count="1" label="bicalutamide"></FilterOption><FilterOption id="37592" count="1" label="brivaracetam"></FilterOption><FilterOption id="16242" count="1" label="cinacalcet"></FilterOption><FilterOption id="52192" count="1" label="dapagliflozin propanediol"></FilterOption><FilterOption id="2910" count="1" label="dapoxetine"></FilterOption><FilterOption id="53200" count="1" label="daratumumab"></FilterOption><FilterOption id="51255" count="1" label="edoxaban"></FilterOption><FilterOption id="10606" count="1" label="eltrombopag"></FilterOption><FilterOption id="11961" count="1" label="erlotinib"></FilterOption><FilterOption id="16026" count="1" label="esomeprazole"></FilterOption><FilterOption id="30682" count="1" label="etravirine"></FilterOption><FilterOption id="13572" count="1" label="exenatide"></FilterOption><FilterOption id="17558" count="1" label="fluoxetine hydrochloride"></FilterOption><FilterOption id="64299" count="1" label="icotinib hydrochloride"></FilterOption><FilterOption id="45998" count="1" label="interferon alfa-2b"></FilterOption><FilterOption id="4469" count="1" label="irbesartan"></FilterOption><FilterOption id="5665" count="1" label="levetiracetam (oral), UCB"></FilterOption><FilterOption id="55852" count="1" label="linagliptin"></FilterOption><FilterOption id="77091" count="1" label="lumicitabine"></FilterOption><FilterOption id="33451" count="1" label="muraglitazar"></FilterOption><FilterOption id="101092" count="1" label="naloxone (prolonged-release tablet, opioid induced constipation), Algobate"></FilterOption><FilterOption id="59553" count="1" label="olmesartan + amlodipine + hydrochlorothiazide (hypertension), Daiichi Sankyo"></FilterOption><FilterOption id="55609" count="1" label="olmesartan medoxomil + amlodipine besylate (hypertension), Daiichi Sankyo"></FilterOption><FilterOption id="46939" count="1" label="olmesartan medoxomil + hydrochlorothiazide (hypertension), Sankyo"></FilterOption><FilterOption id="8946" count="1" label="olmesartan medoxomil"></FilterOption><FilterOption id="13460" count="1" label="oseltamivir"></FilterOption><FilterOption id="16250" count="1" label="PD-217014"></FilterOption><FilterOption id="41705" count="1" label="perampanel"></FilterOption><FilterOption id="4126" count="1" label="pioglitazone"></FilterOption><FilterOption id="29446" count="1" label="piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho"></FilterOption><FilterOption id="4151" count="1" label="pramipexole"></FilterOption><FilterOption id="17814" count="1" label="pregabalin"></FilterOption><FilterOption id="6681" count="1" label="raloxifene"></FilterOption><FilterOption id="4196" count="1" label="ramipril"></FilterOption><FilterOption id="4234" count="1" label="risedronate sodium"></FilterOption><FilterOption id="44417" count="1" label="saxagliptin"></FilterOption><FilterOption id="9742" count="1" label="sodium oxybate"></FilterOption><FilterOption id="4433" count="1" label="somatropin, Horizon Pharma"></FilterOption><FilterOption id="91054" count="1" label="suptavumab"></FilterOption><FilterOption id="56791" count="1" label="tapentadol (sustained release, pain) J&amp;J PRD/Grunenthal"></FilterOption><FilterOption id="5051" count="1" label="telmisartan"></FilterOption><FilterOption id="36332" count="1" label="ticagrelor"></FilterOption><FilterOption id="51186" count="1" label="torcetrapib + atorvastatin"></FilterOption><FilterOption id="4648" count="1" label="venlafaxine hydrochloride"></FilterOption><FilterOption id="2765" count="1" label="zoledronic acid"></FilterOption></Filter><Filter label="Trial Interventions Control In Regimen Name Display" name="trialInterventionsControlInRegimenNameDisplay" total="22"><FilterOption id="32981" count="2" label="darunavir"></FilterOption><FilterOption id="6050" count="2" label="metformin hydrochloride"></FilterOption><FilterOption id="7310" count="2" label="ritonavir"></FilterOption><FilterOption id="44401" count="2" label="vancomycin"></FilterOption><FilterOption id="6242" count="1" label="abacavir"></FilterOption><FilterOption id="2500" count="1" label="amlodipine"></FilterOption><FilterOption id="44438" count="1" label="ciprofloxacin hydrochloride"></FilterOption><FilterOption id="8399" count="1" label="doripenem"></FilterOption><FilterOption id="4728" count="1" label="emtricitabine"></FilterOption><FilterOption id="13928" count="1" label="enoxaparin sodium"></FilterOption><FilterOption id="14336" count="1" label="fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline"></FilterOption><FilterOption id="8832" count="1" label="glimepiride"></FilterOption><FilterOption id="3474" count="1" label="lamivudine"></FilterOption><FilterOption id="17814" count="1" label="pregabalin"></FilterOption><FilterOption id="4196" count="1" label="ramipril"></FilterOption><FilterOption id="56791" count="1" label="tapentadol (sustained release, pain) J&amp;J PRD/Grunenthal"></FilterOption><FilterOption id="5051" count="1" label="telmisartan"></FilterOption><FilterOption id="14493" count="1" label="tenofovir disoproxil fumarate"></FilterOption><FilterOption id="44363" count="1" label="trimethoprim + sulphamethoxazole"></FilterOption><FilterOption id="44375" count="1" label="warfarin"></FilterOption><FilterOption id="44316" count="1" label="zidovudine"></FilterOption><FilterOption id="2765" count="1" label="zoledronic acid"></FilterOption></Filter><Filter label="Trial Category" name="trialCategory" total="9"><FilterOption id="4" count="83" label="Small molecule"></FilterOption><FilterOption id="3" count="15" label="Biological"></FilterOption><FilterOption id="11" count="2" label="Dietary supplement"></FilterOption><FilterOption id="9" count="2" label="Medical procedure"></FilterOption><FilterOption id="16" count="1" label="Behavioral intervention"></FilterOption><FilterOption id="17" count="1" label="Biomarker identification"></FilterOption><FilterOption id="14" count="1" label="Diagnostic"></FilterOption><FilterOption id="12" count="1" label="Herbal preparation"></FilterOption><FilterOption id="18" count="1" label="Pathophysiology"></FilterOption></Filter><Filter label="Trial Outcome Available" name="trialOutcomesAvailable" total="2"><FilterOption id="YES" count="71" label="Yes"></FilterOption><FilterOption id="NO" count="28" label="No"></FilterOption></Filter><Filter label="Trial Actions Primary Interventions Primary" name="trialActionsPrimaryInterventionsPrimary" total="82"><FilterOption id="4020" count="7" label="Sodium glucose transporter-2 inhibitor"></FilterOption><FilterOption id="8805" count="6" label="AMP activated protein kinase stimulator"></FilterOption><FilterOption id="204" count="5" label="HIV protease inhibitor"></FilterOption><FilterOption id="768" count="5" label="HIV-1 protease inhibitor"></FilterOption><FilterOption id="1919" count="5" label="Insulin sensitizer"></FilterOption><FilterOption id="788" count="4" label="Angiotensin II AT-1 receptor antagonist"></FilterOption><FilterOption id="64" count="4" label="Angiotensin II receptor antagonist"></FilterOption><FilterOption id="40" count="4" label="Beta 2 adrenoceptor agonist"></FilterOption><FilterOption id="7424" count="4" label="Cytochrome P450 3A4 inhibitor"></FilterOption><FilterOption id="5537" count="4" label="Dipeptidyl peptidase IV inhibitor"></FilterOption><FilterOption id="120" count="4" label="Factor Xa antagonist"></FilterOption><FilterOption id="173" count="4" label="GABA receptor agonist"></FilterOption><FilterOption id="1016" count="4" label="HIV-1 reverse transcriptase inhibitor"></FilterOption><FilterOption id="2480" count="4" label="PPAR gamma agonist"></FilterOption><FilterOption id="33447" count="3" label="Dihydropyrimidinase related protein 2 modulator"></FilterOption><FilterOption id="3754" count="3" label="EGFR family tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="1833" count="3" label="Non-nucleoside reverse transcriptase inhibitor"></FilterOption><FilterOption id="1832" count="3" label="Nucleoside reverse transcriptase inhibitor"></FilterOption><FilterOption id="498" count="3" label="Sodium channel inhibitor"></FilterOption><FilterOption id="1103" count="3" label="Sodium channel modulator"></FilterOption><FilterOption id="86" count="2" label="Beta lactamase inhibitor"></FilterOption><FilterOption id="50877" count="2" label="CACNA2D1 calcium channel subunit stimulator"></FilterOption><FilterOption id="93" count="2" label="Calcium channel inhibitor"></FilterOption><FilterOption id="138" count="2" label="DNA polymerase inhibitor"></FilterOption><FilterOption id="2585" count="2" label="Glucagon-like peptide 1 receptor agonist"></FilterOption><FilterOption id="7588" count="2" label="HIV-1 integrase inhibitor"></FilterOption><FilterOption id="205" count="2" label="HMG CoA reductase inhibitor"></FilterOption><FilterOption id="12479" count="2" label="Interleukin-1 beta ligand inhibitor"></FilterOption><FilterOption id="281" count="2" label="NMDA receptor antagonist"></FilterOption><FilterOption id="293" count="2" label="Opioid receptor mu agonist"></FilterOption><FilterOption id="4913" count="2" label="P2Y12 purinoceptor antagonist"></FilterOption><FilterOption id="66352" count="2" label="Penicillin binding protein 2X inhibitor"></FilterOption><FilterOption id="3033" count="2" label="PPAR alpha agonist"></FilterOption><FilterOption id="551" count="2" label="RNA DNA polymerase inhibitor"></FilterOption><FilterOption id="15477" count="2" label="Synaptic vesicle glycoprotein 2A modulator"></FilterOption><FilterOption id="381" count="2" label="TNF alpha ligand inhibitor"></FilterOption><FilterOption id="511" count="2" label="TNF antagonist"></FilterOption><FilterOption id="721" count="2" label="TNF binding agent"></FilterOption><FilterOption id="13" count="1" label="5-HT 2 receptor antagonist"></FilterOption><FilterOption id="18" count="1" label="ACE inhibitor"></FilterOption><FilterOption id="5136" count="1" label="ADP ribosyl cyclase-1 inhibitor"></FilterOption><FilterOption id="33" count="1" label="Alpha 2 adrenoceptor agonist"></FilterOption><FilterOption id="53" count="1" label="AMPA receptor antagonist"></FilterOption><FilterOption id="60" count="1" label="Androgen receptor antagonist"></FilterOption><FilterOption id="76" count="1" label="Aromatase inhibitor"></FilterOption><FilterOption id="50960" count="1" label="CACNA2D calcium channel subunit modulator"></FilterOption><FilterOption id="5142" count="1" label="CD40 ligand receptor antagonist"></FilterOption><FilterOption id="7735" count="1" label="CDKN1A gene modulator"></FilterOption><FilterOption id="742" count="1" label="Cholesterol ester transfer protein inhibitor"></FilterOption><FilterOption id="135" count="1" label="DHFR inhibitor"></FilterOption><FilterOption id="431" count="1" label="DNA gyrase inhibitor"></FilterOption><FilterOption id="150" count="1" label="Dopamine D2 receptor antagonist"></FilterOption><FilterOption id="779" count="1" label="Dopamine D3 receptor agonist"></FilterOption><FilterOption id="740" count="1" label="Epidermal growth factor receptor antagonist"></FilterOption><FilterOption id="7125" count="1" label="Epoxide hydrolase inhibitor"></FilterOption><FilterOption id="3756" count="1" label="Erbb2 tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="3758" count="1" label="Erbb3 tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="3760" count="1" label="Erbb4 tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="846" count="1" label="Estrogen receptor modulator"></FilterOption><FilterOption id="447" count="1" label="Exo-alpha sialidase inhibitor"></FilterOption><FilterOption id="13379" count="1" label="Extracellular calcium sensing receptor agonist"></FilterOption><FilterOption id="17216" count="1" label="GABA A receptor alpha-2 subunit modulator"></FilterOption><FilterOption id="17217" count="1" label="GABA A receptor alpha-2 subunit stimulator"></FilterOption><FilterOption id="17246" count="1" label="GABA A receptor delta subunit modulator"></FilterOption><FilterOption id="17247" count="1" label="GABA A receptor delta subunit stimulator"></FilterOption><FilterOption id="177" count="1" label="GABA B receptor agonist"></FilterOption><FilterOption id="21072" count="1" label="Growth hormone ligand"></FilterOption><FilterOption id="208" count="1" label="H+ K+ ATPase inhibitor"></FilterOption><FilterOption id="12349" count="1" label="Hepatitis C virus NS3 protease inhibitor"></FilterOption><FilterOption id="1691" count="1" label="Imidazoline receptor agonist"></FilterOption><FilterOption id="62384" count="1" label="Influenza polymerase basic protein 2 inhibitor"></FilterOption><FilterOption id="51174" count="1" label="Interferon alpha 5 ligand"></FilterOption><FilterOption id="917" count="1" label="Interferon alpha ligand modulator"></FilterOption><FilterOption id="1741" count="1" label="Low molecular weight heparin"></FilterOption><FilterOption id="2652" count="1" label="Nuclear factor kappa B modulator"></FilterOption><FilterOption id="294" count="1" label="Opioid receptor mu antagonist"></FilterOption><FilterOption id="7494" count="1" label="P-Glycoprotein inhibitor"></FilterOption><FilterOption id="52110" count="1" label="Respiratory syncytial virus protein F inhibitor"></FilterOption><FilterOption id="347" count="1" label="RNA polymerase inhibitor"></FilterOption><FilterOption id="3610" count="1" label="Thrombopoietin receptor agonist"></FilterOption><FilterOption id="9140" count="1" label="Tissue plasminogen activator stimulator"></FilterOption><FilterOption id="9320" count="1" label="Topoisomerase IV inhibitor"></FilterOption></Filter><Filter label="Trial Company Collaborator" name="trialCompaniesCollaborator" total="29"><FilterOption id="17810" count="5" label="Eli Lilly &amp; Co"></FilterOption><FilterOption id="14455" count="3" label="Bayer AG"></FilterOption><FilterOption id="16198" count="3" label="Forest Laboratories Inc"></FilterOption><FilterOption id="15065" count="2" label="Bristol-Myers Squibb Co"></FilterOption><FilterOption id="1072647" count="2" label="Institut de Recherches Internationales Servier (France)"></FilterOption><FilterOption id="1033116" count="2" label="PAREXEL International"></FilterOption><FilterOption id="1009547" count="2" label="Sanofi SA"></FilterOption><FilterOption id="1061163" count="1" label="Abbott Vascular"></FilterOption><FilterOption id="1125317" count="1" label="ADIR Association"></FilterOption><FilterOption id="14109" count="1" label="Amgen Inc"></FilterOption><FilterOption id="1091333" count="1" label="BECKMAN LABORATORIES DE MEXICO SA DE CV"></FilterOption><FilterOption id="27847" count="1" label="Boston Scientific Corp"></FilterOption><FilterOption id="15198" count="1" label="Bristol-Myers Squibb Pharmaceuticals Ltd"></FilterOption><FilterOption id="1018807" count="1" label="Covance Inc"></FilterOption><FilterOption id="27150" count="1" label="Daiichi Sankyo Europe GmbH"></FilterOption><FilterOption id="1055369" count="1" label="Demometrica"></FilterOption><FilterOption id="28355" count="1" label="GlaxoSmithKline plc"></FilterOption><FilterOption id="1042949" count="1" label="I N C Research Ltd"></FilterOption><FilterOption id="1101929" count="1" label="IQVIA Holdings Inc"></FilterOption><FilterOption id="1067538" count="1" label="Janssen Research &amp; Development LLC"></FilterOption><FilterOption id="1138956" count="1" label="Janssen-Farmacéutica SA de CV"></FilterOption><FilterOption id="22729" count="1" label="Laboratorios Servier"></FilterOption><FilterOption id="1173828" count="1" label="Laboratorios Servier S.L."></FilterOption><FilterOption id="1068038" count="1" label="ReSearch Pharmaceutical Services, Inc"></FilterOption><FilterOption id="1125025" count="1" label="Servier Research and Development"></FilterOption><FilterOption id="19898" count="1" label="Shionogi &amp; Co Ltd"></FilterOption><FilterOption id="20341" count="1" label="Terumo Corp"></FilterOption><FilterOption id="1084051" count="1" label="The George Institute for Global Health"></FilterOption><FilterOption id="1036007" count="1" label="The George Institute for International Health"></FilterOption></Filter><Filter label="Trial Actions Secondary Interventions Control" name="trialActionsSecondaryInterventionsControl" total="36"><FilterOption id="1545" count="4" label="Anticancer"></FilterOption><FilterOption id="2946" count="3" label="Analgesic"></FilterOption><FilterOption id="1594" count="3" label="Antibacterial"></FilterOption><FilterOption id="70" count="3" label="Anticonvulsant agent"></FilterOption><FilterOption id="991" count="3" label="Antiviral"></FilterOption><FilterOption id="104" count="3" label="Bacterial cell wall synthesis inhibitor"></FilterOption><FilterOption id="38206" count="3" label="Biguanide antidiabetic product"></FilterOption><FilterOption id="646" count="3" label="Bronchodilator"></FilterOption><FilterOption id="399" count="3" label="Hypoglycemic agent"></FilterOption><FilterOption id="2953" count="2" label="Anti-inflammatory"></FilterOption><FilterOption id="2657" count="2" label="Antihypertensive"></FilterOption><FilterOption id="659" count="2" label="Coagulation inhibitor"></FilterOption><FilterOption id="1479" count="2" label="RNA synthesis modulator"></FilterOption><FilterOption id="2667" count="1" label="Antiarteriosclerotic"></FilterOption><FilterOption id="71" count="1" label="Antihypercholesterolemic agent"></FilterOption><FilterOption id="72" count="1" label="Antihyperlipidemic agent"></FilterOption><FilterOption id="3984" count="1" label="Bacterial nucleic acid synthesis inhibitor"></FilterOption><FilterOption id="1535" count="1" label="Beta lactam antibiotic"></FilterOption><FilterOption id="89" count="1" label="Bone resorption inhibitor"></FilterOption><FilterOption id="73547" count="1" label="Carbapenem"></FilterOption><FilterOption id="3189" count="1" label="Corticosteroid agonist"></FilterOption><FilterOption id="1748" count="1" label="Fungicide"></FilterOption><FilterOption id="871" count="1" label="GABA modulator"></FilterOption><FilterOption id="32411" count="1" label="Hepatitis B virus replication inhibitor"></FilterOption><FilterOption id="747" count="1" label="HIV replication inhibitor"></FilterOption><FilterOption id="3246" count="1" label="Insulin release stimulator"></FilterOption><FilterOption id="695" count="1" label="Metastasis inhibitor"></FilterOption><FilterOption id="285" count="1" label="Norepinephrine uptake inhibitor"></FilterOption><FilterOption id="12596" count="1" label="Osteoclast inhibitor"></FilterOption><FilterOption id="312" count="1" label="Platelet aggregation inhibitor"></FilterOption><FilterOption id="2954" count="1" label="Steroidal anti-inflammatory"></FilterOption><FilterOption id="38205" count="1" label="Sulphonylurea antidiabetic product"></FilterOption><FilterOption id="7293" count="1" label="Synergist"></FilterOption><FilterOption id="15187" count="1" label="Systemic dermatological antibacterial product"></FilterOption><FilterOption id="15180" count="1" label="Topical antipruritic product"></FilterOption><FilterOption id="388" count="1" label="Vasodilator"></FilterOption></Filter><Filter label="Biomarker Type" name="trialBiomarkerTypes" total="7"><FilterOption id="31" count="37" label="Physiological"></FilterOption><FilterOption id="32" count="31" label="Biochemical"></FilterOption><FilterOption id="37" count="31" label="Proteomic"></FilterOption><FilterOption id="38" count="30" label="Genomic"></FilterOption><FilterOption id="39" count="21" label="Anthropomorphic"></FilterOption><FilterOption id="75" count="9" label="Cellular"></FilterOption><FilterOption id="40" count="3" label="Structural (imaging)"></FilterOption></Filter><Filter label="Biomarker Role" name="trialBiomarkerRoles" total="3"><FilterOption id="695863716" count="52" label="Therapeutic effect marker"></FilterOption><FilterOption id="730490367" count="18" label="Toxic effect marker"></FilterOption><FilterOption id="1571666123" count="4" label="Disease marker"></FilterOption></Filter><Filter label="Interventions" name="trialInterventions" total="97"><FilterOption id="6050" count="6" label="metformin hydrochloride"></FilterOption><FilterOption id="30712" count="4" label="budesonide + formoterol fumarate, AstraZeneca"></FilterOption><FilterOption id="32981" count="4" label="darunavir"></FilterOption><FilterOption id="7310" count="4" label="ritonavir"></FilterOption><FilterOption id="57592" count="3" label="canagliflozin"></FilterOption><FilterOption id="58762" count="3" label="empagliflozin"></FilterOption><FilterOption id="11603" count="3" label="gefitinib"></FilterOption><FilterOption id="21038" count="3" label="lacosamide"></FilterOption><FilterOption id="55852" count="3" label="linagliptin"></FilterOption><FilterOption id="32677" count="3" label="rivaroxaban"></FilterOption><FilterOption id="42107" count="2" label="ceftaroline fosamil"></FilterOption><FilterOption id="21138" count="2" label="certolizumab pegol"></FilterOption><FilterOption id="10172" count="2" label="efavirenz"></FilterOption><FilterOption id="4728" count="2" label="emtricitabine"></FilterOption><FilterOption id="30682" count="2" label="etravirine"></FilterOption><FilterOption id="54374" count="2" label="gevokizumab"></FilterOption><FilterOption id="3474" count="2" label="lamivudine"></FilterOption><FilterOption id="68827" count="2" label="mirogabalin besylate"></FilterOption><FilterOption id="33451" count="2" label="muraglitazar"></FilterOption><FilterOption id="4126" count="2" label="pioglitazone"></FilterOption><FilterOption id="54488" count="2" label="raltegravir"></FilterOption><FilterOption id="56791" count="2" label="tapentadol (sustained release, pain) J&amp;J PRD/Grunenthal"></FilterOption><FilterOption id="65375" count="2" label="topiramate (extended-release, epilepsy), Upsher-Smith"></FilterOption><FilterOption id="2765" count="2" label="zoledronic acid"></FilterOption><FilterOption id="6242" count="1" label="abacavir"></FilterOption><FilterOption id="54449" count="1" label="afatinib"></FilterOption><FilterOption id="61090" count="1" label="amlodipine + telmisartan"></FilterOption><FilterOption id="3321" count="1" label="anastrozole"></FilterOption><FilterOption id="2807" count="1" label="atorvastatin"></FilterOption><FilterOption id="52209" count="1" label="avibactam sodium + ceftazidime (iv, urinary tract infection), AstraZeneca/Allergan"></FilterOption><FilterOption id="75656" count="1" label="BI-655064"></FilterOption><FilterOption id="3311" count="1" label="bicalutamide"></FilterOption><FilterOption id="37592" count="1" label="brivaracetam"></FilterOption><FilterOption id="44383" count="1" label="carboplatin"></FilterOption><FilterOption id="16242" count="1" label="cinacalcet"></FilterOption><FilterOption id="44438" count="1" label="ciprofloxacin hydrochloride"></FilterOption><FilterOption id="2836" count="1" label="clopidogrel"></FilterOption><FilterOption id="52192" count="1" label="dapagliflozin propanediol"></FilterOption><FilterOption id="2910" count="1" label="dapoxetine"></FilterOption><FilterOption id="53200" count="1" label="daratumumab"></FilterOption><FilterOption id="2953" count="1" label="docetaxel"></FilterOption><FilterOption id="59062" count="1" label="dolutegravir"></FilterOption><FilterOption id="51255" count="1" label="edoxaban"></FilterOption><FilterOption id="10606" count="1" label="eltrombopag"></FilterOption><FilterOption id="13928" count="1" label="enoxaparin sodium"></FilterOption><FilterOption id="4414" count="1" label="eprosartan"></FilterOption><FilterOption id="11961" count="1" label="erlotinib"></FilterOption><FilterOption id="16026" count="1" label="esomeprazole"></FilterOption><FilterOption id="13572" count="1" label="exenatide"></FilterOption><FilterOption id="17558" count="1" label="fluoxetine hydrochloride"></FilterOption><FilterOption id="46890" count="1" label="glibenclamide"></FilterOption><FilterOption id="8832" count="1" label="glimepiride"></FilterOption><FilterOption id="64299" count="1" label="icotinib hydrochloride"></FilterOption><FilterOption id="45998" count="1" label="interferon alfa-2b"></FilterOption><FilterOption id="4469" count="1" label="irbesartan"></FilterOption><FilterOption id="48181" count="1" label="lamivudine + abacavir, GlaxoSmithKline"></FilterOption><FilterOption id="5665" count="1" label="levetiracetam (oral), UCB"></FilterOption><FilterOption id="5148" count="1" label="liraglutide"></FilterOption><FilterOption id="14681" count="1" label="lopinavir + ritonavir"></FilterOption><FilterOption id="77091" count="1" label="lumicitabine"></FilterOption><FilterOption id="6168" count="1" label="moxonidine"></FilterOption><FilterOption id="54142" count="1" label="NAHE-001"></FilterOption><FilterOption id="101092" count="1" label="naloxone (prolonged-release tablet, opioid induced constipation), Algobate"></FilterOption><FilterOption id="59553" count="1" label="olmesartan + amlodipine + hydrochlorothiazide (hypertension), Daiichi Sankyo"></FilterOption><FilterOption id="55609" count="1" label="olmesartan medoxomil + amlodipine besylate (hypertension), Daiichi Sankyo"></FilterOption><FilterOption id="46939" count="1" label="olmesartan medoxomil + hydrochlorothiazide (hypertension), Sankyo"></FilterOption><FilterOption id="8946" count="1" label="olmesartan medoxomil"></FilterOption><FilterOption id="13460" count="1" label="oseltamivir"></FilterOption><FilterOption id="3803" count="1" label="paclitaxel"></FilterOption><FilterOption id="16250" count="1" label="PD-217014"></FilterOption><FilterOption id="41705" count="1" label="perampanel"></FilterOption><FilterOption id="72787" count="1" label="pimodivir"></FilterOption><FilterOption id="29446" count="1" label="piperacillin + tazobactam (injectable), Wyeth/Toyama/Taiho"></FilterOption><FilterOption id="4151" count="1" label="pramipexole"></FilterOption><FilterOption id="17814" count="1" label="pregabalin"></FilterOption><FilterOption id="3317" count="1" label="quetiapine IR"></FilterOption><FilterOption id="6681" count="1" label="raloxifene"></FilterOption><FilterOption id="4196" count="1" label="ramipril"></FilterOption><FilterOption id="5369" count="1" label="ribavirin"></FilterOption><FilterOption id="4234" count="1" label="risedronate sodium"></FilterOption><FilterOption id="44417" count="1" label="saxagliptin"></FilterOption><FilterOption id="9742" count="1" label="sodium oxybate"></FilterOption><FilterOption id="4433" count="1" label="somatropin, Horizon Pharma"></FilterOption><FilterOption id="91054" count="1" label="suptavumab"></FilterOption><FilterOption id="10096" count="1" label="telaprevir"></FilterOption><FilterOption id="5051" count="1" label="telmisartan"></FilterOption><FilterOption id="9032" count="1" label="tenecteplase"></FilterOption><FilterOption id="49219" count="1" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"></FilterOption><FilterOption id="14493" count="1" label="tenofovir disoproxil fumarate"></FilterOption><FilterOption id="36332" count="1" label="ticagrelor"></FilterOption><FilterOption id="12731" count="1" label="tipranavir"></FilterOption><FilterOption id="51186" count="1" label="torcetrapib + atorvastatin"></FilterOption><FilterOption id="44363" count="1" label="trimethoprim + sulphamethoxazole"></FilterOption><FilterOption id="12551" count="1" label="vadimezan"></FilterOption><FilterOption id="5265" count="1" label="valproic acid (oral extended-release), Sanofi"></FilterOption><FilterOption id="4648" count="1" label="venlafaxine hydrochloride"></FilterOption><FilterOption id="44316" count="1" label="zidovudine"></FilterOption></Filter><Filter label="Endpoint Index Primary" name="trialEndpointIndexPrimary" total="100"><FilterOption id="1359" count="9" label="Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels - Change in HbA1c"></FilterOption><FilterOption id="1358" count="4" label="Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels"></FilterOption><FilterOption id="1535" count="4" label="Non-insulin dependent diabetes - Assessment of Morbidity"></FilterOption><FilterOption id="25873" count="4" label="Pain - Assessment of Intensity of Pain"></FilterOption><FilterOption id="5987" count="3" label="Asthma - Assessment of Exacerbations - Time to first exacerbation"></FilterOption><FilterOption id="16816" count="3" label="Herpesvirus infection - Assessment of Post Herpetic Neuralgia"></FilterOption><FilterOption id="1580" count="3" label="Non-insulin dependent diabetes - Assessment of Blood Pressure (BP)"></FilterOption><FilterOption id="1548" count="3" label="Non-insulin dependent diabetes - Assessment of Cardiovascular Events - Assessment of myocardial infarction"></FilterOption><FilterOption id="1561" count="3" label="Non-insulin dependent diabetes - Assessment of Mortality/Death Rates - Cardiovascular mortality"></FilterOption><FilterOption id="26033" count="3" label="Pain - Assessment of adverse events"></FilterOption><FilterOption id="5986" count="2" label="Asthma - Assessment of Exacerbations - Severity of exacerbation"></FilterOption><FilterOption id="14742" count="2" label="Bacterial skin infection - Assessment of Clinical Response - Clinical success/cure"></FilterOption><FilterOption id="690" count="2" label="Cardiac failure - Assessment of Cardiovascular Events - Assessment of fatal/non-fatal myocardial infarction"></FilterOption><FilterOption id="2494" count="2" label="Coronary artery disease - Assessment of Cardiovascular Events - Fatal MI/Non-fatal MI"></FilterOption><FilterOption id="2622" count="2" label="Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality"></FilterOption><FilterOption id="2621" count="2" label="Coronary artery disease - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="2616" count="2" label="Coronary artery disease - Assessment of Other Cardiovascular Events - Heart failure (New onset /Worsening)"></FilterOption><FilterOption id="2515" count="2" label="Coronary artery disease - Assessment of Thrombotic/Thromboembolic Events - Fatal /Non-fatal stroke"></FilterOption><FilterOption id="11369" count="2" label="Diabetic complication - Assessment of Mortality/Death Rates - Cardiovascular mortality"></FilterOption><FilterOption id="22587" count="2" label="End stage renal disease - Assessment of Disease Progression"></FilterOption><FilterOption id="22596" count="2" label="End stage renal disease - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="22507" count="2" label="End stage renal disease - Assessment of Serum Creatinine"></FilterOption><FilterOption id="22537" count="2" label="End stage renal disease - Glycemic Control Analysis - Assessment of glycosylated hemoglobin (HbA1c)"></FilterOption><FilterOption id="17164" count="2" label="Epilepsy - Assessment of Therapy Related Outcomes - Assessment of drop-out rate/withdrawal rate"></FilterOption><FilterOption id="17156" count="2" label="Epilepsy - Assessment of adverse events"></FilterOption><FilterOption id="3808" count="2" label="Hepatitis C virus infection - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="9255" count="2" label="HIV infection - Assessment of Therapy Related Outcomes - Assessment of treatment discontinuation"></FilterOption><FilterOption id="9213" count="2" label="HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels"></FilterOption><FilterOption id="9195" count="2" label="HIV infection - Assessment of virological response"></FilterOption><FilterOption id="40" count="2" label="Hypertension - Assessment of Diastolic Blood Pressure (DBP) - Seated DBP"></FilterOption><FilterOption id="170" count="2" label="Hypertension - Assessment of Hemoglobin A1c (HbA1c) Levels"></FilterOption><FilterOption id="16" count="2" label="Hypertension - Assessment of Systolic Blood Pressure (SBP)"></FilterOption><FilterOption id="23051" count="2" label="Lipid metabolism disorder - Assessment of Low-Density Lipoprotein (LDL)"></FilterOption><FilterOption id="8523" count="2" label="Lung tumor - Assessment of Disease Progression"></FilterOption><FilterOption id="8481" count="2" label="Lung tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="23553" count="2" label="Menopause - Assessment of Bone - Assessment by Bone mineral density (BMD)"></FilterOption><FilterOption id="1624" count="2" label="Non-insulin dependent diabetes - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="1540" count="2" label="Non-insulin dependent diabetes - Assessment of Stroke"></FilterOption><FilterOption id="13771" count="2" label="Osteoporosis - Assessment of Bone - Assessment by Bone mineral density (BMD)"></FilterOption><FilterOption id="25875" count="2" label="Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]"></FilterOption><FilterOption id="24177" count="2" label="Stroke - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="2925" count="1" label="Acute coronary syndrome - Assessment of Cardiovascular Events - Cardiogenic shock"></FilterOption><FilterOption id="2927" count="1" label="Acute coronary syndrome - Assessment of Cardiovascular Events - Heart failure"></FilterOption><FilterOption id="2860" count="1" label="Acute coronary syndrome - Assessment of Cardiovascular Events - Recurrent ischemic events/Recurrent MI"></FilterOption><FilterOption id="2980" count="1" label="Acute coronary syndrome - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="2940" count="1" label="Acute coronary syndrome - Assessment of Therapy Related Outcomes - Efficacy parameters"></FilterOption><FilterOption id="2869" count="1" label="Acute coronary syndrome - Assessment of Thrombotic/Thromboembolic Events - Ischemic stroke"></FilterOption><FilterOption id="2952" count="1" label="Acute coronary syndrome - Assessment of hospitalization"></FilterOption><FilterOption id="3160" count="1" label="Ankylosing spondylitis - Assessment of Enthesitis"></FilterOption><FilterOption id="3169" count="1" label="Ankylosing spondylitis - Assessment of Fatigue"></FilterOption><FilterOption id="3146" count="1" label="Ankylosing spondylitis - Assessment of Pain - Numeric rating scale (NRS)"></FilterOption><FilterOption id="3174" count="1" label="Ankylosing spondylitis - Assessment of Spinal Stiffness"></FilterOption><FilterOption id="3289" count="1" label="Ankylosing spondylitis - Other Disease Activity Measures"></FilterOption><FilterOption id="3185" count="1" label="Ankylosing spondylitis - Physician Global Assessment of Disease Activity - Physician's assessment of local disease activity as measured by joint swelling/pain"></FilterOption><FilterOption id="3186" count="1" label="Ankylosing spondylitis - Response to Therapy (BASDAI criteria)"></FilterOption><FilterOption id="5985" count="1" label="Asthma - Assessment of Exacerbations - Number/rate/frequency/duration of exacerbation"></FilterOption><FilterOption id="5959" count="1" label="Asthma - Assessment of Forced Expiratory Flow (FEF) - Forced expiratory flow 25-75%"></FilterOption><FilterOption id="5960" count="1" label="Asthma - Assessment of Forced Expiratory Flow (FEF) - Post bronchodilator FEF"></FilterOption><FilterOption id="5943" count="1" label="Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1) - Change in post bronchodilator FEV1"></FilterOption><FilterOption id="5954" count="1" label="Asthma - Assessment of Forced Vital Capacity (FVC) - FVC post bronchodilator response"></FilterOption><FilterOption id="6005" count="1" label="Asthma - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of exhaled nitric oxide"></FilterOption><FilterOption id="5933" count="1" label="Asthma - Assessment of Peak Expiratory Flow/Flow Rate (PEFR)"></FilterOption><FilterOption id="5925" count="1" label="Asthma - Assessment of Pulmonary Function - Inspiratory capacity"></FilterOption><FilterOption id="27645" count="1" label="Asthma - Patient Reported Outcomes/Quality of Life Assessments - Asthma control test (ACT)"></FilterOption><FilterOption id="9576" count="1" label="Atrial fibrillation - Assessment of Blood Coagulation"></FilterOption><FilterOption id="9492" count="1" label="Atrial fibrillation - Assessment of Cardiovascular Events - Assessment of fatal/non-fatal myocardial infarction"></FilterOption><FilterOption id="9491" count="1" label="Atrial fibrillation - Assessment of Cardiovascular Events"></FilterOption><FilterOption id="9508" count="1" label="Atrial fibrillation - Assessment of Cerebrovascular Events - Assessment of non fatal stroke"></FilterOption><FilterOption id="9502" count="1" label="Atrial fibrillation - Assessment of Cerebrovascular Events"></FilterOption><FilterOption id="9510" count="1" label="Atrial fibrillation - Assessment of Hemorrhagic Complications - Assessment of major bleeding events"></FilterOption><FilterOption id="9439" count="1" label="Atrial fibrillation - Assessment of Mortality/Death Rates - Assessment of cardiovascular death"></FilterOption><FilterOption id="9660" count="1" label="Atrial fibrillation - Assessment of hospitalization - Assessment of cardiovascular hospitalization"></FilterOption><FilterOption id="9444" count="1" label="Atrial fibrillation - Assessments of Composite Endpoints"></FilterOption><FilterOption id="9676" count="1" label="Atrial fibrillation - Protocol Specified Other Endpoints - Assessment of prescription changes/rescue medication uses"></FilterOption><FilterOption id="14754" count="1" label="Bacterial skin infection - Assessment of Clinical Symptoms"></FilterOption><FilterOption id="9921" count="1" label="Bipolar disorder - Assessment of Bipolar Disorder Symptoms"></FilterOption><FilterOption id="9937" count="1" label="Bipolar disorder - Assessment of Depression Severity by Specific Criteria - Assessment by Montgomery-Asberg Depression Scale (MADRS)"></FilterOption><FilterOption id="10037" count="1" label="Bipolar disorder - Assessment of Disease Relapse/Recurrence - Assessment of time to recurrence"></FilterOption><FilterOption id="9932" count="1" label="Bipolar disorder - Assessment of Manic Symptoms by Specific Scales - Assessment by Young Mania Rating Scale (YMRS)"></FilterOption><FilterOption id="9954" count="1" label="Bipolar disorder - Assessment of Neuropsychological Function - Assessment by Clinical Global Impression (CGI)"></FilterOption><FilterOption id="9952" count="1" label="Bipolar disorder - Assessment of Psychiatric Symptoms"></FilterOption><FilterOption id="9926" count="1" label="Bipolar disorder - Assessment of Therapy Related Outcomes - Assessment of symptom improvement"></FilterOption><FilterOption id="9315" count="1" label="Breast tumor - Imaging/Radiological Assessments - Assessment by ultrasonography"></FilterOption><FilterOption id="19374" count="1" label="Cancer supportive care - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="19412" count="1" label="Cancer supportive care - Protocol Specified Other Endpoints - Assessment of Other Treatment or Procedure Related Outcomes"></FilterOption><FilterOption id="983" count="1" label="Cardiac failure - Assessment of Mortality/Death Rates - Other cardiovascular mortality"></FilterOption><FilterOption id="558" count="1" label="Cardiac failure - Assessment of Non Cardiovascular Events - Assessment of cerebrovascular adverse events (Stroke/TIA)"></FilterOption><FilterOption id="830" count="1" label="Cardiac failure - Assessment of hospitalization - Hospitalization due to heart failure"></FilterOption><FilterOption id="44775" count="1" label="Chronic obstructive pulmonary disease - Assessment of Clinical Symptoms"></FilterOption><FilterOption id="4479" count="1" label="Chronic obstructive pulmonary disease - Assessment of Exacerbations - Assessment of exacerbation severity - moderate"></FilterOption><FilterOption id="4480" count="1" label="Chronic obstructive pulmonary disease - Assessment of Exacerbations - Assessment of exacerbation severity - severe"></FilterOption><FilterOption id="4473" count="1" label="Chronic obstructive pulmonary disease - Assessment of Exacerbations"></FilterOption><FilterOption id="6894" count="1" label="Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Flow (FEF)"></FilterOption><FilterOption id="4283" count="1" label="Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - FEV1 trough response"></FilterOption><FilterOption id="4277" count="1" label="Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1)"></FilterOption><FilterOption id="4288" count="1" label="Chronic obstructive pulmonary disease - Assessment of Forced Vital Capacity (FVC)"></FilterOption><FilterOption id="4365" count="1" label="Chronic obstructive pulmonary disease - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of exhaled nitric oxide"></FilterOption><FilterOption id="4306" count="1" label="Chronic obstructive pulmonary disease - Assessment of Inspiratory Capacity (IC)"></FilterOption><FilterOption id="4570" count="1" label="Chronic obstructive pulmonary disease - Assessment of Therapy Related Outcomes - Efficacy"></FilterOption><FilterOption id="30250" count="1" label="Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Modified medical research council dyspnoea scale (MMRC)"></FilterOption></Filter><Filter label="Sponsors/Collaborators" name="trialCompanies" total="89"><FilterOption id="14190" count="21" label="AstraZeneca plc"></FilterOption><FilterOption id="1091809" count="12" label="Janssen-Cilag International NV (BE)"></FilterOption><FilterOption id="1067538" count="10" label="Janssen Research &amp; Development LLC"></FilterOption><FilterOption id="14881" count="9" label="Boehringer Ingelheim International GmbH"></FilterOption><FilterOption id="18767" count="7" label="Pfizer Inc"></FilterOption><FilterOption id="17810" count="6" label="Eli Lilly &amp; Co"></FilterOption><FilterOption id="15065" count="5" label="Bristol-Myers Squibb Co"></FilterOption><FilterOption id="1020322" count="5" label="Daiichi Sankyo Inc"></FilterOption><FilterOption id="23137" count="5" label="Novartis AG"></FilterOption><FilterOption id="20452" count="5" label="UCB SA"></FilterOption><FilterOption id="30062" count="4" label="AstraZeneca AB"></FilterOption><FilterOption id="14455" count="4" label="Bayer AG"></FilterOption><FilterOption id="22586" count="4" label="Boehringer Ingelheim Corp"></FilterOption><FilterOption id="22546" count="4" label="Boehringer Ingelheim GmbH"></FilterOption><FilterOption id="22554" count="3" label="Boehringer Ingelheim BV"></FilterOption><FilterOption id="1122527" count="3" label="Boehringer Ingelheim Finland Ky"></FilterOption><FilterOption id="22563" count="3" label="Boehringer Ingelheim Ltd"></FilterOption><FilterOption id="1123634" count="3" label="Daiichi Sankyo Development Ltd"></FilterOption><FilterOption id="16198" count="3" label="Forest Laboratories Inc"></FilterOption><FilterOption id="1122528" count="3" label="SCS Boehringer Ingelheim Comm.V"></FilterOption><FilterOption id="14109" count="2" label="Amgen Inc"></FilterOption><FilterOption id="22545" count="2" label="Boehringer Ingelheim AB"></FilterOption><FilterOption id="22549" count="2" label="Boehringer Ingelheim Austria GmbH"></FilterOption><FilterOption id="22555" count="2" label="Boehringer Ingelheim Ellas AE"></FilterOption><FilterOption id="16587" count="2" label="Grunenthal GmbH"></FilterOption><FilterOption id="1072647" count="2" label="Institut de Recherches Internationales Servier (France)"></FilterOption><FilterOption id="1003570" count="2" label="Janssen R&amp;D (Ireland)"></FilterOption><FilterOption id="17392" count="2" label="Janssen-Cilag Ltd"></FilterOption><FilterOption id="17332" count="2" label="Johnson &amp; Johnson"></FilterOption><FilterOption id="1033116" count="2" label="PAREXEL International"></FilterOption><FilterOption id="1009547" count="2" label="Sanofi SA"></FilterOption><FilterOption id="22186" count="2" label="Solvay Pharmaceuticals Inc"></FilterOption><FilterOption id="22784" count="2" label="UCB Pharma Inc"></FilterOption><FilterOption id="22598" count="2" label="Unilfarma Lda"></FilterOption><FilterOption id="21321" count="2" label="Upsher-Smith Laboratories Inc"></FilterOption><FilterOption id="20954" count="2" label="XOMA Corp"></FilterOption><FilterOption id="13601" count="1" label="Abbott Laboratories"></FilterOption><FilterOption id="21152" count="1" label="Abbott Products GmbH"></FilterOption><FilterOption id="1061163" count="1" label="Abbott Vascular"></FilterOption><FilterOption id="1072507" count="1" label="AbbVie Inc"></FilterOption><FilterOption id="1125317" count="1" label="ADIR Association"></FilterOption><FilterOption id="16924" count="1" label="Astra Pharmaceuticals (HK) Ltd"></FilterOption><FilterOption id="16919" count="1" label="Astra-IDL Ltd"></FilterOption><FilterOption id="1091333" count="1" label="BECKMAN LABORATORIES DE MEXICO SA DE CV"></FilterOption><FilterOption id="22582" count="1" label="Boehringer Ingelheim (Canada) Ltd"></FilterOption><FilterOption id="1103352" count="1" label="Boehringer Ingelheim Espana Sa"></FilterOption><FilterOption id="22556" count="1" label="Boehringer Ingelheim France SARL"></FilterOption><FilterOption id="22560" count="1" label="Boehringer Ingelheim Italia SpA"></FilterOption><FilterOption id="22566" count="1" label="Boehringer Ingelheim Pharma Ges mbH"></FilterOption><FilterOption id="22590" count="1" label="Boehringer Ingelheim SA"></FilterOption><FilterOption id="27847" count="1" label="Boston Scientific Corp"></FilterOption><FilterOption id="15198" count="1" label="Bristol-Myers Squibb Pharmaceuticals Ltd"></FilterOption><FilterOption id="1018807" count="1" label="Covance Inc"></FilterOption><FilterOption id="27150" count="1" label="Daiichi Sankyo Europe GmbH"></FilterOption><FilterOption id="1055369" count="1" label="Demometrica"></FilterOption><FilterOption id="1044439" count="1" label="Develco Pharma Schweiz Ag"></FilterOption><FilterOption id="1016499" count="1" label="Digna Biotech SL"></FilterOption><FilterOption id="15872" count="1" label="Eisai Co Ltd"></FilterOption><FilterOption id="29708" count="1" label="Ferring Pharmaceuticals SA"></FilterOption><FilterOption id="28355" count="1" label="GlaxoSmithKline plc"></FilterOption><FilterOption id="1042949" count="1" label="I N C Research Ltd"></FilterOption><FilterOption id="17259" count="1" label="Ipsen"></FilterOption><FilterOption id="1101929" count="1" label="IQVIA Holdings Inc"></FilterOption><FilterOption id="30131" count="1" label="Janssen Diagnostics BVBA"></FilterOption><FilterOption id="17397" count="1" label="Janssen Farmaceutica SA de CV"></FilterOption><FilterOption id="17408" count="1" label="Janssen Pharmaceutical KK"></FilterOption><FilterOption id="25863" count="1" label="Janssen Pharmaceuticals Inc"></FilterOption><FilterOption id="17401" count="1" label="Janssen-Cilag SA"></FilterOption><FilterOption id="1138956" count="1" label="Janssen-Farmacéutica SA de CV"></FilterOption><FilterOption id="17534" count="1" label="Johnson &amp; Johnson (Pvt) Ltd"></FilterOption><FilterOption id="29481" count="1" label="Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC"></FilterOption><FilterOption id="22729" count="1" label="Laboratorios Servier"></FilterOption><FilterOption id="1173828" count="1" label="Laboratorios Servier S.L."></FilterOption><FilterOption id="18614" count="1" label="Novo Nordisk A/S"></FilterOption><FilterOption id="23634" count="1" label="Novo Nordisk Bioindustriale Srl"></FilterOption><FilterOption id="19087" count="1" label="Pierre Fabre SA"></FilterOption><FilterOption id="1089968" count="1" label="Quintiles East Asia Pte Ltd"></FilterOption><FilterOption id="19214" count="1" label="Regeneron Pharmaceuticals Inc"></FilterOption><FilterOption id="1068038" count="1" label="ReSearch Pharmaceutical Services, Inc"></FilterOption><FilterOption id="1125025" count="1" label="Servier Research and Development"></FilterOption><FilterOption id="19898" count="1" label="Shionogi &amp; Co Ltd"></FilterOption><FilterOption id="20341" count="1" label="Terumo Corp"></FilterOption><FilterOption id="1084051" count="1" label="The George Institute for Global Health"></FilterOption><FilterOption id="1036007" count="1" label="The George Institute for International Health"></FilterOption><FilterOption id="1104050" count="1" label="UCB Biopharma SPRL"></FilterOption><FilterOption id="29819" count="1" label="UCB BIOSCIENCES GmbH"></FilterOption><FilterOption id="1050515" count="1" label="ViiV Healthcare Ltd"></FilterOption><FilterOption id="27724" count="1" label="Warner Chilcott plc"></FilterOption><FilterOption id="14112" count="1" label="Wyeth"></FilterOption></Filter><Filter label="Last Changed Date By Day" name="trialDateChangeLastByDay" total="85"><FilterOption count="4" label="2018-10-15"></FilterOption><FilterOption count="2" label="2013-09-14"></FilterOption><FilterOption count="2" label="2013-12-02"></FilterOption><FilterOption count="2" label="2018-06-02"></FilterOption><FilterOption count="2" label="2018-11-14"></FilterOption><FilterOption count="2" label="2018-11-27"></FilterOption><FilterOption count="2" label="2019-01-24"></FilterOption><FilterOption count="2" label="2019-01-25"></FilterOption><FilterOption count="2" label="2019-01-26"></FilterOption><FilterOption count="2" label="2019-03-07"></FilterOption><FilterOption count="2" label="2019-03-21"></FilterOption><FilterOption count="2" label="2019-06-13"></FilterOption><FilterOption count="1" label="2012-09-05"></FilterOption><FilterOption count="1" label="2014-01-28"></FilterOption><FilterOption count="1" label="2014-03-18"></FilterOption><FilterOption count="1" label="2014-04-07"></FilterOption><FilterOption count="1" label="2014-05-28"></FilterOption><FilterOption count="1" label="2015-02-24"></FilterOption><FilterOption count="1" label="2015-04-30"></FilterOption><FilterOption count="1" label="2015-09-28"></FilterOption><FilterOption count="1" label="2015-11-30"></FilterOption><FilterOption count="1" label="2016-08-24"></FilterOption><FilterOption count="1" label="2016-11-26"></FilterOption><FilterOption count="1" label="2017-01-27"></FilterOption><FilterOption count="1" label="2017-03-03"></FilterOption><FilterOption count="1" label="2017-03-04"></FilterOption><FilterOption count="1" label="2017-04-01"></FilterOption><FilterOption count="1" label="2017-04-04"></FilterOption><FilterOption count="1" label="2017-04-14"></FilterOption><FilterOption count="1" label="2017-07-03"></FilterOption><FilterOption count="1" label="2017-08-18"></FilterOption><FilterOption count="1" label="2017-09-22"></FilterOption><FilterOption count="1" label="2017-12-06"></FilterOption><FilterOption count="1" label="2018-01-23"></FilterOption><FilterOption count="1" label="2018-03-16"></FilterOption><FilterOption count="1" label="2018-04-05"></FilterOption><FilterOption count="1" label="2018-05-02"></FilterOption><FilterOption count="1" label="2018-05-12"></FilterOption><FilterOption count="1" label="2018-05-19"></FilterOption><FilterOption count="1" label="2018-05-23"></FilterOption><FilterOption count="1" label="2018-06-04"></FilterOption><FilterOption count="1" label="2018-06-06"></FilterOption><FilterOption count="1" label="2018-06-18"></FilterOption><FilterOption count="1" label="2018-06-26"></FilterOption><FilterOption count="1" label="2018-06-28"></FilterOption><FilterOption count="1" label="2018-06-29"></FilterOption><FilterOption count="1" label="2018-06-30"></FilterOption><FilterOption count="1" label="2018-07-07"></FilterOption><FilterOption count="1" label="2018-07-09"></FilterOption><FilterOption count="1" label="2018-08-27"></FilterOption><FilterOption count="1" label="2018-10-04"></FilterOption><FilterOption count="1" label="2018-10-13"></FilterOption><FilterOption count="1" label="2018-10-14"></FilterOption><FilterOption count="1" label="2018-10-26"></FilterOption><FilterOption count="1" label="2018-11-01"></FilterOption><FilterOption count="1" label="2018-11-12"></FilterOption><FilterOption count="1" label="2018-11-15"></FilterOption><FilterOption count="1" label="2018-11-17"></FilterOption><FilterOption count="1" label="2018-11-28"></FilterOption><FilterOption count="1" label="2018-11-29"></FilterOption><FilterOption count="1" label="2018-12-03"></FilterOption><FilterOption count="1" label="2018-12-04"></FilterOption><FilterOption count="1" label="2018-12-05"></FilterOption><FilterOption count="1" label="2018-12-07"></FilterOption><FilterOption count="1" label="2018-12-27"></FilterOption><FilterOption count="1" label="2018-12-28"></FilterOption><FilterOption count="1" label="2019-01-10"></FilterOption><FilterOption count="1" label="2019-01-16"></FilterOption><FilterOption count="1" label="2019-01-17"></FilterOption><FilterOption count="1" label="2019-02-04"></FilterOption><FilterOption count="1" label="2019-02-11"></FilterOption><FilterOption count="1" label="2019-03-18"></FilterOption><FilterOption count="1" label="2019-03-20"></FilterOption><FilterOption count="1" label="2019-04-04"></FilterOption><FilterOption count="1" label="2019-04-16"></FilterOption><FilterOption count="1" label="2019-05-13"></FilterOption><FilterOption count="1" label="2019-05-14"></FilterOption><FilterOption count="1" label="2019-05-18"></FilterOption><FilterOption count="1" label="2019-05-27"></FilterOption><FilterOption count="1" label="2019-06-12"></FilterOption><FilterOption count="1" label="2019-06-14"></FilterOption><FilterOption count="1" label="2019-06-20"></FilterOption><FilterOption count="1" label="2019-06-22"></FilterOption><FilterOption count="1" label="2019-06-25"></FilterOption><FilterOption count="1" label="2019-06-26"></FilterOption></Filter><Filter label="Trial Date End By Month" name="trialDateEndByMonth" total="72"><FilterOption count="4" label="201101"></FilterOption><FilterOption count="3" label="200606"></FilterOption><FilterOption count="3" label="201212"></FilterOption><FilterOption count="2" label="200601"></FilterOption><FilterOption count="2" label="201010"></FilterOption><FilterOption count="2" label="201203"></FilterOption><FilterOption count="2" label="201209"></FilterOption><FilterOption count="2" label="201301"></FilterOption><FilterOption count="2" label="201305"></FilterOption><FilterOption count="2" label="201501"></FilterOption><FilterOption count="2" label="201504"></FilterOption><FilterOption count="2" label="201602"></FilterOption><FilterOption count="2" label="201609"></FilterOption><FilterOption count="2" label="201807"></FilterOption><FilterOption count="1" label="200309"></FilterOption><FilterOption count="1" label="200402"></FilterOption><FilterOption count="1" label="200508"></FilterOption><FilterOption count="1" label="200509"></FilterOption><FilterOption count="1" label="200511"></FilterOption><FilterOption count="1" label="200603"></FilterOption><FilterOption count="1" label="200605"></FilterOption><FilterOption count="1" label="200607"></FilterOption><FilterOption count="1" label="200610"></FilterOption><FilterOption count="1" label="200702"></FilterOption><FilterOption count="1" label="200704"></FilterOption><FilterOption count="1" label="200707"></FilterOption><FilterOption count="1" label="200709"></FilterOption><FilterOption count="1" label="200803"></FilterOption><FilterOption count="1" label="200804"></FilterOption><FilterOption count="1" label="200805"></FilterOption><FilterOption count="1" label="200806"></FilterOption><FilterOption count="1" label="200808"></FilterOption><FilterOption count="1" label="200810"></FilterOption><FilterOption count="1" label="200811"></FilterOption><FilterOption count="1" label="200812"></FilterOption><FilterOption count="1" label="200902"></FilterOption><FilterOption count="1" label="200907"></FilterOption><FilterOption count="1" label="200909"></FilterOption><FilterOption count="1" label="200910"></FilterOption><FilterOption count="1" label="200911"></FilterOption><FilterOption count="1" label="200912"></FilterOption><FilterOption count="1" label="201005"></FilterOption><FilterOption count="1" label="201008"></FilterOption><FilterOption count="1" label="201012"></FilterOption><FilterOption count="1" label="201102"></FilterOption><FilterOption count="1" label="201109"></FilterOption><FilterOption count="1" label="201201"></FilterOption><FilterOption count="1" label="201204"></FilterOption><FilterOption count="1" label="201207"></FilterOption><FilterOption count="1" label="201303"></FilterOption><FilterOption count="1" label="201310"></FilterOption><FilterOption count="1" label="201403"></FilterOption><FilterOption count="1" label="201405"></FilterOption><FilterOption count="1" label="201408"></FilterOption><FilterOption count="1" label="201503"></FilterOption><FilterOption count="1" label="201508"></FilterOption><FilterOption count="1" label="201510"></FilterOption><FilterOption count="1" label="201512"></FilterOption><FilterOption count="1" label="201605"></FilterOption><FilterOption count="1" label="201612"></FilterOption><FilterOption count="1" label="201701"></FilterOption><FilterOption count="1" label="201702"></FilterOption><FilterOption count="1" label="201703"></FilterOption><FilterOption count="1" label="201704"></FilterOption><FilterOption count="1" label="201707"></FilterOption><FilterOption count="1" label="201709"></FilterOption><FilterOption count="1" label="201711"></FilterOption><FilterOption count="1" label="201803"></FilterOption><FilterOption count="1" label="201804"></FilterOption><FilterOption count="1" label="201805"></FilterOption><FilterOption count="1" label="201912"></FilterOption><FilterOption count="1" label="202105"></FilterOption></Filter><Filter label="Trial Date Start By Month" name="trialDateStartByMonth" total="73"><FilterOption count="4" label="200405"></FilterOption><FilterOption count="3" label="200410"></FilterOption><FilterOption count="3" label="200605"></FilterOption><FilterOption count="3" label="201005"></FilterOption><FilterOption count="3" label="201007"></FilterOption><FilterOption count="2" label="200307"></FilterOption><FilterOption count="2" label="200406"></FilterOption><FilterOption count="2" label="200505"></FilterOption><FilterOption count="2" label="200612"></FilterOption><FilterOption count="2" label="200803"></FilterOption><FilterOption count="2" label="200903"></FilterOption><FilterOption count="2" label="201010"></FilterOption><FilterOption count="2" label="201103"></FilterOption><FilterOption count="2" label="201210"></FilterOption><FilterOption count="2" label="201212"></FilterOption><FilterOption count="2" label="201401"></FilterOption><FilterOption count="2" label="201406"></FilterOption><FilterOption count="2" label="201501"></FilterOption><FilterOption count="1" label="199509"></FilterOption><FilterOption count="1" label="200111"></FilterOption><FilterOption count="1" label="200203"></FilterOption><FilterOption count="1" label="200205"></FilterOption><FilterOption count="1" label="200301"></FilterOption><FilterOption count="1" label="200304"></FilterOption><FilterOption count="1" label="200311"></FilterOption><FilterOption count="1" label="200402"></FilterOption><FilterOption count="1" label="200404"></FilterOption><FilterOption count="1" label="200407"></FilterOption><FilterOption count="1" label="200412"></FilterOption><FilterOption count="1" label="200510"></FilterOption><FilterOption count="1" label="200511"></FilterOption><FilterOption count="1" label="200601"></FilterOption><FilterOption count="1" label="200604"></FilterOption><FilterOption count="1" label="200608"></FilterOption><FilterOption count="1" label="200609"></FilterOption><FilterOption count="1" label="200702"></FilterOption><FilterOption count="1" label="200703"></FilterOption><FilterOption count="1" label="200705"></FilterOption><FilterOption count="1" label="200706"></FilterOption><FilterOption count="1" label="200708"></FilterOption><FilterOption count="1" label="200804"></FilterOption><FilterOption count="1" label="200808"></FilterOption><FilterOption count="1" label="200810"></FilterOption><FilterOption count="1" label="200904"></FilterOption><FilterOption count="1" label="200905"></FilterOption><FilterOption count="1" label="200906"></FilterOption><FilterOption count="1" label="200909"></FilterOption><FilterOption count="1" label="200910"></FilterOption><FilterOption count="1" label="201002"></FilterOption><FilterOption count="1" label="201003"></FilterOption><FilterOption count="1" label="201006"></FilterOption><FilterOption count="1" label="201008"></FilterOption><FilterOption count="1" label="201009"></FilterOption><FilterOption count="1" label="201109"></FilterOption><FilterOption count="1" label="201111"></FilterOption><FilterOption count="1" label="201201"></FilterOption><FilterOption count="1" label="201203"></FilterOption><FilterOption count="1" label="201205"></FilterOption><FilterOption count="1" label="201206"></FilterOption><FilterOption count="1" label="201208"></FilterOption><FilterOption count="1" label="201309"></FilterOption><FilterOption count="1" label="201402"></FilterOption><FilterOption count="1" label="201403"></FilterOption><FilterOption count="1" label="201407"></FilterOption><FilterOption count="1" label="201410"></FilterOption><FilterOption count="1" label="201506"></FilterOption><FilterOption count="1" label="201507"></FilterOption><FilterOption count="1" label="201512"></FilterOption><FilterOption count="1" label="201601"></FilterOption><FilterOption count="1" label="201607"></FilterOption><FilterOption count="1" label="201610"></FilterOption><FilterOption count="1" label="201703"></FilterOption><FilterOption count="1" label="201707"></FilterOption></Filter><Filter label="Trial Phase" name="trialPhase" total="10"><FilterOption id="C3" count="50" label="Phase 3 Clinical"></FilterOption><FilterOption id="C4" count="20" label="Phase 4 Clinical"></FilterOption><FilterOption id="NS" count="7" label="Phase not specified"></FilterOption><FilterOption id="C3B" count="6" label="Phase 3b Clinical"></FilterOption><FilterOption id="PNA" count="6" label="Phase Not Applicable"></FilterOption><FilterOption id="C2" count="4" label="Phase 2 Clinical"></FilterOption><FilterOption id="C2B" count="3" label="Phase 2b Clinical"></FilterOption><FilterOption id="C1" count="1" label="Phase 1 Clinical"></FilterOption><FilterOption id="C12" count="1" label="Phase 1/Phase 2 Clinical"></FilterOption><FilterOption id="C23" count="1" label="Phase 2/Phase 3 Clinical"></FilterOption></Filter><Filter label="Inclusion Criteria Index" name="trialInclusionCriteriaIndex" total="100"><FilterOption id="584" count="14" label="Non-insulin dependent diabetes - Subjects with Diabetes Mellitus - Subjects with type 2 diabetes mellitus"></FilterOption><FilterOption id="901" count="13" label="Non-insulin dependent diabetes - Subjects with specific level of glycemic control - Subjects with Moderate Glycemic Control"></FilterOption><FilterOption id="606" count="11" label="Non-insulin dependent diabetes - Subjects with specific level of glycemic control - Subjects with Good Glycemic Control"></FilterOption><FilterOption id="607" count="11" label="Non-insulin dependent diabetes - Subjects with specific level of glycemic control - Subjects with Poor/Inadequate Glycemic Control"></FilterOption><FilterOption id="5418" count="7" label="HIV infection - Subjects with HIV Infection - Subjects with HIV-1 infection"></FilterOption><FilterOption id="610" count="7" label="Non-insulin dependent diabetes - Obese Subjects - Obese subjects (Grade 2 obesity, BMI= 30 to 39.9)"></FilterOption><FilterOption id="609" count="7" label="Non-insulin dependent diabetes - Obese Subjects - Overweight subjects (Grade 1 obesity, BMI= 25 to 29.9)"></FilterOption><FilterOption id="22262" count="6" label="Pain - Protocol Specified Other Inclusion Criteria"></FilterOption><FilterOption id="15257" count="5" label="Epilepsy - Subjects with Diagnosis of Epilepsy - Subjects with partial onset epilepsy"></FilterOption><FilterOption id="612" count="5" label="Non-insulin dependent diabetes - Obese Subjects - Subjects with morbid obesity (Grade 3 obesity, BMI=40)"></FilterOption><FilterOption id="22090" count="5" label="Pain - Subjects Based on Duration of Pain - Subjects with chronic pain"></FilterOption><FilterOption id="22150" count="5" label="Pain - Subjects Based on Pain Scale Ratings - Based on Numerical Rating Scale [NRS]"></FilterOption><FilterOption id="4322" count="4" label="Asthma - Subjects with Diagnosis of Asthma"></FilterOption><FilterOption id="1068" count="4" label="Coronary artery disease - Subjects with Coronary Artery Disease (CAD)"></FilterOption><FilterOption id="5317" count="4" label="HIV infection - Subjects with Protocol Specified HIV Viral Load"></FilterOption><FilterOption id="905" count="4" label="Non-insulin dependent diabetes - Subjects with History of/Scheduled to Receive Therapy - Subjects on/agreeing to maintain stable dose of oral hypoglycemic agents"></FilterOption><FilterOption id="22093" count="4" label="Pain - Subjects by disease severity - Subjects with moderate pain"></FilterOption><FilterOption id="22368" count="3" label="Asthma - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for asthma drugs"></FilterOption><FilterOption id="2060" count="3" label="Chronic obstructive pulmonary disease - Subjects with Diagnosis of COPD"></FilterOption><FilterOption id="1084" count="3" label="Coronary artery disease - Subjects with Myocardial Infarction (MI) - Prior history of myocardial infarction"></FilterOption><FilterOption id="17664" count="3" label="End stage renal disease - Subjects with Diabetes/Diabetic Nephropathy"></FilterOption><FilterOption id="15273" count="3" label="Epilepsy - Subjects with Epilepsy based on Seizure Type - Subjects with complex partial seizures"></FilterOption><FilterOption id="15274" count="3" label="Epilepsy - Subjects with Epilepsy based on Seizure Type - Subjects with partial seizures with secondary generalization"></FilterOption><FilterOption id="15272" count="3" label="Epilepsy - Subjects with Epilepsy based on Seizure Type - Subjects with simple partial seizures"></FilterOption><FilterOption id="15330" count="3" label="Epilepsy - Subjects with History of/Scheduled to Receive Therapy - Subjects on stable drug regimen"></FilterOption><FilterOption id="15730" count="3" label="Herpesvirus infection - Subjects with Varicella Zoster Virus Infections - Subjects with shingles/herpes zoster"></FilterOption><FilterOption id="5375" count="3" label="HIV infection - Subjects Refractory/Intolerant to Anti Retroviral Therapy"></FilterOption><FilterOption id="1" count="3" label="Hypertension - Subjects with Primary/Essential Hypertension"></FilterOption><FilterOption id="20758" count="3" label="Menopause - Subjects with Protocol Specified Menstrual Status - Postmenopausal subjects"></FilterOption><FilterOption id="691" count="3" label="Non-insulin dependent diabetes - Subjects on diet/exercise therapy"></FilterOption><FilterOption id="1047" count="3" label="Non-insulin dependent diabetes - Treatment Naive Subjects"></FilterOption><FilterOption id="8685" count="3" label="Osteoporosis - Subjects with Postmenopausal Osteoporosis"></FilterOption><FilterOption id="8682" count="3" label="Osteoporosis - Subjects with Primary Osteoporosis"></FilterOption><FilterOption id="22364" count="2" label="Asthma - Subjects with Persistent Asthma - Subjects with mild persistent asthma"></FilterOption><FilterOption id="22365" count="2" label="Asthma - Subjects with Persistent Asthma - Subjects with moderate persistent asthma"></FilterOption><FilterOption id="22366" count="2" label="Asthma - Subjects with Persistent Asthma - Subjects with severe persistent asthma"></FilterOption><FilterOption id="13724" count="2" label="Bacterial skin infection - Subjects with Complicated Skin and Skin Structure Infections"></FilterOption><FilterOption id="2066" count="2" label="Chronic obstructive pulmonary disease - Subjects with Protocol Specified Symptom Scales/Scores - Subjects with GOLD Stage 2/Moderate COPD"></FilterOption><FilterOption id="2067" count="2" label="Chronic obstructive pulmonary disease - Subjects with Protocol Specified Symptom Scales/Scores - Subjects with GOLD Stage 3/Severe COPD"></FilterOption><FilterOption id="4304" count="2" label="Chronic obstructive pulmonary disease - Subjects with specific cigarette smoking activity - Subjects with smoking history of &gt;= 10 pack years"></FilterOption><FilterOption id="1212" count="2" label="Coronary artery disease - Coronary Angiogram Findings Suggestive of/Confirmed CAD/CHD - Multiple vessel coronary artery disease"></FilterOption><FilterOption id="1125" count="2" label="Coronary artery disease - Coronary Artery Disease Subjects with Metabolic/Systemic/Other Disorders - Subjects with cerebrovascular diseases or disorders"></FilterOption><FilterOption id="1126" count="2" label="Coronary artery disease - Coronary Artery Disease Subjects with Metabolic/Systemic/Other Disorders - Subjects with peripheral artery disease"></FilterOption><FilterOption id="3878" count="2" label="Coronary artery disease - Subjects at Risk of Developing Disease - Diabetes mellitus"></FilterOption><FilterOption id="3876" count="2" label="Coronary artery disease - Subjects at Risk of Developing Disease - Subjects with cardiovascular risk factors"></FilterOption><FilterOption id="1171" count="2" label="Coronary artery disease - Subjects with History of /Scheduled for Coronary Revascularization Therapy - PTCA (percutaneous transluminal coronary angioplasty)/Stent placement"></FilterOption><FilterOption id="1174" count="2" label="Coronary artery disease - Subjects with History of/Scheduled for Cardiac Surgery/Intervention - Subjects with history of/undergoing coronary artery bypass graft surgery (CABG)"></FilterOption><FilterOption id="1085" count="2" label="Coronary artery disease - Subjects with angina"></FilterOption><FilterOption id="17667" count="2" label="End stage renal disease - Subjects co-morbid with renal disease/disorder - Subjects with other cardiac disease/associated nephropathy"></FilterOption><FilterOption id="17691" count="2" label="End stage renal disease - Subjects with History of/Scheduled to Receive Therapy - Subjects on antidiabetics"></FilterOption><FilterOption id="17638" count="2" label="End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 2 chronic kidney disease"></FilterOption><FilterOption id="17642" count="2" label="End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 3 chronic kidney disease"></FilterOption><FilterOption id="15345" count="2" label="Epilepsy - Subjects with Medically Intractable Epilepsy"></FilterOption><FilterOption id="4441" count="2" label="Head and neck tumor - Subjects with Progressive/Treatment Refractory Disease"></FilterOption><FilterOption id="4794" count="2" label="Head and neck tumor - Subjects with Specific Histological Sub-type of Head and Neck Cancer - Subjects with squamous cell head and neck carcinoma"></FilterOption><FilterOption id="6663" count="2" label="Hepatitis C virus infection - Subjects Infected with HCV Genotype 1"></FilterOption><FilterOption id="1751" count="2" label="Hepatitis C virus infection - Subjects with Chronic Hepatitis C Infection"></FilterOption><FilterOption id="1764" count="2" label="Hepatitis C virus infection - Subjects with Positive Serological Markers for Hepatitis C - Subjects positive for HCV RNA"></FilterOption><FilterOption id="5348" count="2" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent HAART (Highly Active Anti Retroviral Therapy)"></FilterOption><FilterOption id="5347" count="2" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent protease inhibitors"></FilterOption><FilterOption id="5344" count="2" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy"></FilterOption><FilterOption id="55" count="2" label="Hypertension - Subjects with Diabetes Mellitus - Subjects co-morbid with type 2 diabetes mellitus"></FilterOption><FilterOption id="80" count="2" label="Hypertension - Subjects with History of/Scheduled to Receive Therapy - Subjects on monotherapy"></FilterOption><FilterOption id="78" count="2" label="Hypertension - Treatment Naive Subjects"></FilterOption><FilterOption id="3940" count="2" label="Lung tumor - Subjects with Advanced/Metastatic Cancer"></FilterOption><FilterOption id="3900" count="2" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)"></FilterOption><FilterOption id="20773" count="2" label="Menopause - Subjects with Protocol Specified Bone Mineral Density(BMD)"></FilterOption><FilterOption id="1043" count="2" label="Non-insulin dependent diabetes - Non-Obese Subjects"></FilterOption><FilterOption id="627" count="2" label="Non-insulin dependent diabetes - Subjects co-morbid with cardiovascular disease/disorder - Subjects co-morbid with coronary artery disease"></FilterOption><FilterOption id="663" count="2" label="Non-insulin dependent diabetes - Subjects with Co-morbid Conditions - Subjects co-morbid with stroke"></FilterOption><FilterOption id="679" count="2" label="Non-insulin dependent diabetes - Subjects with History of/Scheduled to Receive Therapy - Subjects on/treated with combinational oral agents"></FilterOption><FilterOption id="6695" count="2" label="Non-insulin dependent diabetes - Subjects with History/Scheduled for Surgery/Intervention - Subjects with history of limb/foot amputation"></FilterOption><FilterOption id="6696" count="2" label="Non-insulin dependent diabetes - Subjects with History/Scheduled for Surgery/Intervention - Subjects with previous limb bypass surgery/PTA (percutaneous transluminal angioplasty)"></FilterOption><FilterOption id="633" count="2" label="Non-insulin dependent diabetes - Subjects with Vascular Diseases - Subjects with peripheral vascular disease"></FilterOption><FilterOption id="6694" count="2" label="Non-insulin dependent diabetes - Subjects with history of cardiac surgery/intervention"></FilterOption><FilterOption id="8681" count="2" label="Osteoporosis - Subjects at Risk of Developing Disease - Women at risk of developing osteoporosis"></FilterOption><FilterOption id="13262" count="2" label="Osteoporosis - Subjects with Fracture - Subjects with vertebral fractures"></FilterOption><FilterOption id="8709" count="2" label="Osteoporosis - Subjects with Normal/Acceptable Laboratory Criteria"></FilterOption><FilterOption id="22148" count="2" label="Pain - Subjects Based on Pain Scale Ratings"></FilterOption><FilterOption id="22094" count="2" label="Pain - Subjects by disease severity - Subjects with severe pain"></FilterOption><FilterOption id="22253" count="2" label="Pain - Subjects with History of/Scheduled for Therapy for other Indication - Subjects with history/scheduled to receive other drug therapies"></FilterOption><FilterOption id="22211" count="2" label="Pain - Subjects with History of/Scheduled to Receive Therapy - Subjects with history/scheduled to receive opioids"></FilterOption><FilterOption id="22098" count="2" label="Pain - Subjects with Neuropathic Pain - Subjects with post herpetic neuralgia"></FilterOption><FilterOption id="22129" count="2" label="Pain - Subjects with Somatic Pain - Subjects with back pain"></FilterOption><FilterOption id="22127" count="2" label="Pain - Subjects with Somatic Pain - Subjects with fibromyalgia"></FilterOption><FilterOption id="33145" count="2" label="Respiratory syncytial virus infection - Protocol Specified Other Inclusion Criteria"></FilterOption><FilterOption id="1311" count="1" label="Acute coronary syndrome - Subjects with Abnormal ECG/ Echocardiographic Findings - ST-segment elevation"></FilterOption><FilterOption id="2037" count="1" label="Ankylosing spondylitis - Active Ankylosing Spondylitis - Axial Involvement"></FilterOption><FilterOption id="1569" count="1" label="Ankylosing spondylitis - Subjects with Protocol Specified Compliance Status - Subjects able to comply with the study protocol procedures/ requirements"></FilterOption><FilterOption id="1559" count="1" label="Ankylosing spondylitis - Subjects with Protocol Specified Participation Status - Subjects able/willing to provide written informed consent"></FilterOption><FilterOption id="2875" count="1" label="Asthma - Protocol Specified Other Inclusion Criteria"></FilterOption><FilterOption id="4269" count="1" label="Asthma - Subjects Included based on Diagnostic/Therapeutic Guidelines for Asthma - Subjects Meeting Amercian Thoricac Society Criteria"></FilterOption><FilterOption id="22367" count="1" label="Asthma - Subjects co-morbid with pulmonary diseases/disorders - Subjects co-morbid with chronic obstructive pulmonary disease"></FilterOption><FilterOption id="2710" count="1" label="Asthma - Subjects with Exacerbations/Acute Asthma"></FilterOption><FilterOption id="2719" count="1" label="Asthma - Subjects with Levels of Asthma Control - Subjects with poorly controlled/not well controlled asthma"></FilterOption><FilterOption id="5658" count="1" label="Atrial fibrillation - Protocol Specified Other Inclusion Criteria"></FilterOption><FilterOption id="33669" count="1" label="Atrial fibrillation - Subjects Fulfilling Protocol Specific Diagnostic Criteria"></FilterOption><FilterOption id="5564" count="1" label="Atrial fibrillation - Subjects at Risk of Developing Disease - Subjects with cardiac intervention"></FilterOption><FilterOption id="5563" count="1" label="Atrial fibrillation - Subjects at Risk of Developing Disease - Subjects with cardiovascular diseases/disorders as a risk factor"></FilterOption><FilterOption id="5558" count="1" label="Atrial fibrillation - Subjects at Risk of Developing Disease - Subjects with coronary artery disease"></FilterOption></Filter><Filter label="Trial Interventions Control Alone Name Display" name="trialInterventionsControlAloneNameDisplay" total="10"><FilterOption id="44375" count="2" label="warfarin"></FilterOption><FilterOption id="2807" count="1" label="atorvastatin"></FilterOption><FilterOption id="2836" count="1" label="clopidogrel"></FilterOption><FilterOption id="3188" count="1" label="gabapentin"></FilterOption><FilterOption id="32355" count="1" label="indacaterol"></FilterOption><FilterOption id="6050" count="1" label="metformin hydrochloride"></FilterOption><FilterOption id="54142" count="1" label="NAHE-001"></FilterOption><FilterOption id="2902" count="1" label="Oxis Turbuhaler"></FilterOption><FilterOption id="17814" count="1" label="pregabalin"></FilterOption><FilterOption id="8165" count="1" label="tiotropium bromide"></FilterOption></Filter><Filter label="Trial Actions Primary Interventions Control" name="trialActionsPrimaryInterventionsControl" total="34"><FilterOption id="8805" count="3" label="AMP activated protein kinase stimulator"></FilterOption><FilterOption id="40" count="3" label="Beta 2 adrenoceptor agonist"></FilterOption><FilterOption id="50960" count="2" label="CACNA2D calcium channel subunit modulator"></FilterOption><FilterOption id="7424" count="2" label="Cytochrome P450 3A4 inhibitor"></FilterOption><FilterOption id="111" count="2" label="Factor IIa antagonist"></FilterOption><FilterOption id="113" count="2" label="Factor IX antagonist"></FilterOption><FilterOption id="114" count="2" label="Factor VII antagonist"></FilterOption><FilterOption id="119" count="2" label="Factor X antagonist"></FilterOption><FilterOption id="17217" count="2" label="GABA A receptor alpha-2 subunit stimulator"></FilterOption><FilterOption id="17247" count="2" label="GABA A receptor delta subunit stimulator"></FilterOption><FilterOption id="173" count="2" label="GABA receptor agonist"></FilterOption><FilterOption id="204" count="2" label="HIV protease inhibitor"></FilterOption><FilterOption id="768" count="2" label="HIV-1 protease inhibitor"></FilterOption><FilterOption id="57003" count="2" label="Peptidoglycan recognition protein inhibitor"></FilterOption><FilterOption id="10583" count="2" label="Vitamin K epoxide reductase inhibitor"></FilterOption><FilterOption id="18" count="1" label="ACE inhibitor"></FilterOption><FilterOption id="64" count="1" label="Angiotensin II receptor antagonist"></FilterOption><FilterOption id="2588" count="1" label="Calcium channel inhibitor L-type"></FilterOption><FilterOption id="135" count="1" label="DHFR inhibitor"></FilterOption><FilterOption id="431" count="1" label="DNA gyrase inhibitor"></FilterOption><FilterOption id="138" count="1" label="DNA polymerase inhibitor"></FilterOption><FilterOption id="1016" count="1" label="HIV-1 reverse transcriptase inhibitor"></FilterOption><FilterOption id="205" count="1" label="HMG CoA reductase inhibitor"></FilterOption><FilterOption id="51174" count="1" label="Interferon alpha 5 ligand"></FilterOption><FilterOption id="1741" count="1" label="Low molecular weight heparin"></FilterOption><FilterOption id="261" count="1" label="Muscarinic M1 receptor antagonist"></FilterOption><FilterOption id="262" count="1" label="Muscarinic M3 receptor antagonist"></FilterOption><FilterOption id="259" count="1" label="Muscarinic receptor antagonist"></FilterOption><FilterOption id="1832" count="1" label="Nucleoside reverse transcriptase inhibitor"></FilterOption><FilterOption id="293" count="1" label="Opioid receptor mu agonist"></FilterOption><FilterOption id="4913" count="1" label="P2Y12 purinoceptor antagonist"></FilterOption><FilterOption id="66340" count="1" label="Penicillin binding protein inhibitor"></FilterOption><FilterOption id="551" count="1" label="RNA DNA polymerase inhibitor"></FilterOption><FilterOption id="9320" count="1" label="Topoisomerase IV inhibitor"></FilterOption></Filter><Filter label="Trial Indications Adverse" name="trialIndicationsAdverse" total="100"><FilterOption id="148" count="15" label="Headache"></FilterOption><FilterOption id="226" count="15" label="Nausea"></FilterOption><FilterOption id="102" count="12" label="Diarrhea"></FilterOption><FilterOption id="3454" count="12" label="Dizziness"></FilterOption><FilterOption id="445" count="10" label="Hypoglycemia"></FilterOption><FilterOption id="829" count="9" label="Fatigue"></FilterOption><FilterOption id="2274" count="9" label="Rhinopharyngitis"></FilterOption><FilterOption id="1009" count="8" label="Urinary tract infection"></FilterOption><FilterOption id="404" count="6" label="Constipation"></FilterOption><FilterOption id="17" count="5" label="Anemia"></FilterOption><FilterOption id="2439" count="5" label="Arthralgia"></FilterOption><FilterOption id="552" count="5" label="Bleeding"></FilterOption><FilterOption id="3062" count="5" label="Death"></FilterOption><FilterOption id="3073" count="5" label="Drowsiness"></FilterOption><FilterOption id="402" count="5" label="Edema"></FilterOption><FilterOption id="2954" count="5" label="Weight gain"></FilterOption><FilterOption id="3221" count="4" label="Back pain"></FilterOption><FilterOption id="82" count="4" label="Cough"></FilterOption><FilterOption id="110" count="4" label="Emesis"></FilterOption><FilterOption id="750" count="4" label="Insomnia"></FilterOption><FilterOption id="1991" count="4" label="Neutropenia"></FilterOption><FilterOption id="20" count="4" label="Pain"></FilterOption><FilterOption id="360" count="4" label="Pneumonia"></FilterOption><FilterOption id="324" count="4" label="Thrombocytopenia"></FilterOption><FilterOption id="3038" count="3" label="Appetite loss"></FilterOption><FilterOption id="1091" count="3" label="Bone injury"></FilterOption><FilterOption id="432" count="3" label="Dyspepsia"></FilterOption><FilterOption id="2400" count="3" label="Dyspnea"></FilterOption><FilterOption id="1833" count="3" label="Fever"></FilterOption><FilterOption id="224" count="3" label="Myocardial infarction"></FilterOption><FilterOption id="3020" count="3" label="Skin rash"></FilterOption><FilterOption id="65" count="3" label="Stroke"></FilterOption><FilterOption id="516" count="3" label="Upper respiratory tract infection"></FilterOption><FilterOption id="2955" count="3" label="Weight loss"></FilterOption><FilterOption id="9" count="2" label="Aggression"></FilterOption><FilterOption id="13" count="2" label="Alopecia"></FilterOption><FilterOption id="2595" count="2" label="Aphasia"></FilterOption><FilterOption id="1542" count="2" label="Atrial fibrillation"></FilterOption><FilterOption id="55" count="2" label="Cardiac failure"></FilterOption><FilterOption id="1185" count="2" label="Chronic obstructive pulmonary disease"></FilterOption><FilterOption id="93" count="2" label="Depression"></FilterOption><FilterOption id="3795" count="2" label="Febrile neutropenia"></FilterOption><FilterOption id="3078" count="2" label="Genital tract infection"></FilterOption><FilterOption id="746" count="2" label="Infectious disease"></FilterOption><FilterOption id="191" count="2" label="Influenza virus infection"></FilterOption><FilterOption id="1039" count="2" label="Myalgia"></FilterOption><FilterOption id="69" count="2" label="Renal failure"></FilterOption><FilterOption id="812" count="2" label="Tremor"></FilterOption><FilterOption id="2434" count="2" label="Vertigo"></FilterOption><FilterOption id="3609" count="1" label="Agitation"></FilterOption><FilterOption id="15" count="1" label="Amnesia"></FilterOption><FilterOption id="25" count="1" label="Anxiety disorder"></FilterOption><FilterOption id="1875" count="1" label="Atrioventricular block"></FilterOption><FilterOption id="1788" count="1" label="Balanitis"></FilterOption><FilterOption id="556" count="1" label="Brain disease"></FilterOption><FilterOption id="50" count="1" label="Bronchitis"></FilterOption><FilterOption id="3090" count="1" label="Bronchospasm"></FilterOption><FilterOption id="651" count="1" label="Cancer"></FilterOption><FilterOption id="3050" count="1" label="Chill"></FilterOption><FilterOption id="2625" count="1" label="Cholelithiasis"></FilterOption><FilterOption id="353" count="1" label="Cognitive disorder"></FilterOption><FilterOption id="1956" count="1" label="Confusion"></FilterOption><FilterOption id="1559" count="1" label="Congestive heart failure"></FilterOption><FilterOption id="2700" count="1" label="Contusion"></FilterOption><FilterOption id="3026" count="1" label="Diabetic ketoacidosis"></FilterOption><FilterOption id="359" count="1" label="Diuresis"></FilterOption><FilterOption id="2673" count="1" label="Dysarthria"></FilterOption><FilterOption id="2085" count="1" label="Dysphagia"></FilterOption><FilterOption id="1077" count="1" label="Embolism"></FilterOption><FilterOption id="3093" count="1" label="Emotional lability"></FilterOption><FilterOption id="781" count="1" label="Encephalitis"></FilterOption><FilterOption id="1835" count="1" label="Epistaxis"></FilterOption><FilterOption id="501" count="1" label="Extrapyramidal syndrome"></FilterOption><FilterOption id="129" count="1" label="Gastrointestinal disease"></FilterOption><FilterOption id="395" count="1" label="Gastrointestinal function disorder"></FilterOption><FilterOption id="1659" count="1" label="Gynecomastia"></FilterOption><FilterOption id="2291" count="1" label="Hematuria"></FilterOption><FilterOption id="154" count="1" label="Hepatitis"></FilterOption><FilterOption id="173" count="1" label="Hypercalcemia"></FilterOption><FilterOption id="1821" count="1" label="Hyperglycemia"></FilterOption><FilterOption id="2738" count="1" label="Hyperkalemia"></FilterOption><FilterOption id="505" count="1" label="Hypersensitivity"></FilterOption><FilterOption id="180" count="1" label="Hyperuricemia"></FilterOption><FilterOption id="444" count="1" label="Hypocalcemia"></FilterOption><FilterOption id="3676" count="1" label="Ischemic stroke"></FilterOption><FilterOption id="680" count="1" label="Leukopenia"></FilterOption><FilterOption id="511" count="1" label="Lower respiratory tract infection"></FilterOption><FilterOption id="1992" count="1" label="Lymphocytopenia"></FilterOption><FilterOption id="2794" count="1" label="Mastalgia"></FilterOption><FilterOption id="2379" count="1" label="Mixed urinary incontinence"></FilterOption><FilterOption id="668" count="1" label="Muscle weakness"></FilterOption><FilterOption id="3006" count="1" label="Nasal congestion"></FilterOption><FilterOption id="684" count="1" label="Nutritional disorder"></FilterOption><FilterOption id="245" count="1" label="Osteoarthritis"></FilterOption><FilterOption id="454" count="1" label="Pollakiuria"></FilterOption><FilterOption id="279" count="1" label="Pruritus"></FilterOption><FilterOption id="1084" count="1" label="Psychomotor disorder"></FilterOption><FilterOption id="286" count="1" label="Renal disease"></FilterOption><FilterOption id="114" count="1" label="Sepsis"></FilterOption><FilterOption id="304" count="1" label="Sleep disorder"></FilterOption></Filter></Filters><SearchResults><Trial Id="99397"><Indications><Indication>Ischemic stroke</Indication><Indication>Myocardial infarction</Indication><Indication>Peripheral vascular disease</Indication></Indications><ActionsPrimaryInterventionsControl><Action>P2Y12 purinoceptor antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>P2Y12 purinoceptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Platelet aggregation inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Platelet aggregation inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Oral quick release formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Abbott Vascular</Company><Company>Amgen Inc</Company><Company>Bayer AG</Company><Company>Boston Scientific Corp</Company><Company>Terumo Corp</Company></CompaniesCollaborator><CompaniesSponsor><Company>AstraZeneca AB</Company><Company>AstraZeneca plc</Company></CompaniesSponsor><Countries><Country>France</Country><Country>Spain</Country><Country>Russian Federation</Country><Country>Mexico</Country><Country>Thailand</Country><Country>Philippines</Country><Country>Turkey</Country><Country>Poland</Country><Country>South Korea</Country><Country>Bulgaria</Country><Country>Czech Republic</Country><Country>Hungary</Country><Country>Sweden</Country><Country>Chile</Country><Country>US</Country><Country>Italy</Country><Country>Netherlands</Country><Country>UK</Country><Country>Brazil</Country><Country>Slovakia</Country><Country>Ukraine</Country><Country>China</Country><Country>Canada</Country><Country>Argentina</Country><Country>Vietnam</Country><Country>Japan</Country><Country>South Africa</Country><Country>Romania</Country><Country>Germany</Country></Countries><DateChangeLast>2019-06-13T00:00:00Z</DateChangeLast><DateEnd>2016-09-26T00:00:00Z</DateEnd><DateStart>2012-12-04T00:00:00Z</DateStart><Identifiers><Identifier>2011-004616-36</Identifier><Identifier>CTR20132021</Identifier><Identifier>D5135C00001</Identifier><Identifier>EUCLID</Identifier><Identifier>JapicCTI-132060</Identifier><Identifier>NCT01732822</Identifier><Identifier>PHRR130916-000118</Identifier></Identifiers><IndicationsAdverse><Indication>Bleeding</Indication><Indication>Dyspnea</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>clopidogrel alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>ticagrelor alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>13885</PatientCountEnrollment><Phase>Phase 3b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective of this randomized, double-blind, parallel-group, multicenter, phase IIIb study was to compare the safety and efficacy of long-term treatment with ticagrelor versus clopidogrel on the event rate of the composite of cardiovascular (CV) death, myocardial infarction (MI) and ischemic stroke for the prevention of major adverse cardiovascular events in patients with established/symptomatic  peripheral artery disease (PAD). The primary safety objective was to evaluate thrombolysis</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Cardiovascular Events - Assessment of myocardial infarction</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Mortality/Death Rates - All-cause death</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Mortality/Death Rates - Cardiovascular mortality</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Stroke</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Vascular Indices or Parameters - Target vessel revascularization (TVR)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>EUCLID: A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease</TitleDisplay><PatientSegmentTerms><PatientSegment>Peripheral vascular disease - Subjects with History of PAD Interventions</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Ankle-brachial index </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated</BiomarkerName></BiomarkerNames><PrimaryCompletionDate></PrimaryCompletionDate><TrialDuration>45 Months</TrialDuration><NumberOfSites>683</NumberOfSites><ContactNames><Name>Information Centre</Name><Name>Juan Valdez</Name><Name>Peter Held, MD</Name><Name>William R Hiatt, MD</Name></ContactNames></Trial><Trial Id="93718"><Indications><Indication>Constipation</Indication></Indications><CompaniesSponsor><Company>Solvay Pharmaceuticals Inc</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-01-26T00:00:00Z</DateChangeLast><DateEnd>2006-06-30T00:00:00Z</DateEnd><DateStart>2002-03-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT00160290</Identifier><Identifier>S105.4.106</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Plantago ovata alone</Intervention><Intervention>lactulose alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>97</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><Teaser>The purpose of this study was to demonstrate that lactulose acts as a stool softener, relieving the pain at defecation, improving the number of defecations and regulating the colonic transit time in patients suffering of hemorrhoids or anal fissure; to compare efficacy and quality of life in patients treated either with lactulose or plantago ovata.</Teaser><TrialCategories><Category>Dietary supplement</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Trial to Evaluate Effect of Lactulose on Hard Stools in Patients With Hemorrhoids or Anal Fissures</TitleDisplay><PrimaryCompletionDate type="Actual">2006-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>51 Months</TrialDuration><NumberOfSites>8</NumberOfSites><ContactNames><Name>Global Clinical Director Solvay</Name></ContactNames></Trial><Trial Id="91273"><Indications><Indication>Uveitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Interleukin-1 beta ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiarteriosclerotic</Action><Action>Anticancer monoclonal antibody</Action><Action>Hypoglycemic agent</Action><Action>Ophthalmological agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>BECKMAN LABORATORIES DE MEXICO SA DE CV</Company><Company>Institut de Recherches Internationales Servier (France)</Company><Company>Laboratorios Servier</Company></CompaniesCollaborator><CompaniesSponsor><Company>XOMA Corp</Company></CompaniesSponsor><Countries><Country>Australia</Country><Country>South Korea</Country><Country>Austria</Country><Country>Armenia</Country><Country>US</Country><Country>Argentina</Country><Country>France</Country><Country>Tunisia</Country><Country>Russian Federation</Country><Country>Israel</Country><Country>China</Country><Country>Brazil</Country><Country>Portugal</Country><Country>Taiwan</Country><Country>Hong Kong</Country><Country>Turkey</Country><Country>Mexico</Country><Country>Poland</Country><Country>Germany</Country><Country>UK</Country><Country>South Africa</Country><Country>Spain</Country><Country>Greece</Country></Countries><DateChangeLast>2019-01-24T00:00:00Z</DateChangeLast><DateStart>2012-08-31T00:00:00Z</DateStart><Identifiers><Identifier>2012-001610-42</Identifier><Identifier>EYEGUARD-A</Identifier><Identifier>NCT01684345</Identifier><Identifier>U1111-1135-1431</Identifier><Identifier>X052130/CL3-78989-005</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>gevokizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>200</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><Teaser>The purpose of this study was to evaluate the efficacy of gevokizumab in the treatment of active non-infectious intermediate, posterior, or pan- uveitis. The objective of this study was to demonstrate the superiority of gevokizumab compared to placebo in the treatment of patients with active non infectious intermediate, posterior, or pan-uveitis. The secondary objectives were to assess the effect of gevokizumab on the other efficacy endpoints and to evaluate its safety. The trial substudy attached</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Uveitis - Assessment of Medication Use</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>EYEGUARD-A: Safety and Efficacy Study of Gevokizumab to Treat Active Non-Infectious Uveitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Uveitis - Subjects with Non-Infectious Uveitis</PatientSegment><PatientSegment>Uveitis - Subjects with Posterior Uveitis</PatientSegment><PatientSegment>Uveitis - Subjects with specific disease - Subjects with Panuveitis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Intraocular pressure </BiomarkerName><BiomarkerName> Visual acuity</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-02-29T00:00:00Z</PrimaryCompletionDate><NumberOfSites>121</NumberOfSites><ContactNames><Name>Clinical Studies Department</Name><Name>Institut de Recherches Internationales Servier</Name></ContactNames></Trial><Trial Id="8904"><Indications><Indication>Non-insulin dependent diabetes</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Dipeptidyl peptidase IV inhibitor</Action><Action>Insulin sensitizer</Action><Action>PPAR gamma agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>DPP IV inhibitor antidiabetic product</Action><Action>Hypoglycemic agent</Action><Action>Neuroprotectant</Action><Action>Vulnerary agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation systemic</Technology><Technology>Daily dosing</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Boehringer Ingelheim Corp</Company></CompaniesSponsor><Countries><Country>Portugal</Country><Country>Hungary</Country><Country>Japan</Country><Country>Austria</Country><Country>Greece</Country><Country>Romania</Country><Country>Spain</Country></Countries><DateChangeLast>2018-06-04T00:00:00Z</DateChangeLast><DateStart>2008-03-31T00:00:00Z</DateStart><Identifiers><Identifier>1218.15</Identifier><Identifier>2007-002456-41</Identifier><Identifier>JapicCTI-080563</Identifier><Identifier>NCT00641043</Identifier></Identifiers><IndicationsAdverse><Indication>Gastrointestinal function disorder</Indication><Indication>Hypoglycemia</Indication><Indication>Nutritional disorder</Indication><Indication>Weight gain</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>pioglitazone alone</Intervention><Intervention>Variable regimens including BI-1356 + pioglitazone , linagliptin , pioglitazone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>389</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The objective of the study was to investigate the efficacy, safety and tolerability of BI-1356 (linagliptin) (5 mg qd) compared to placebo given for 24 weeks as initial combination therapy with pioglitazone 30 mg in patients with type 2 diabetes mellitus with insufficient glycemic control.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels - Change in HbA1c</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Glycemic Control Analysis - Assessment of fasting blood glucose</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Glycemic Control Analysis - Hypoglycemia rate (Rate of hypoglycemic events)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Efficacy Versus Placebo as Initial Combination Therapy With Pioglitazone</TitleDisplay><PatientSegmentTerms><PatientSegment>Non-insulin dependent diabetes - Oral Hypoglycemic Treatment Naive Type 2 Diabetes Subjects</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects on Treatment/Requiring &gt;1 Antidiabetic Agent</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Moderate Glycemic Control</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Poor/Inadequate Glycemic Control</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Diastolic blood pressure </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> Systolic blood pressure </BiomarkerName><BiomarkerName> Total body mass </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Triglycerides</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2009-06-30T00:00:00Z</PrimaryCompletionDate><NumberOfSites>33</NumberOfSites><ContactNames><Name>Boehringer Ingelheim</Name></ContactNames></Trial><Trial Id="87498"><Indications><Indication>Pyelonephritis</Indication><Indication>Urinary tract infection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>DHFR inhibitor</Action><Action>DNA gyrase inhibitor</Action><Action>Penicillin binding protein inhibitor</Action><Action>Topoisomerase IV inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Beta lactamase inhibitor</Action><Action>DHFR inhibitor</Action><Action>DNA gyrase inhibitor</Action><Action>Topoisomerase IV inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Antibacterial</Action><Action>Bacterial cell wall synthesis inhibitor</Action><Action>Bacterial nucleic acid synthesis inhibitor</Action><Action>Beta lactam antibiotic</Action><Action>Carbapenem</Action><Action>Fungicide</Action><Action>Systemic dermatological antibacterial product</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antibacterial</Action><Action>Bacterial nucleic acid synthesis inhibitor</Action><Action>Beta lactam antibiotic</Action><Action>Cephalosporin</Action><Action>Fungicide</Action><Action>Synergist</Action><Action>Systemic dermatological antibacterial product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibiotic</Technology><Technology>Drug combination</Technology><Technology>Film coating</Technology><Technology>Formulation powder</Technology><Technology>Granule</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Forest Laboratories Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>AstraZeneca AB</Company><Company>Pfizer Inc</Company></CompaniesSponsor><Countries><Country>Bulgaria</Country><Country>South Korea</Country><Country>Spain</Country><Country>US</Country><Country>Italy</Country><Country>Romania</Country><Country>Germany</Country><Country>Israel</Country><Country>Argentina</Country><Country>Poland</Country><Country>Czech Republic</Country><Country>Mexico</Country><Country>Peru</Country><Country>UK</Country><Country>Taiwan</Country><Country>Russian Federation</Country><Country>Ukraine</Country><Country>Croatia</Country></Countries><DateChangeLast>2019-06-26T00:00:00Z</DateChangeLast><DateEnd>2014-08-31T00:00:00Z</DateEnd><DateStart>2012-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2011-005722-21</Identifier><Identifier>D4280C00004</Identifier><Identifier>DRKS00006480</Identifier><Identifier>NCT01599806</Identifier><Identifier>RECAPTURE 2</Identifier></Identifiers><IndicationsAdverse><Indication>Constipation</Indication><Indication>Diarrhea</Indication><Indication>Headache</Indication><Indication>Nausea</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>Variable regimens including ciprofloxacin hydrochloride , doripenem , trimethoprim + sulphamethoxazole</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including avibactam sodium + ceftazidime (iv, urinary tract infection), AstraZeneca/Allergan , ciprofloxacin hydrochloride , trimethoprim + sulphamethoxazole</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>583</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this phase III, randomized, multi-center, double-blind, double-dummy, parallel-group, comparative study was to evaluate the effects of ceftazidime/avibactam compared to doripenem for treating hospitalized patients with complicated urinary tract infections, including acute pyelonephritis [ 1690998 ], [ 1775422 ], [ 1791906 ]. The primary objectives of the trial was: To assess the noninferiority of ceftazidime-avibactam ( ceftazidime/avibactam , formerly CAZ-104) compared with doripenem</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Pain - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions - Genitourinary disease related outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Urinary tract infection - Assessment of Clinical Response - Assessment of Clinical Cure</EndpointIndex><EndpointIndex>Urinary tract infection - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Urinary tract infection - Assessment of Microbiological Response - Eradication of uropathogen</EndpointIndex><EndpointIndex>Urinary tract infection - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>RECAPTURE 2: Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Other Types of Pain - Subjects with pain associated with infections</PatientSegment><PatientSegment>Urinary tract infection - Subjects with Complicated Urinary Tract Infection</PatientSegment><PatientSegment>Urinary tract infection - Subjects with Pyelonephritis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>22 Months</TrialDuration><NumberOfSites>83</NumberOfSites><ContactNames><Name>Information Centre</Name><Name>Paul Newell, MBBS, MRCP</Name></ContactNames></Trial><Trial Id="8540"><Indications><Indication>Cardiovascular disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>ACE inhibitor</Action><Action>Angiotensin II receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antihypertensive</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Boehringer Ingelheim (Canada) Ltd</Company><Company>Boehringer Ingelheim International GmbH</Company></CompaniesSponsor><Countries><Country>Portugal</Country><Country>Italy</Country><Country>France</Country><Country>Ukraine</Country><Country>Turkey</Country><Country>Switzerland</Country><Country>Russian Federation</Country><Country>Norway</Country><Country>Sweden</Country><Country>Germany</Country><Country>Singapore</Country><Country>Malaysia</Country><Country>Philippines</Country><Country>Denmark</Country><Country>Puerto Rico</Country><Country>Belgium</Country><Country>Thailand</Country><Country>China</Country><Country>Australia</Country><Country>Hungary</Country><Country>South Korea</Country><Country>Spain</Country><Country>Taiwan</Country><Country>UK</Country><Country>Finland</Country><Country>Greece</Country><Country>Czech Republic</Country><Country>Hong Kong</Country><Country>Slovakia</Country><Country>Netherlands</Country><Country>United Arab Emirates</Country><Country>South Africa</Country><Country>Ireland</Country><Country>Mexico</Country><Country>New Zealand</Country><Country>Canada</Country><Country>Argentina</Country><Country>Austria</Country><Country>US</Country><Country>Brazil</Country><Country>Poland</Country></Countries><DateChangeLast>2018-11-01T00:00:00Z</DateChangeLast><DateEnd>2008-06-30T00:00:00Z</DateEnd><DateStart>2001-11-30T00:00:00Z</DateStart><Identifiers><Identifier>10.1186</Identifier><Identifier>502.373</Identifier><Identifier>ISRCTN16228603</Identifier><Identifier>NCT00034931</Identifier><Identifier>NCT00153101</Identifier><Identifier>NMRR-08-54-1209</Identifier><Identifier>ONTARGET/TRANSCEND</Identifier></Identifiers><IndicationsAdverse><Indication>Cough</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>ramipril alone</Intervention><Intervention>telmisartan alone</Intervention><Intervention>ramipril plus telmisartan</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>31546</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objectives of this ONTARGET study were to determine if: Telmisartan 80 mg daily and ramipril 10 mg daily combination therapy was be more effective in reducing the composite endpoint of cardiovascular (CV) death, myocardial infarction (MI), stroke or hospitalization for congestive heart failure (CHF) compared with ramipril 10 mg alone. Telmisartan 80 mg daily was be at least as effective as (ie, not less effective than) ramipril 10 mg daily, on this endpoint. The primary objective of  TRANSCEND</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Atrial fibrillation - Assessment of Cardiovascular Events - Assessment of fatal/non-fatal myocardial infarction</EndpointIndex><EndpointIndex>Atrial fibrillation - Assessment of Cardiovascular Events - Assessment of heart failure</EndpointIndex><EndpointIndex>Atrial fibrillation - Assessment of Cerebrovascular Events - Assessment of non fatal stroke</EndpointIndex><EndpointIndex>Atrial fibrillation - Assessment of Device/Procedure Related Outcomes</EndpointIndex><EndpointIndex>Atrial fibrillation - Assessment of Incidence of Atrial Fibrillation - Assessment of incidence of symptomatic AF episodes</EndpointIndex><EndpointIndex>Atrial fibrillation - Assessment of Mortality/Death Rates - Assessment of cardiovascular death</EndpointIndex><EndpointIndex>Atrial fibrillation - Assessment of hospitalization - Assessment of cardiovascular hospitalization</EndpointIndex><EndpointIndex>Atrial fibrillation - Assessments of Composite Endpoints</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Cardiovascular Events - Assessment of fatal/non-fatal myocardial infarction</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Cardiovascular Events - Reintervention/Revascularization</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Cardiovascular Events - Worsening of Heart Failure</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Clinical Symptoms - Assessment of arrhythmia</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Mortality/Death Rates - Other cardiovascular mortality</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Non Cardiovascular Events - Assessment of cerebrovascular adverse events (Stroke/TIA)</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Non Cardiovascular Events - Metabolic events</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Renal Function - Assessment of renal events</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Safety and Tolerability - Edema</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of adverse events</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of hospitalization - Hospitalization due to heart failure</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of hospitalization - Hospitalization due to other cardiovascular events</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Adverse Events - Neurological complications</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Adverse Events - Renal dysfunction/Complications/Requirement for dialysis</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Blood Pressure (BP)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiovascular Events - Fatal MI/Non-fatal MI</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Clinical Symptoms - Assessment of arrhythmia</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Morbidity - Diabetes(new onset/progressive/with comorbidity)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Other Cardiovascular Events - Heart failure (New onset /Worsening)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Reperfusion/Revascularization - Need for a revascularization procedure</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Thrombotic/Thromboembolic Events - Fatal /Non-fatal stroke</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of hospitalization - Admissions for CAD and adverse events of CAD</EndpointIndex><EndpointIndex>Diabetic complication - Anthropometric Assessments</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Adverse Events - Angioedema</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Blood Pressure (BP)</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Cardiovascular Events</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Cardiovascular Events - Assessment of myocardial infarction</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Cardiovascular Events - Heart failure</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Diabetic Events/Risk Factors</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Morbidity</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Mortality/Death Rates - Cardiovascular mortality</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Renal Dysfunction/Events</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Stroke</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Therapy Related Outcomes - Assessment of drop-out rate/withdrawal rate</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of hospitalization - Hospitalization due to cardiovascular events</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of hospitalization - Hospitalization due to heart failure</EndpointIndex><EndpointIndex>Diabetic complication - Glycemic Control Analysis - Assessment of fasting blood glucose</EndpointIndex><EndpointIndex>Diabetic complication - Neurological Assessments - Cognitive function</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Cardiac Function - Assessment of blood pressure</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Serum Creatinine</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Serum Electrolytes - Assessment of plasma potassium</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of adverse events</EndpointIndex><EndpointIndex>Hypertension - Assessment of Cardiovascular Events - Assessment of myocardial infarction</EndpointIndex><EndpointIndex>Hypertension - Assessment of Cardiovascular Events - Heart failure</EndpointIndex><EndpointIndex>Hypertension - Assessment of Metabolic Parameters - Diabetes</EndpointIndex><EndpointIndex>Hypertension - Assessment of Mortality/Death Rates - Cardiovascular mortality</EndpointIndex><EndpointIndex>Hypertension - Assessment of Stroke</EndpointIndex><EndpointIndex>Hypertension - Assessment of hospitalization - Hospitalization due to heart failure</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Anthropometric Assessments</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Adverse Events - Angioedema</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Blood Pressure (BP)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Cardiovascular Events</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Cardiovascular Events - Assessment of myocardial infarction</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Cardiovascular Events - Heart failure</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Diabetic Events/Risk Factors</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Morbidity</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Mortality/Death Rates - Cardiovascular mortality</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Neuropsychological Function - Assessment by Mini-Mental State Examination (MMSE)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Renal Dysfunction/Events</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Stroke</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of hospitalization - Hospitalization due to cardiovascular events</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of hospitalization - Hospitalization due to heart failure</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Glycemic Control Analysis - Assessment of fasting blood glucose</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Neurological Assessments - Cognitive function</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>ONTARGET/TRANSCEND: Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High-Risk for Cardiovascular Events: Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo</TitleDisplay><PatientSegmentTerms><PatientSegment>Atrial fibrillation - Subjects at risk of developing disease</PatientSegment><PatientSegment>Atrial fibrillation - Subjects at risk of developing disease - Subjects with cardiac intervention</PatientSegment><PatientSegment>Atrial fibrillation - Subjects at risk of developing disease - Subjects with coronary artery disease</PatientSegment><PatientSegment>Atrial fibrillation - Subjects at risk of developing disease - Subjects with diabetes mellitus</PatientSegment><PatientSegment>Atrial fibrillation - Subjects at risk of developing disease - Subjects with other cardiovascular disorders</PatientSegment><PatientSegment>Cardiac failure - Subjects at risk of developing disease - Subjects with coronary artery disease as a risk factor</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Angina</PatientSegment><PatientSegment>Coronary artery disease - Subjects with High Cardiovascular Risk Profile</PatientSegment><PatientSegment>Coronary artery disease - Subjects with High Cardiovascular Risk Profile - Diabetes mellitus/impaired glucose tolerance</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Multiple Vessel CAD</PatientSegment><PatientSegment>End stage renal disease - Subjects with Diabetes/Diabetic Nephropathy</PatientSegment><PatientSegment>End stage renal disease - Subjects with Other Cardiac Disease/Associated Nephropathy</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with comorbid conditions - Subjects with heart disease</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with diabetic nephropathy</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with diabetic retinopathy</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Albumin </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Systolic blood pressure </BiomarkerName><BiomarkerName> Urinary protein</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2008-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>79 Months</TrialDuration><NumberOfSites>586</NumberOfSites><ContactNames><Name>Boehringer Ingelheim</Name><Name>Dato Dr Singaraveloo</Name></ContactNames></Trial><Trial Id="84732"><Indications><Indication>Rheumatoid arthritis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>TNF alpha ligand inhibitor</Action><Action>TNF antagonist</Action><Action>TNF binding agent</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibody fragment</Technology><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>PEGylated formulation</Technology><Technology>Protein conjugated</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>ReSearch Pharmaceutical Services, Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>UCB SA</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-06-29T00:00:00Z</DateChangeLast><DateEnd>2014-03-31T00:00:00Z</DateEnd><DateStart>2012-01-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT01526434</Identifier><Identifier>RA0053</Identifier><Identifier>SONAR-12</Identifier><Identifier>UCB-CER-2010-01</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>certolizumab pegol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>81</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The main objective was to assess Health-Related Quality of Life (HRQoL) according to physical function, as measured by a specific Questionnaire (Health Assessment Questionnaire), in Rheumatoid Arthritis (RA) patients who begin therapy with sc Anti-Tumor Necrosis Factor alpha (TNF-alpha) certolizumab pegol (CZP).</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Pain - Assessment by Global Assessment Scales</EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures - Assessment of Inflammatory/Immunological Markers</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of procedural outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions - Musculoskeletal disease related outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex><EndpointIndex>Pain - Clinical Assessments - Assessment of hematological function</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C-reactive protein (CRP)/high sensitivity C-reactive protein (hs-CRP)</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Safety and Tolerability - Injection/infusion site reactions</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of adverse events</EndpointIndex><EndpointIndex>Rheumatoid arthritis - DAS-28 (Disease Activity Score) Response</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Evaluation of Joints</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Hematological Assessments - Erythrocyte sedimentation rate (ESR)</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by SF-36/SF-12</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Patient Reported Outcomes/Quality of Life Assessments - Health Assessment Questionnaire-Disability Index (HAQ-DI)</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Patient Reported Outcomes/Quality of Life Assessments - Patient assessment of pain</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Synovium Biomarkers/Joint Aspirate Analysis - Rheumatoid Factor (RF)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SONAR-12: Health-Related Quality of Life and Patient-Reported Outcomes in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Somatic Pain - Subjects with arthritic pain</PatientSegment><PatientSegment>Rheumatoid arthritis - Active Rheumatoid Arthritis</PatientSegment><PatientSegment>Rheumatoid arthritis - Subjects on Rheumatoid Arthritis Therapy - Biological DMARDs</PatientSegment><PatientSegment>Rheumatoid arthritis - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Rheumatoid arthritis - Treatment Naive Subjects - TNF-alpha inhibitor naive</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-reactive protein </BiomarkerName><BiomarkerName> Complement C3 </BiomarkerName><BiomarkerName> Complement C4 </BiomarkerName><BiomarkerName> Rheumatoid factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>26 Months</TrialDuration><NumberOfSites>10</NumberOfSites><ContactNames><Name>UCB Clinical Trial Call Center</Name></ContactNames></Trial><Trial Id="83937"><Indications><Indication>Hepatitis C virus infection</Indication><Indication>Liver cirrhosis</Indication><Indication>Liver fibrosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Hepatitis C virus NS3 protease inhibitor</Action><Action>P-Glycoprotein inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>Hepatitis C virus replication inhibitor</Action><Action>RNA synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Nucleoside synthesis</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Janssen-Cilag International NV (BE)</Company></CompaniesSponsor><Countries><Country>Netherlands</Country><Country>Austria</Country><Country>Sweden</Country><Country>Australia</Country><Country>Russian Federation</Country><Country>Spain</Country><Country>Germany</Country><Country>France</Country><Country>Czech Republic</Country><Country>Italy</Country><Country>Poland</Country><Country>UK</Country><Country>Luxembourg</Country><Country>New Zealand</Country><Country>Brazil</Country><Country>Switzerland</Country><Country>Hungary</Country><Country>Greece</Country><Country>Serbia</Country><Country>Romania</Country><Country>Slovakia</Country><Country>Belgium</Country></Countries><DateChangeLast>2016-08-24T00:00:00Z</DateChangeLast><Identifiers><Identifier>2010-023669-23</Identifier><Identifier>CR017857</Identifier><Identifier>HEP3002</Identifier><Identifier>NCT01508286</Identifier><Identifier>VX-950HEP3002</Identifier></Identifiers><IndicationsAdverse><Indication>Anemia</Indication><Indication>Fatigue</Indication><Indication>Hyperuricemia</Indication><Indication>Nausea</Indication><Indication>Neutropenia</Indication><Indication>Pruritus</Indication><Indication>Skin rash</Indication><Indication>Stevens Johnson syndrome</Indication><Indication>Thrombocytopenia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Variable regimens including peginterferon alfa , ribavirin , telaprevir , telaprevir + peginterferon alfa + ribavirin</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>3216</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The purpose of this early access program was to provide telaprevir to patients with a specific type of hepatitis C viral infection (termed 'genotype 1') who are expected to benefit from telaprevir -based therapy but who reside in countries in which telaprevir is not yet commercially available and who are not eligible for enrollment into a clinical study of telaprevir . The study also aimed to collect information on the safety and adverse events with telaprevir treatment in combination with</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Hepatic Morbidities - Cirrhosis</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Liver Fibrosis</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects</TitleDisplay><PatientSegmentTerms><PatientSegment>Hepatitis C virus infection - Subjects Infected with HCV Genotype 1</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with Chronic Hepatitis C Infection</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with Compensated Liver Disease</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with comorbid conditions - Subjects with cirrhosis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate></PrimaryCompletionDate><NumberOfSites>126</NumberOfSites><ContactNames><Name>Janssen Biologics BV</Name></ContactNames></Trial><Trial Id="83581"><Indications><Indication>Bacterial skin infection</Indication><Indication>Complicated skin and skin structure infection</Indication><Indication>Staphylococcus aureus infection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Peptidoglycan recognition protein inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Penicillin binding protein 2X inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Antibacterial</Action><Action>Bacterial cell wall synthesis inhibitor</Action><Action>RNA synthesis modulator</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Antibacterial</Action><Action>Cephalosporin</Action><Action>Systemic dermatological antibacterial product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibiotic</Technology><Technology>Capsule formulation</Technology><Technology>Formulation powder</Technology><Technology>Glycoprotein</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Forest Laboratories Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>AstraZeneca AB</Company><Company>Pfizer Inc</Company></CompaniesSponsor><Countries><Country>UK</Country><Country>Peru</Country><Country>Hong Kong</Country><Country>France</Country><Country>Philippines</Country><Country>Slovakia</Country><Country>Croatia</Country><Country>Romania</Country><Country>US</Country><Country>Mexico</Country><Country>Austria</Country><Country>Poland</Country><Country>Brazil</Country><Country>Italy</Country><Country>Russian Federation</Country><Country>Israel</Country><Country>Taiwan</Country><Country>Czech Republic</Country><Country>Australia</Country><Country>South Korea</Country><Country>Chile</Country><Country>Spain</Country><Country>Greece</Country><Country>South Africa</Country><Country>Belgium</Country><Country>Argentina</Country><Country>China</Country><Country>Germany</Country><Country>Turkey</Country><Country>Bulgaria</Country><Country>Ukraine</Country></Countries><DateChangeLast>2019-06-20T00:00:00Z</DateChangeLast><DateEnd>2015-01-31T00:00:00Z</DateEnd><DateStart>2012-05-31T00:00:00Z</DateStart><Identifiers><Identifier>2011-004013-16</Identifier><Identifier>COVERS</Identifier><Identifier>D3720C00001</Identifier><Identifier>NCT01499277</Identifier></Identifiers><InterventionsControlDisplay><Intervention>aztreonam plus vancomycin</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>ceftaroline fosamil alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>802</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to evaluate the effects of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of patients with complicated bacterial skin and soft tissue infections. The primary objective of this phase III, multicenter, randomized, double-blind, comparative study was to assess whether ceftaroline fosamil was non-inferior to vancomycin plus aztreonam in the clinical cure rate at the test of cure visit in both the modified intent-to-treat and clinically evaluable anlaysis</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bacterial skin infection - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Bacterial skin infection - Assessment of Clinical Response - Clinical success/cure</EndpointIndex><EndpointIndex>Bacterial skin infection - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Bacterial skin infection - Assessment of Incidence of Bacterial Skin Infection</EndpointIndex><EndpointIndex>Bacterial skin infection - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Bacterial skin infection - Assessment of Microbiological Response</EndpointIndex><EndpointIndex>Bacterial skin infection - Assessment of Microbiological Response - Persistence/colonization</EndpointIndex><EndpointIndex>Bacterial skin infection - Assessment of Microbiological Response - Super-infection</EndpointIndex><EndpointIndex>Bacterial skin infection - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Bacterial skin infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Bacterial skin infection - Assessment of Vital Signs</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>COVERS: Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections</TitleDisplay><PatientSegmentTerms><PatientSegment>Bacterial skin infection - Subjects with Complicated Skin and Skin Structure Infections</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Alkaline phosphatase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Bilirubin </BiomarkerName><BiomarkerName> Blood platelets </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> QT interval</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>32 Months</TrialDuration><NumberOfSites>102</NumberOfSites><ContactNames><Name>AstraZeneca Clinical Study Information</Name><Name>David Melnick, MSD</Name><Name>For Information call</Name><Name>For information call</Name><Name>Information Centre</Name><Name>Noaman Akhtar</Name></ContactNames></Trial><Trial Id="8168"><Indications><Indication>Myocardial infarction</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Low molecular weight heparin</Action><Action>P2Y12 purinoceptor antagonist</Action><Action>Tissue plasminogen activator stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Coagulation inhibitor</Action><Action>Fibrinolysis stimulator</Action><Action>Platelet aggregation inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Film coating</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Glycoprotein</Technology><Technology>Intravenous formulation</Technology><Technology>Oligosaccharide</Technology><Technology>Oral formulation</Technology><Technology>Prodrug</Technology><Technology>Protein recombinant</Technology><Technology>Recombinant enzyme</Technology><Technology>Small molecule therapeutic</Technology><Technology>Subcutaneous formulation</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Boehringer Ingelheim International GmbH</Company></CompaniesSponsor><Countries><Country>Italy</Country><Country>Poland</Country><Country>Germany</Country><Country>France</Country><Country>Greece</Country><Country>Serbia</Country><Country>Canada</Country><Country>Spain</Country><Country>Peru</Country><Country>Brazil</Country><Country>UK</Country><Country>Belgium</Country><Country>Chile</Country><Country>Russian Federation</Country><Country>Austria</Country><Country>Norway</Country></Countries><DateChangeLast>2018-06-02T00:00:00Z</DateChangeLast><DateEnd>2012-09-30T00:00:00Z</DateEnd><DateStart>2008-03-31T00:00:00Z</DateStart><Identifiers><Identifier>1123.28</Identifier><Identifier>2007-001219-44</Identifier><Identifier>NCT00623623</Identifier><Identifier>STREAM</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Percutaneous coronary intervention (PCI) alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including clopidogrel , enoxaparin sodium , tenecteplase</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1891</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This study aimed to evaluate, in a proof of concept approach, the outcome of patients presenting with acute ST-elevation myocardial infarction within 3 h of symptom onset in either a pre-hospital setting or community hospital emergency room without a PCI facility.</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Cardiovascular Events - Cardiogenic shock</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Cardiovascular Events - Heart failure</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Cardiovascular Events - Recurrent ischemic events/Recurrent MI</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Co-morbidity</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Hemorrhagic Complications</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Therapy Related Outcomes - Efficacy parameters</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Therapy Related Outcomes - Safety parameters</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Thrombotic/Thromboembolic Events - Ischemic stroke</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of hospitalization</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiovascular Events - Cardiogenic shock</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiovascular Events - Recurrent MI</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Hemorrhagic Complications</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Other Cardiovascular Events - Heart failure (New onset /Worsening)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Therapy Related Outcomes - Efficacy/feasibility Assessment</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Therapy Related Outcomes - Safety assessment</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Thrombotic/Thromboembolic Events - Nonfatal cerebral infarction /Ischemic stroke</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of hospitalization</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>STREAM: Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction</TitleDisplay><PatientSegmentTerms><PatientSegment>Acute coronary syndrome - ST Segment Elevation Myocardial Infarction(STEMI) Subjects</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Unstable Coronary Artery Disease - ST elevation myocardial infarction (STEMI)</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate></PrimaryCompletionDate><TrialDuration>54 Months</TrialDuration><NumberOfSites>107</NumberOfSites><ContactNames><Name>A. Gershlick</Name><Name>Boehringer Ingelheim</Name><Name>Professor F. Van de Werf</Name></ContactNames></Trial></SearchResults></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialResultsOutput>